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ABSTRACT 
 
Stacey Beth Foti: Novel AAV-mediated Therapeutic Strategies for Epilepsy 
(Under the direction of Thomas McCown and Richard Jude Samulski) 
 
 
 Epilepsy afflicts 2.1 million people in the United States, and many patients 
develop drug resistant seizures.  For these patients, gene therapy may be an attractive 
treatment option.  Recent studies have shown that viral vector-mediated expression of 
neuropeptides such as galanin and neuropeptide Y (NPY) can attenuate seizure sensitivity 
and prevent seizure-induced cell death in the brain.  NPY13-36 is a C-terminal peptide 
fragment of NPY that activates the NPY-Y2 receptor, thought to mediate the anti-seizure 
activity.  Therefore we investigated if recombinant adeno-associated virus (AAV)-
mediated expression and constitutive secretion of NPY or NPY13-36 could alter limbic 
seizure sensitivity.  We found that AAV-mediated delivery of both NPY and NPY13-36 
attenuates limbic seizures, and provides a vector technology platform for delivering 
therapeutic peptide fragments with increased receptor selectivity.   
 To further explore the potential of this platform, we utilized a strategic approach 
to deliver multiple neuropeptides simultaneously.  To achieve this, we used a proteolytic 
strategy such that our vectors contained a single promoter driving expression of a 
cleavable chimeric fusion protein of galanin and NPY13-36.  The chimeric fusion protein 
contained a linker sequence capable of being cleaved by the intracellular protease furin, 
and also contained a fibronectin constitutive secretion signal (FIB) sequence.  We first 
characterized several constructs in vitro, and determined that 1) a single FIB 
 iv 
 
sequence was sufficient to cause secretion of both proteins, 2) the proteins were cleaved 
from one another regardless of position relative to the cleavage sequence, 3) cleavage 
efficiency of secreted proteins was 100%, 4) if the cleavage sequence was absent, 
uncleaved fusion protein was secreted into the medium.     
We then tested these constructs in a limbic seizure model, and showed that all of 
our vectors were capable of attenuating limbic seizure sensitivity.  However, no 
additional efficacy was observed with the vector delivering both galanin and NPY13-36.  
Surprisingly, the level of attenuation was less than with previously published single 
peptide vectors, suggesting reduced translation efficiency.  This body of work describes a 
gene therapy vector technology platform to express and constitutively secrete single and 
multiple proteins from transduced cells, and to deliver peptide fragments that are capable 
of selective receptor targeting.   
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Chapter 1 
Introduction
 
I.A. Epilepsy 
About 2.1 million people in the United States are living with epilepsy (Hirtz, 
Thurman et al. 2007), with a world wide prevalence of 1 percent (Hauser, Hesdorffer et 
al. 1990), making epilepsy one of the most common neurological diseases.  Epilepsy 
syndromes can be classified into two major categories based on the origin of seizure 
activity.  In generalized epilepsy the seizure originates bilaterally from the cerebral 
hemispheres and typically involves the whole brain.  For partial or focal epilepsy, the 
area of seizure genesis is localized to one or more defined areas termed foci, although it 
may spread to involve the entire brain.   
Temporal lobe epilepsy (TLE), is a partial epilepsy where seizure genesis occurs 
in temporal lobe structures such as the hippocampus and amygdala, and is the most 
frequent and severe form of adult focal epilepsy (Cohen, Navarro et al. 2002).  Patients 
with TLE can have seizures that cause them to lose consciousness.  If the seizures go 
untreated, they can lead to severe brain damage.  Having epilepsy is not only debilitating, 
it can also be a significant economic burden.  The estimated annual economic cost of 
epilepsy in the United States including the direct cost of treatment and the indirect costs 
such as lost productivity and wages is 12.5 billion dollars (Shafer and Begley 2000).  
There is a critical need for effective epilepsy treatment.  Currently, the preferred   
treatment method for epilepsy is to administer anti-epileptic drugs (AEDs) to arrest the 
seizures or at least reduce their frequency and intensity.  If seizures are left untreated, 
they can increase in duration and subsequently cause more activity-induced pathology in 
the brain.  The AEDs attempt to prevent seizure activity by four major mechanisms: (1) 
increasing gamma-aminobutyric acid (GABA)-ergic actions which are predominantly 
inhibitory; (2) decreasing excitatory glutamatergic transmission; (3) decreasing voltage-
dependant calcium release; and (4) decreasing voltage-dependant sodium conductance 
(Ure and Perassolo 2000).   
Since seizures seem to result from hyperexcitable networks of neurons, the AEDs 
are designed to enhance inhibitory neurotransmission and hyperpolarize neurons.  
Unfortunately, even with new AEDs available, the number of drug resistant epilepsies 
has not decreased (Loscher and Leppik 2002).  Patients who continue to exhibit 
intractable seizures or those who develop intolerable side effects while on AEDs are 
considered to have medically refractory epilepsy.  Unfortunately, 30–40% of all patients 
with epilepsy have medically intractable seizures, and only half of these patients are 
candidates for surgery (Shafer, Hauser et al. 1988; Engel, Levesque et al. 1992; Sander 
1993; Siegel 2004), which is currently one of the few treatment options for medically 
refractory patients.  Additionally, 20% of the patients who do undergo temporal lobe 
surgery will still have seizures post-operatively (Spencer, Spencer et al. 1984).   
Even though surgical techniques have become more refined, several factors still 
limit success.  The highest surgical success rate is achieved if the epileptogenic tissue can 
be directly removed using procedures like focus surgery, anterior temporal lobectomy, 
and total lobe resection (See Figure 1-1).   Lower success is achieved when the area of   
 2
3 
  
Figure 1-1. Different Types of Epilepsy Surgery (modified from Siegel 2003). 
A. Temporal lobectomy, B. Selective amygdalo-hippocampectomy, C. Frontal 
lobectomy, and D. Anatomical hemispherectomy.  Arrows show where brain has been 
resected.  Surgery is currently the only alternative for the 30% of patients who develop 
intractable epilepsy.  Gene therapy represents a potential treatment that is less invasive. 
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seizure genesis overlaps with tissues that serve important sensory or motor functions.  For 
these patients, preventing seizure spread by surgically interrupting the hyperexcitable 
circuits is accomplished through procedures like amygdalo-hippocampectomy and 
corpuscollosectomy.  Surgical complications such as visual field deficits, transient or 
persistent hemiparesis, infections, epidural hematoma, dysphasia, global memory deficits, 
and transient psychosis or depression may also limit success (Siegel 2004).  Although 
current surgical procedures can be beneficial to patients, more effective and potentially 
less invasive treatment strategies need to be designed. 
Theoretically, a gene therapy approach to seizure suppression is an attractive 
alternative treatment option for focal epilepsy.  Focal epilepsy arises from a 
circumscribed and hyperexcitable network of neurons whose synchronous electrical 
discharge creates seizure activity. Since the area of seizure genesis is confined, the 
localized nature of in vivo gene therapy should prove capable of influencing a site that 
initiates seizure activity, therefore preventing the cascade leading to seizure spread.  One 
significant advantage of localized gene delivery is the limited exposure of the rest of the 
brain and body to the therapeutic compounds, thereby minimizing the potential for 
unwanted side effects.  Furthermore, gene therapy allows for localized de novo synthesis 
of the therapeutic compounds in the brain, surmounting the difficulty of delivering 
therapeutic compounds with short half-lives across the otherwise impermeable blood 
brain barrier.        
I.B. Gene Therapy 
The primary goal of gene therapy is to provide long term and effective treatment 
of a disease by delivering therapeutic genes into the patient’s target cells.  Gene therapy 
5 
offers the possibility that chronic disease progression (which occurs with medically 
intractable seizures) can be halted and the symptoms can be controlled, substantially 
increasing the quality of life for the patient.  Using a virus as a means to deliver 
therapeutic genes circumvents many of the problems that non-viral vector-based gene 
therapy is subject to, such as inefficient gene transfer and transient gene expression 
(Huang, Hung et al. 1999).  In order to complete their lifecycle, viruses must efficiently 
deliver their genes into the nucleus of a host cell.  Thus, viruses can be exploited as 
excellent gene delivery tools by substituting therapeutic genes in place of viral genes.   
Focal epilepsy would be very amenable to viral gene therapy particularly because 
viruses like adenovirus (Ad), lentivirus, and adeno-associated virus (AAV) are capable of 
infecting post-mitotic neurons.  This provides direct access to the cells responsible for 
generating and propagating the seizure activity; and which are otherwise difficult to 
genetically manipulate.  Ad is a non-enveloped, double stranded DNA virus that causes 
mild upper respiratory tract infections in humans.  Ad vectors have a large packaging 
capacity (up to 37kb), can infect both dividing and quiescent cells, and remains episomal 
after infection, with a very low probability of randomly integrating into the host cell’s 
chromosomes (Schiedner, Morral et al. 1998; Harui, Suzuki et al. 1999).  The use of Ad 
vectors in the brain is controversial because it has been reported to cause vector-
associated toxicity and inflammation (Wood, Charlton et al. 1996; Thomas, Birkett et al. 
2001; McMenamin, Lantos et al. 2004).  In addition, Ad-mediated gene expression is 
unstable in the brain over time (Thomas, Birkett et al. 2001; McMenamin, Lantos et al. 
2004).   
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Lentiviral vectors (HIV based) are effective in transducing neurons, do not seem 
to cause cytotoxicity upon central nervous system (CNS) infection, and are capable of 
long term transgene expression (Blomer, Naldini et al. 1997; Bosch, Perret et al. 2000).  
However, since lentiviral vectors randomly integrate into the host cell’s genome, they can 
cause insertional mutagenesis.  These random insertions may disrupt or activate cellular 
genes including oncogenes.  Recently, class 1 non-integrative lentiviral vectors derived 
from HIV type 1 were developed and characterized in brain tissue (Philippe, Sarkis et al. 
2006; Yanez-Munoz, Balaggan et al. 2006).   These vectors can be further modified to be 
self-inactivating (Miyoshi, Blomer et al. 1998), a combination that substantially reduces 
the risks of insertional mutagenesis and replication-competence, thereby generating safer 
lentiviral vectors for gene therapy in the brain.   
AAV vectors which are based on a non-pathogenic and replication deficient virus 
offer the safest method of viral gene delivery in the brain.  In addition, AAV vectors are 
capable of long term stable gene expression and do not elicit an immune response upon 
infection, making it the viral vector of choice in clinical trials for neurological diseases 
(see Table 1-1 and http://www.wiley.co.uk/wileychi/genmed/clinical/). 
I.C. AAV Biology 
Wild type AAV (wtAAV) is a non-enveloped single stranded DNA virus 
belonging to the Parvovirus family.  Although the virus is prevalent in the human 
population (about 80% of humans are seropositive to AAV2 (Tobiasch, Rabreau et al. 
1994), infection is not associated with any known disease (Blacklow, Hoggan et al. 
1968).  Because of this, the virus is said to be nonpathogenic.  AAV is classified as a 
dependovirus because it is replication deficient, and cannot cause a productive infection  
7 
Table 1-1. Current AAV-mediated Gene Therapy Clinical Trials for Neurological 
Diseases. This data is current to July 2007.  For more details on these clinical trials please 
see: http://www.wiley.co.uk/wileychi/genmed/clinical/ 
 
Trial ID: Title: Gene Disease 
US-469 Subthalamic GAD Gene Transfer in 
Parkinson’s Disease Patients Who Are 
Candidates for Deep Brain Stimulation. 
Glutamic acid 
decarboxylase 65-
67 (GAD 65-67) 
 
Parkinson's Disease 
 
US-593 A Phase I Open-Label Safety Study of 
Intrastriatal Infusion of Adeno-
Associated Virus Encoding Human 
Aromatic L-amino Acid Decarboxylase 
(AAV-hAADC-2) in Subjects with 
Advanced Parkinson's Disease 
Aromatic L-amino 
Acid Decarboxylase 
(AADC) 
Parkinson's Disease 
 
US-623 A Phase I/II, Dose-Escalating, 
Randomized and Controlled Study to 
Assess the Safety, Tolerability, and 
Efficacy of CERE-110 [Adeno-Associated 
Virus (AAV)-based, Vector-Mediated 
Delivery of beta-Nerve Growth Factor 
(NGF)] in Subjects with Mild to Moderate 
Alzheimer's Disease 
Nerve growth factor 
(NGF) 
 
Alzheimer's Disease 
 
US-669 Hippocampal NPY Gene Transfer in 
Subjects with Intractable Temporal Lobe 
Epilepsy 
Neuropeptide Y 
(NPY) 
 
Epilepsy 
 
US-689 A Phase I, Open-Label Study of CERE-
120 (Adeno-Associated Virus Serotype 2 
[AAV2]-Neurturin [NTN]) to Assess the 
Safety and Tolerability of Intrastriatal 
Delivery to Subjects with Idiopathic 
Parkinson's Disease 
Neurturin (NTN) 
 
Parkinson's Disease 
 
US-788 Multicenter, Randomized, Double-Blind, 
Sham Surgery-Controlled Study of 
CERE-120 (Adeno-Associated Virus 
Serotype 2 [AAV2]-Neurturin [NTN]) to 
Assess the Efficacy and Safety of 
Bilateral Intraputamenal (IPu) Delivery 
in Subjects With Idiopathic Parkinson's 
Disease 
Neurturin (NTN) 
 
Parkinson's Disease 
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unless facilitated by a helper virus such as Ad or Herpes Simplex virus (HSV) (Buller, 
Janik et al. 1981; Bauer and Monreal 1986). When helper viruses are absent and the host 
cell is not subjected to DNA damaging agents or metabolic inhibitors, AAV will establish 
a latent infection within the cell (Yalkinoglu, Heilbronn et al. 1988).  This latent infection 
will occur by site-specific integration of AAV into the host genome at human 
chromosome 19q13.3qter AAVS1 site (Samulski, Zhu et al. 1991; Muzyczka 1992), by 
AAV persistence as an episome within the nucleus (Yue and Duan 2003; McCarty, 
Young et al. 2004), or by random integration at chromosomal double-strand breaks 
(Miller, Petek et al. 2004).  AAV is stable in this latent state and can persist for years 
until rescued by helper virus co-infection, which reinitiates the lytic cycle (Cheung, 
Hoggan et al. 1980) (see Figure 1-2). 
AAV virions are comprised of a linear single-stranded DNA genome of 4.7 kb, 
which is encapsidated by a non-enveloped icosahedral shell, measuring approximately 22 
nm in diameter.  The elegant simplicity of the genome is astounding, with only two genes 
rep (replication) and cap (capsid) encoding nonstructural and structural proteins 
respectively.  From a single open reading frame (ORF) the rep gene encodes four 
replication proteins (Rep78, Rep 68, Rep 52, and Rep 40), which collectively are 
responsible for site-specific integration, DNA nicking, and helicase activity.  Rep 
proteins also respond to intracellular cues (like the presence of helper virus) to regulate 
the AAV promoters that drive expression of its genome (Pereira, McCarty et al. 1997).  
The cap gene encodes three overlapping proteins (VP1, VP2, and VP3) which differ from 
each other only by their N terminus (Rose, Maizel et al. 1971; Berns and Linden 1995).  
Together they assemble into the capsid which is made up of 60 subunits with  
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Figure 1-2 AAV Latent and Lytic Life Cycles. 
In the absence of helper virus, AAV latently integrates into host chromosomes, with 70% 
of the genomes being targeted to the human chromosome 19q13.3qter AAVS1 site.  If the 
cells are then superinfected with a helper virus, AAV enters its lytic phase and initiates 
virus replication. AAV can also immediately enter its lytic phase upon helper virus co-
infection, resulting in the replication of both AAV and the helper virus.   
wtAAV
19q13.3qter 
Ad
Helper Virus 
Co-infection
Cell Lysis
Helper Virus 
Infection
Cell Lysis
Latent Infection
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approximately a 1:1:20 ratio and T=1 icosahedral symmetry (Rose, Maizel et al. 1971; 
Muzyczka 1992).  The rep and cap genes are flanked by the AAV inverted terminal 
repeats (TR), which are the only cis-acting elements required for genome replication and 
packaging (Samulski, Chang et al. 1987; Samulski, Chang et al. 1989).  
I.D. AAV Vectors 
Since the AAV TR is the only required cis-element for replication and 
encapsidation, the two viral genes (rep and cap) can be removed and replaced by a 
transgene expression cassette (see Figure 1-3).  As long as rep and cap are provided in 
trans, AAV vectors can be produced and subsequently purified.  Building on experiments 
by Ferrari et al., (1996) which demonstrated that Ad helper function could be conferred 
using noninfectious Ad DNA, pioneering work was done by Xiao, Li, and Samulski, 
allowing production of high titer AAV vectors in the absence of contaminating helper 
viruses (Ferrari, Samulski et al. 1996; Ferrari, Xiao et al. 1997; Xiao, Li et al. 1998).  
Consequently these vectors are safer for clinical trial applications.  In addition, there are 
approximately 300 nucleotides of viral DNA present in the AAV vector expression 
cassette (the TR), and this sequence is not translated into viral proteins.  Perhaps this lack 
of translated viral proteins reduces the risk of AAV vector genomes eliciting a host cell 
immune response, and may contribute to the longevity of transgene expression (longer 
than 3 years in humans) (Duan, Sharma et al. 1998; Jiang, Pierce et al. 2006).   
Along with its lack of immunogenicity and pathogenicity, AAV vectors have a 
broad tissue tropism (e.g. brain, liver, muscle) and can transduce both mitotic and 
quiescent cells (During, Samulski et al. 1998; Song, Morgan et al. 1998; Ye, Rivera et al. 
1999; Acland, Aguirre et al. 2001; Flotte 2001), reinforcing the suitability of rAAV for  
11 
 
 
 
Figure 1-3. Comparing wtAAV to rAAV.   
A. The wtAAV genome encodes two viral genes, the rep and cap, and is flanked by 
terminal repeats (TR). The four Rep proteins: Rep78, Rep68, Rep52 and Rep40 are 
responsible for site-specific integration, DNA nicking, and helicase activity.  All four 
proteins are transcribed from the p5 and p19 promoters and by alternative splicing.  The 
three viral structural proteins VP1, VP2, and VP3 share the same C-terminus and form 
trimers and pentamers that ultimately come together and encapsidate the single stranded 
genome.  They are transcribed from the p40 promoter and by alternative splicing.     
B. Since the AAV terminal repeats are the only cis-elements required for viral vector 
(a.k.a. recombinant AAV or rAAV) production, rep and cap can be removed and 
replaced by a transgene expression cassette.  As long as rep and cap are provided in 
trans, AAV vectors can be produced and subsequently purified.   
wtAAV 
A. 
p19 p40 polyA
Rep Cap 
Vp2 
Vp1 
Vp3 
Rep 78 
Rep 52 
Rep 40 
Rep 68 
p5 
Promoter Transgene 
rAAV 
B. 
polyA
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clinical trials in brain.  Several AAV serotypes have been tested in the brain, although not 
every serotype was tested at the same time in the same model.  While there is some 
variability, some generalizations can be made: capsids from AAV9, AAV8, AAV7, and 
AAV5 cause transduction in neurons (and a few glia) farthest from the site of injection 
(Klein, Dayton et al. 2006; Taymans, Vandenberghe et al. 2007; Klein, Dayton et al. 
2008), followed by AAV1 (Burger, Gorbatyuk et al. 2004) which still transduces neurons 
farther away than AAV2, which seems to have the most localized effects.  AAV4 appears 
to transduce ependymal cells exclusively, severely limiting its use as a vector for 
neurological diseases (Davidson, Stein et al. 2000).  Furthermore, with the discovery of 
novel serotypes and the ability to engineer new capsid mutations by rational design and 
directed evolution approaches, it is now possible to enhance viral transduction and 
targeting (see Chapter 5 for detailed discussion).  
Despite its many advantages, there are a few drawbacks to using AAV vectors.  
Perhaps the primary concern is the vector’s limited packaging capacity (approximately 
5kb).  AAV vectors can package genomes up to 6kb, but infectivity drops dramatically 
when the genome is larger than that of wtAAV (Grieger and Samulski 2005).  However, 
there are elegant ways of surmounting this obstacle, such as shortening and optimizing 
the components of the expression cassette (promoter, therapeutic gene sequence, and 
polyA), or employing a split vector system.  A split vector system divides the coding 
sequence of the transgene in two, such that each one is packaged in a separate vector 
which relies upon co-infection, and the ability of AAV vectors to concatamerize with one 
another to allow gene expression (Duan, Yue et al. 2003).   
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Another concern that potentially limits AAV vector efficiency is the ability and 
speed with which the infected cells orchestrate viral genome second strand synthesis.  
Since traditional AAV vectors are single stranded, the DNA must be converted to a 
double stranded form before gene expression can be initiated, and the process is 
dependent upon the host cell-mediated DNA synthesis (Ferrari, Samulski et al. 1996; 
Fisher, Gao et al. 1996).  One way to overcome this obstacle was pioneered by McCarty 
et al, and involves generating a self-complimentary AAV vector (scAAV) that upon 
uncoating could fold back on itself through intramolecular base pairing, creating a 
duplexed form (McCarty, Monahan et al. 2001; McCarty, Fu et al. 2003; Wang, Ma et al. 
2003).  Once duplexed, the efficiency with which transcriptionally active double stranded 
molecules are formed is greatly enhanced.  Not only does this scAAV vector allow gene 
expression to occur much faster, it also has been reported to increase the level of 
transgene expression (McCarty, Monahan et al. 2001; Yang, Schmidt et al. 2002).  While 
these vectors have shown great promise, they are even further limited in their packaging 
capacity to around 2.3kb (Wu, Zhao et al. 2007), which may restrict the range of 
therapeutic applications. 
I.E. Potential Gene Therapy Targets for Epilepsy 
Due to the diverse etiology of epilepsy, there are sure to be multiple genes and 
mechanisms involved in seizure genesis and epilepsy-induced pathology.  While this may 
mean that there will not be “one cure to fit them all,” many potential therapeutic targets 
can be investigated.  Seizure activity is most likely the result of inadequate neuronal 
inhibition, excessive neuronal excitation, or a combination of the two states (Engel 1996; 
Holmes 1997; Bernard, Hirsch et al. 1999; Ying and Najm 2002).  Neuronal inhibition is 
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primarily achieved through GABAergic neurotransmission, and loss of this inhibition has 
been implicated in epilepsy, making GABA a good therapeutic target.  This is evident by 
the fact that many of clinically effective AEDs enhance GABA action either by 
increasing the time GABA remains in the synapse (by blocking its intracellular 
catabolism or by blocking its reuptake transporter, GAT1), or by acting at GABA 
receptors (to increase chloride ion flux into the neuron which hyperpolarizes it and 
prevents the firing of new action potentials).   
As mentioned before, many patients with epilepsy do not respond to these drugs, 
and some patients respond initially, but relapse over time.  Perhaps the same problems 
will occur with gene therapies directed at GABA.  One possible mechanism for decreased 
drug efficacy is GABA receptor desensitization, a process whereby overstimulation leads 
to the removal of the receptors at and around the synapse by endocytosis (Galpern, Miller 
et al. 1990; Qi, Yao et al. 2006), eventually causing a loss of GABA binding, and shifts 
the neuronal inhibitory tone toward excitation.  Once neurons become hyperexcitable, 
they fire action potentials and release glutamate until synchronized excitation can cause 
hyperexcitable circuits that kindle seizure genesis.  If left untreated, excitotoxicity ensues, 
leading to epilepsy-induced pathologies like hippocampal sclerosis, mossy fiber 
sprouting, and neuronal death.  In fact, administration of a glutamate agonist, kainic acid 
is the model we and others use to induce limbic seizures in naïve animals, emphasizing 
that a reduction in glutamate action can be a good therapeutic target. There is evidence 
from many investigators that epilepsy enhances several other excitatory neurotransmitters 
like glycine, aspartate, acetylcholine, N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methylisoxazole-4- propionic acid (AMPA), and second messengers like 
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calcium and cyclic GMP (Ure and Perassolo 2000).  Even channels for ions such as 
sodium, potassium, and calcium regulate neuronal excitability, and their manipulation 
could provide in vivo seizure control.  However, a liability with many of these targets in a 
gene therapy context is that success will depend on the pattern of neuronal transduction, 
i.e. the type of neuron and its position within a functional circuit will influence seizure 
outcome.  For example, reducing excitatory tone of a primary output neuron will reduce 
overall excitability, but reducing excitatory tone of an inhibitory interneuron may actually 
increase seizure severity.    
Perhaps the therapeutic target that holds the greatest potential for treating focal 
epilepsy is neuropeptides.  Neuropeptides are larger than classical neurotransmitters but 
smaller than most proteins, and have less complex tertiary structure.  Their main function 
is to modulate the release of neurotransmitters, which can influence neuronal excitability.  
Neuropeptides diffuse more slowly (100-500ms) but bind tighter to their receptors than 
classical neuropeptides (2-5ms), enabling slow long-lasting changes (Hokfelt, Bartfai et 
al. 2003).  They can also travel to receptors somewhat distant from their release site, a 
phenomenon called volume transmission that was first described by Agnati and Fuxe in 
1986 (Agnati, Bjelke et al. 1995).  Since neuropeptides can influence autoreceptors as 
well as the receptors on surrounding neurons, transduction of a few cells within the 
seizure focus may result in more wide-spread seizure suppression that is independent of 
transduction pattern.  To date, the neuropeptides best studied as therapeutics for epilepsy 
are neuropeptide Y (NPY) and galanin (see Table 1-2), but others such as dynorphin, 
somatostatin, and cholecystokinin have shown some promise. 
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Table 1-2. Potential Therapeutic Targets that Influence Seizure Behavior. 
Abbreviations are: AAV: adeno-associated virus; ASPA: aspartoacylase; Ad: adenovirus; CB: cytomegalovirus enhancer, chicken 
beta-actin promoter; CMV: cytomegalovirus promoter; GAD: glutamic acid decarboxylase; GDNF: glial-derived neurotrophic factor; 
ICP10PK: ICP 10 protein kinase; ih: intrahippocampal; ip: intraperitoneal; NMDA: N-methyl-D-aspartate; NPY: Neuropeptide Y; 
NSE: neuron- specific enolase; SER: spontaneously epileptic rats; SN: substantia nigra; TET off: tetracycline-off regulatable 
promoter; WPRE: woodchuck hepatitis virus post-transcriptional element. 
Target  Placement  Delivery vector  Experimental model Functional effect  References  
 
Adenosine  
 
Intracerebroventricular  
 
Grafting of fibroblasts 
or myoblasts 
 
Hippocampal kindling  Suppression of generalized seizures  
(Huber, Padrun et al. 
2001; Guttinger, 
Padrun et al. 2005) 
Anti NMDA  Collicular cortex  AAV-CMV vector  Focal electrical stimulation  Increased seizure threshold  (Haberman, Criswell et al. 2002) 
   AAV-TEToff vector  
  
Decreased seizure threshold  
(Haberman, Criswell 
et al. 2002) 
 Orogastric tube delivers vector to 
stomach (oral vaccine) 
 
AAV-CMV 
 
Kainic acid ip 
 
Seizure inhibition, 
neuroprotection 
(During, Symes et al. 
2000) 
 
ASPA  
 
Intracerebroventricular  
 
Ad-CB vector  
 
Spontaneous seizures in 
SER  
 
Transiently reduced incidence of 
tonic seizures  (2 weeks) 
(Seki, Matsubayashi 
et al. 2004) 
Cholecystokinin  Intracerebroventricular Lipofectin and plasmid Audiogenic seizure-prone rats  
Transient seizure inhibition  (1 
week) (Zhang, Li et al. 1997) 
GABAAR Hippocampus AAV-GABAR4 Pilocarpine-induced Status Epilepticus 
Transiently reduced spontaneous 
seizures (4 weeks) 
(Raol, Lund et al. 
2006) 
GAD65  Anterior SN  Grafting of neuronal or glial cell lines  Entorhinal kindling  Delayed rate of kindling  
(Thompson, 
Anantharam et al. 
2000) 
 
 
 
Posterior SN  
 
  
 
Faster rate of kindling  
(Thompson, 
Anantharam et al. 
2000) 
  Anterior SN  
 
Grafting neuronal cell 
line 
 
Pilocarpine-induced Status 
Epilepticus  
 
Reduced spontaneous seizures  
(Thompson and 
Suchomelova 2004) 
  Piriform cortex  
 
Grafting neuronal cell 
line 
 
Amygdala kindling  
 
Increased threshold to seizures  
(Gernert, Thompson 
et al. 2002) 
GAD67 SN pars reticulata 
Grafting of mixed 
neuronal and glial cell 
line  
Kainic acid ip Delayed seizure behavior (Castillo, Mendoza et al. 2006) 
Galanin  Collicular cortex  
AAV-TEToff 
vector+FIB secretory 
sequence 
 Increased seizure threshold  (Haberman, Samulski et al. 2003) 
  Hippocampus  
AAV-TEToff 
vector+FIB secretory 
sequence  
 
Kainic acid ip  
 
Neuroprotection  
(Haberman, Samulski 
et al. 2003) 
   AAV-NSE 
vector+WPRE  
 
Kainic acid ih  
 
Reduced number of seizures  
(Lin, Richichi et al. 
2003) 
  Piriform cortex  
 
AAV-CB vector+FIB 
secretory sequence  
 
Kainic acid ip  
 
Seizure inhibition  
(McCown 2006) 
   Focal electrical stimulation Increased seizure threshold (McCown 2006) 
GDNF 
 
Hippocampus 
 
AAV-CB 
vector+WPRE 
 
Hippocampal kindling 
 
Decreased number of generalized 
seizures, increased seizure 
threshold 
(Kanter-Schlifke, 
Georgievska et al. 
2007) 
  
Hippocampus  
 
Ad-CMV vector 
 
Kainic acid ip 
 
Delayed seizure behaviors, 
neuroprotective 
(Yoo, Lee et al. 2006) 
 
 
ICP10PK 
 
 
Intranasal vaccine 
 
 
HSV-2∆RR –ICP10 
vector 
 
 
Kainic acid ip 
 
 
Reduced seizure behaviors, 
neuroprotection 
(Laing, Gober et al. 
2006; Laing and 
Aurelian 2008) 
 
NPY  
 
Hippocampus  
 
AAV-NSE 
vector+WPRE 
Kainic acid ih  
 
Delayed seizure behavior  
(Richichi, Lin et al. 
2004) 
    Hippocampal kindling  
 
Increased seizure threshold and 
delayed rate of kindling  
(Richichi, Lin et al. 
2004) 
  Piriform cortex 
 
AAV-CB vector+FIB 
secretory sequence 
Kainic acid ip 
 
Reduced and delayed seizure 
behaviors 
(Foti, Haberman et al. 
2007) 
 
NPY 13-36 
 
Piriform cortex 
 
AAV-CB vector+FIB 
secretory sequence 
Kainic acid ip 
 
Reduced and delayed seizure 
behaviors 
(Foti, Haberman et al. 
2007) 
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I.F. Ex Vivo Gene Therapy 
There are two basic modalities for gene therapy: ex vivo gene therapy which relies 
on genetically modifying cells in vitro then implanting them into the target tissue, or in 
vivo gene therapy where the transfer of genetic material occurs directly within the host 
via viral or non-viral mediated gene delivery (see Figure 1-4).  To date, ex vivo gene 
therapy experiments in brain have been carried out using fibroblasts (Huber, Padrun et al. 
2001), myoblasts (Lisovoski, Wahrmann et al. 1997; Guttinger, Padrun et al. 2005), CNS 
progenitor cells (Martinez-Serrano and Bjorklund 1997), immortalized neurons (Gernert, 
Thompson et al. 2002; Longhi, Watson et al. 2004), and astrocytes (Lundberg, Horellou 
et al. 1996; Ericson, Wictorin et al. 2002).  In order for this ex vivo approach to be 
successful in treating epilepsy, the implanted cells must be engineered to secrete a 
product that will enhance neuronal inhibition.  In the Boison lab, genetically engineered 
fibroblasts (Huber, Padrun et al. 2001) and myoblasts (Guttinger, Padrun et al. 2005) 
were made to secrete the inhibitory neuromodulator adenosine, and then grafted into the 
lateral ventricles or hippocampus of rats.  While the rate of limbic kindling was 
significantly attenuated during the first week post-implantation, by the fourth week there 
was a drastic reduction of seizure suppression.  The authors determined that the loss of 
therapeutic efficacy was due to low viability of the grafted cells.  These results point to a 
universal problem with ex vivo gene therapy: the loss of graft viability over time.  With 
regard to epilepsy gene therapy, the gene product must remain functional for a long 
period of time, hence the clinical potential of grafting modified cells in the brain is very 
low (McCown 2004).     
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Figure 1-4. Ex Vivo versus In Vivo Viral Gene Delivery. 
2. Culture Cells
4. Inject Genetically Modified 
Cells into Rodent
3. Infect Cells with Virus Encoding 
Therapeutic Gene
1. Harvest Cells from Rodent
A. Ex Vivo Viral Gene Therapy
B. In Vivo Viral Gene Therapy
1. Inject Virus Encoding Therapeutic Gene Directly 
into Rodent
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  More recently the Boison lab has used genetically engineered human 
mesenchymal stem cells (hMSC) where lentiviral RNAi mediates knockdown of 
adenosine kinase (ADK), the gene responsible for adenosine metabolism and influx from 
the extracellular space back into cells (Ren, Li et al. 2007).  The authors demonstrate 
reduced seizure duration and neuronal loss after graft implantation in the hippocampus 
followed by intra-amygdaloid injection of kainic acid  (Ren, Li et al. 2007).  This type of 
approach would be compatible with autologous cell grafting in patients, and thus 
represents a potential clinical therapy if the grafts of mesenchymal stem cells can remain 
viable in the brain over time.   
The Boison lab is also currently exploring implantation of genetically modified 
embryonic stem cell-derived neural precursors with biallelic genetic disruption of ADK 
(Li, Steinbeck et al. 2007).  Implanting these grafts into the hippocampus caused 
increased levels of extracellular adenosine and suppressed kindling epileptogenesis (Li, 
Steinbeck et al. 2007).  While the authors only conducted these experiments for 26 days, 
they see integration of the grafted cells and neuronal maturation markers expressed in 
about half of their grafted cells; leading the authors to speculate that graft viability may 
extend beyond the limited time course analyzed. 
I.G. In Vivo Viral Vector-Mediated Alterations in Receptor Function  
 As mentioned before, enhancing inhibitory receptor function may be an effective 
target for antiepileptic gene therapy.  Thus, an obvious approach would be to increase 
GABA-mediated fast neuronal inhibition, which is achieved through GABAA receptors 
(GABRs).  GABRs are made up of several subunits whose combinations confer a range 
of pharmacological function.  For example, it has been reported that GABRs rich in 
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GABRα4 and poor in GABRα1 have been found in both humans with temporal lobe 
epilepsy and in rodent models of epilepsy, and show reduced GABA-mediated inhibition 
in the presence of zinc (Buhl, Otis et al. 1996; Gibbs, Shumate et al. 1997; Brooks-Kayal, 
Shumate et al. 1998; Brooks-Kayal, Shumate et al. 1999).  In addition, after pilocarpine-
induced status epilepticus, GABRα4 expression increases while GABRα1 expression 
decreases in the dentate gyrus of adult rats (Brooks-Kayal, Shumate et al. 1998).  While 
these adult rats go on to develop spontaneous seizures, postnatal day 10 rats that are 
subjected to the same paradigm fail to develop spontaneous seizures (Zhang, Raol et al. 
2004).  Furthermore, the postnatal day 10 rats exhibit an increase in GABRα1 expression    
in dentate gyrus neurons (Zhang, Raol et al. 2004), suggesting that overexpression of 
GABRα1 may confer seizure protection if overexpressed in the adults.  To investigate 
this hypothesis, Raol et al. used an AAV5 vector to express GABRα1 from the GABRα4 
promoter in adult rats subsequently injected with pilocarpine (Raol, Lund et al. 2006).  
While it was a good idea to use a conditional promoter whose expression is known to be 
upregulated by pilocarpine treatment, only transient expression of the transgene GABRα1 
was observed (about 4 weeks).  A more robust promoter like the constitutively active 
cytomegalovirus enhancer, chicken beta-actin promoter (CB) could be used to prevent 
this.  Even though the effects were transient and not uniform, some seizure protection 
was observed; however, about 30% of the rats receiving GABRα1 developed behavioral 
phenotypes that were not desirable, including excessive sedation, and anorexia (Raol, 
Lund et al. 2006).  These results point to a therapeutic liability that must be considered, 
and may be a universal risk of directly manipulating fast neuronal inhibition.          
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Another strategy to limit seizure activity would be to reduce or block excitatory 
amino-acid receptors, which may help restore inhibitory tone and prevent excitotoxicity.  
Since activation of NMDA receptors has been shown to increase seizure sensitivity 
(McCown, Givens et al. 1987), it is logical to try to limit their activation.  In fact, NMDA 
channels are a good target for a gene therapy approach because although they are 
comprised of multiple subunits that are coded for by several genes, each channel must 
have the required NR1 subunit to be fully functional (Monyer, Sprengel et al. 1992; 
Hollmann and Heinemann 1994; Yamakura and Shimoji 1999).  Therefore, knockdown 
of NMDAR1 protein should result in fewer functional NMDA channels.  Haberman et al. 
tested this hypothesis using an NMDAR1 antisense construct delivered by an AAV2 
vector (Haberman, Criswell et al. 2002).  While in vitro NMDAR1 receptor function and 
in vivo NMDAR1 protein levels were significantly reduced, the seizure behavior outcome 
was complicated by the promoter choice.  When the antisense construct was driven by the 
CMV promoter, a significant increase in the amount of current was necessary to elicit a 
focal seizure (Haberman, Criswell et al. 2002).  However, when expression of the same 
antisense construct was driven by the tet-off promoter, there was a significant decrease in 
the amount of current necessary to elicit a focal seizure.  The authors go on to show that 
the plausible explanation for the opposing results is that when the CMV promoter was 
driving expression of the antisense NMDAR1, a majority of the transduced neurons were 
primary output neurons that benefit from a reduction in excitatory input.  When the tet-
off promoter was used, the majority of transduced neurons were inhibitory interneurons, 
and the resulting reduction in NMDA activation increased the overall excitatory tone and 
seizure sensitivity (Haberman, Criswell et al. 2002).  This highlights another very 
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important liability when modulating receptors, ion channels, or even neurotransmitters 
and transporters: results may be dependant upon the pattern of transduction.          
I.H. In Vivo Viral Vector-Mediated Expression of Neuropeptides and Peptide 
Fragments 
 Neuropeptides and their receptors are found in areas often associated with seizure 
generation, and their physiological effects are predominantly inhibitory suggesting anti-
convulsant action.  In particular, both galanin and NPY (and their analogs) have anti-
convulsant effects in several models of experimentally induced seizures (Mazarati, Liu et 
al. 1998; Mazarati, Hohmann et al. 2000; Mazarati and Wasterlain 2002; Haberman, 
Samulski et al. 2003; Mazarati 2004; McCown 2006; Foti, Haberman et al. 2007).    
Experimental evidence suggests that prolonged overstimulation, such as recurring 
seizures, depletes galanergic innervation (Mazarati, Liu et al. 1998) and destroys a subset 
of GABA-ergic NPY containing interneurons in the hippocampus (Sloviter 1991; Sperk, 
Marksteiner et al. 1992; Schwarzer, Williamson et al. 1995).  This finding was also 
validated in patients with mesial temporal lobe sclerosis (de Lanerolle, Kim et al. 1989).  
Taken together, these data suggest that overexpressing galanin and NPY in the ictogenic 
brain regions may not only suppress seizures and prevent them from spreading, but might 
also compensate for depleted neuropeptides, conferring some neuroprotection.   
The use of AAV vectors to express galanin and NPY in the hippocampus and 
piriform cortex has been explored with very good results.  Haberman et al. first 
demonstrated the anti-seizure efficacy of vector-mediated neuropeptide gene expression, 
using a novel platform designed to circumvent the potential liabilities of viral vector 
tropism (Haberman, Criswell et al. 2002; Haberman, Samulski et al. 2003).  An AAV2 
vector was constructed in which the coding sequence for the active galanin peptide was 
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preceded by the secretory signal sequence of the laminar protein, fibronectin. Thus, the 
active peptide would be constitutively secreted from the transduced cell.  The elegance of 
this approach hinges on the fact that the newly synthesized neuropeptide will be 
packaged in vesicles and continuously released, independent of neuronal activity, 
essentially bypassing the traditional neuropeptide regulatory pathways. These studies 
showed that the fibronectin secretion signal sequence (FIB) did cause constitutive 
secretion of the gene product from transfected cells in vitro and, upon transduction in 
vivo, significantly attenuated focal seizure sensitivity and prevented seizure-induced 
hippocampal cell damage (Haberman, Samulski et al. 2003).  
In a subsequent publication, Lin et al. found that AAV mediated expression of a 
human galanin cDNA significantly decreased the number of kainic acid-induced seizure 
episodes, but this approach did not alter seizure latency or kainic acid-induced neuronal 
damage (Lin, Richichi et al. 2003).  McCown then used an AAV2 vector where 
expression was driven by the constitutively active CB promoter to deliver galanin to the 
piriform cortex in rats (McCown 2006).  The vector also contained the FIB sequence to 
mediate constitutive secretion of the expressed galanin.  This approach not only 
prevented electrographic seizures, as measured by electroencephalography (EEG), but 
also completely blocked seizure behavior, while delivery of green fluorescent protein 
(GFP) had no effect (McCown 2006).  Furthermore, in a kindling paradigm, vector-
derived galanin caused a significant increase in the amount of current necessary to elicit 
limbic seizures compared to GFP control (McCown 2006).  Taken together, these 
experiments suggest that the piriform cortex is directly involved in mediating the onset 
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and severity of kainic acid-induced seizure behaviors.  Thus, the piriform cortex is a good 
place to deliver and test potential therapeutic targets for anti-seizure efficacy.        
As previously discussed, there is evidence to suggest that NPY can exhibit anti-
seizure activity in vivo (Woldbye, Larsen et al. 1997; Mazarati and Wasterlain 2002; 
Vezzani, Michalkiewicz et al. 2002), by acting primarily through NPY Y1, Y2, and Y5  
G protein-coupled receptors in brain (Parker and Herzog 1999; Redrobe, Dumont et al. 
1999).  Each of these receptors has been reported to affect seizure genesis, but not via the 
same mechanism.  For example, in the dentate gyrus, activation of Y1 receptors results in 
increased neuronal excitation (seizure permissive) (Brooks, Kelly et al. 1987), while 
activation of Y2 (Colmers, Klapstein et al. 1991; El Bahh, Cao et al. 2002; Vezzani and 
Sperk 2004) and Y5 receptors (Woldbye, Larsen et al. 1997; Marsh, Baraban et al. 1999; 
Baraban 2002) mediate inhibitory and anti-convulsant actions.  In addition, it has been 
demonstrated that in epileptic tissue from patients (Furtinger, Pirker et al. 2001) and 
rodents (Kofler, Kirchmair et al. 1997; Schwarzer, Kofler et al. 1998) Y1 receptors are 
downregulated, whereas Y2 receptors are upregulated.  Even Y5 receptors are transiently 
upregulated following kindling and kainic acid-induced seizures (Kopp, Nanobashvili et 
al. 1999; Vezzani, Moneta et al. 2000).  Taken together, these results suggest that when 
designing anti-epileptic therapeutics, it may be advantageous to deliver Y2/Y5-preferring 
agonists.  In fact, acute intracerebral delivery of the Y2 receptor preferring agonist 
NPY13-36 reduces seizure susceptibility following systemic kainic acid administration 
(Vezzani, Moneta et al. 2000; Vezzani, Rizzi et al. 2000).  These data suggest NPY13-36 
would be a good candidate to use in a rAAV vector to treat epilepsy. By using the FIB 
secretion strategy, we have the capability of expressing and constitutively secreting 
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peptide fragments, which have demonstrated receptor selectivity. Thus, we infused 
AAV2 vectors that mediate expression and constitutive secretion of NPY or the peptide 
fragment NPY13-36 into the piriform cortex, and evaluated their ability to suppress 
kainic acid-induced limbic seizure behaviors (see Chapter 3).  
I.I. Combination Therapy 
 Delivering individual inhibitory neuropeptides to the brain to prevent seizures has 
been well studied (see above), but to date no one has tried to deliver multiple 
neuropeptides simultaneously from an AAV vector.  In the last 20 years, many different 
virus-based strategies were explored to co-express two genes from vectors: 1. internal 
promoters, 2. internal initiation (IRES), 3. self-processing peptides (CHYSEL), 4. fusion 
proteins, 5. proteolytic processing, and finally 6. a combination of separate vectors where 
each carries one transgene (see Figure 1-5).  Internal promoter vectors (sometimes 
referred to as bicistronic vectors) have two transcriptional units, each with its own open 
reading frame that results in the production of two proteins.  While these vectors are quite 
popular, problems arise because of the uncoupled transcription of both genes.  For 
example, it has been reported that transcriptional interference and promoter silencing can 
result in the transcription of only one gene (Hippenmeyer and Krivi 1991; Nakajima, 
Ikenaka et al. 1993; Zaboikin and Schuening 1998).   
Internal initiation vectors have two sites of translation initiation and two open 
reading frames on a single transcript.  The first open reading frame is cap-dependent, 
while translation of the second open reading frame depends upon an internal sequence 
called an internal ribosomal entry site (IRES).  The main concern with IRES vectors is 
the reduced expression of the gene downstream of the IRES (typically 20-50% less than   
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Figure 1-5. Strategies to Co-express Gene Products.  
A) Internal promoter vectors have two transcriptional units, each with its own open reading frame 
that results in the production of two proteins.  B) Internal initiation vectors have a single 
transcript with two open reading frames and two sites of translation.  The first open reading frame 
is cap-dependent, while translation of the second open reading frame depends upon an internal 
sequence called an internal ribosomal entry site (IRES).  C) Self-processing peptide or cis-acting 
hydrolase element (CHYSEL) vectors have a single transcriptional unit with a single open 
reading frame and one site of translation.  The CHYSEL sequence is inserted in frame between 
the two protein sequences, and upon translation, the CHYSEL produces a disruption in 
translation.  D) Proteolytic processing vectors also have a single transcriptional unit with a single 
open reading frame and one site of translation.  The proteolytic cleavage sequence is cloned in 
frame as a linker, and a chimeric fusion protein is generated that is capable of undergoing post-
translational cleavage in the presence of trans proteases.  E) Fusion protein vectors have a single 
transcriptional unit with a single open reading frame and one site of translation.  A single 
chimeric fused protein is generated.  (Arrows depict promoters, star depicts cleavage site)  
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the expression of the upstream gene) (Mizuguchi, Xu et al. 2000).  Perhaps the biggest 
drawback of both vector strategies discussed so far (internal promoters and IRES) is that 
they contain large DNA sequences (often >0.5kb), which compete with the transgene for 
a limited amount of space in an AAV vector (around 4.7kb).  
Self-processing peptide or cis-acting hydrolase element (CHYSEL) vectors have a 
single transcriptional unit and one site of translation with a single open reading frame.  
The CHYSEL sequence is inserted in frame between the two protein sequences, and upon 
translation, the CHYSEL produces a disruption in translation.  The ribosome then 
releases the first protein and continues to translate the second protein, resulting in the 
production of two proteins (Donnelly, Luke et al. 2001).  While it has been demonstrated 
that higher levels of the second protein are achieved when using CHYSEL in contrast to 
IRES (Furler, Paterna et al. 2001), a potential problem is that after processing, the 
CHYSEL sequence remains fused to the C-terminus of the upstream protein, and an extra 
proline residue will be added to the N-terminus of the second protein (de Felipe 2002).  
This extra sequence may interfere with protein bioactivity, especially with relatively 
small proteins such as neuropeptides that need to bind to receptors to initiate signaling.   
Fusion protein vectors are the simplest way to co-express two proteins using a 
single transcriptional unit and open reading frame.  However, because both proteins 
remain attached to each other, there may be a potential loss of function of one or both 
proteins, especially if trying to deliver neuropeptides where high affinity receptor binding 
is required to initiate signaling cascades.  In addition, since fusion proteins are not 
cleaved from one another, transport to different subcellular compartments is not feasible. 
Therefore, fusion protein strategies could not be used to deliver both secreted proteins 
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and intracellular or membrane bound proteins, further limiting the applicability of this 
approach.   
There are also major drawbacks with using a co-infection of two separate vectors 
where each carries one transgene.  Three populations of transduced neurons will result 
based on a Poisson distribution: some neurons will be transduced only by the first vector, 
some neurons will be transduced only by the second vector, and some neurons will be 
transduced by both.  This kind of transduction pattern can complicate the analysis of 
transgene interactions, because the observed therapeutic effects will not be attributable 
solely to the co-transduced neurons.  For these reasons we chose to pursue a proteolytic 
processing vector strategy where a fusion protein gene product is processed into separate 
bioactive proteins. This method will ensure that each transduced neuron expresses both 
gene products, and utilizes only a small amount of the AAV vector genome, since 
proteolytic cleavage consensus sequences can be as small as two amino acids (Seidah and 
Chretien 1999).  In addition, we can use this same strategy in the future to express more 
than two therapeutic peptides simultaneously, and to manipulate the ratios of expressed 
peptides by inserting multiple copies of the same peptide.  Furthermore, by using a single 
vector we can reduce viral particle number (and viral capsid proteins), which would 
likely increase clinical safety.  
 As mentioned above, neuropeptides are typically synthesized as large pro-proteins 
that upon being packaged into vesicles get cleaved into their mature form before 
secretion.  Furin is one such pro-protein convertase that is active in the constitutive 
secretory pathway, and cleaves pro-proteins like neurotrophins, hormones, receptors, 
plasma proteins, matrix metalloproteinases, viral envelope glycoproteins, and bacterial 
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endotoxins (Nakayama 1997).  Furin cleaves precursors into bioactive proteins by 
recognizing and cleaving strings of basic amino acids such as arginines and lysines.  In 
addition, furin is ubiquitously expressed in neurons and glia throughout the brain (Day, 
Schafer et al. 1993), making it an ideal pro-protein convertase to target with our 
constitutively secreted neuropeptides platform.   The furin pathway has already been used 
in a gene therapy context where a furin cleavage site was engineered into the rat 
preproinsulin-I gene, which was then packaged into a recombinant retroviral vector and 
delivered to the liver (Muzzin, Eisensmith et al. 1997).  It was shown that correctly 
processed and functional insulin could be secreted from the ectopic organ (Muzzin, 
Eisensmith et al. 1997).  In a subsequent study, Margaritis et al. used a furin cleavage 
consensus sequence in an AAV vector cassette between Factor VIIa subunits, then 
delivered the vector into the spleens of hemophiliac mice (Margaritis, Arruda et al. 2004).  
Phenotypic correction was achieved using this strategy (Margaritis, Arruda et al. 2004).   
While both of these studies demonstrate that engineering a furin cleavage 
consensus sequence into a transgene can be successful in a gene therapy context, only 
one functional protein was delivered.  In a study by Gaken et al., a furin cleavage 
consensus sequence was cloned in frame as a linker between two different proteins, 
yielding a chimeric protein that can be post-translationally cleaved (Gaken, Jiang et al. 
2000).  These constructs contained combinations of cytokines or a cytokine and a trans-
membrane protein.  They were packaged into retroviral constructs and used to infect 
several cell lines where furin cleavage efficiency was evaluated.  The authors reported 
around 50% cleavage efficiency (Gaken, Jiang et al. 2000).   
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Previous experiments suggest that it is possible to use a proteolytic strategy to 
deliver multiple peptides from AAV vectors, but to date no one has tried.  We are in a 
unique position to conduct these experiments and combine them with our constitutively 
secreted neuropeptides platform.  We expect improved cleavage efficiencies over 
previous attempts because we are using a FIB sequence that will direct our chimeric 
protein to the constitutive secretory pathway where furin is most active (Van de Ven, 
Creemers et al. 1991).  We first proved the concept that the therapeutic gene galanin and 
the reporter gene GFP could be correctly cleaved from one another and secreted into the 
medium of transfected cells in vitro.  Then, we evaluated the in vivo function of each 
protein by packaging the cleavable galanin-GFP gene into AAV2 vectors, and infusing 
them into the piriform cortex of rats that subsequently received injections of kainic acid 
(see Chapter 3).  We visualized the GFP protein expression in the piriform cortex 
confirming its function, and we evaluated the ability of vector-derived galanin to block 
the limbic seizure behaviors elicited by the kainic acid administration.  Finally, we 
replaced the reporter gene with NPY13-36 and evaluated the combined effects of vector-
derived galanin plus NPY13-36 on kainic acid-induced limbic seizures (see Chapter 3).
Chapter 2 
Methods 
 
II.A. rAAV Vectors: Cloning and Construction 
II.A.1.  Cloning Plasmids for rAAV-CB-FIB-NPY and rAAV-CB-FIB-NPY13-36  
 
The expression cassette backbone is the same for both NPY and NPY13-36 
plasmids, where gene expression is driven by the hybrid chicken beta-actin promoter, the 
mature coding sequence of the transgene is followed by the SV-40 polyadenylation 
sequence (polyA), and the cassette is flanked by AAV2 TRs.  The full length NPY active 
peptide sequence was amplified by RT-PCR from rat brain RNA using primers directed 
to the mature peptide sequence, such that melting and reannealing of two separate PCR 
products resulted in 5’ AgeI and 3’ NotI overhangs (Zeng 1998).  The 3’ primer included 
a stop codon to properly terminate translation.  The sequence of the primers used is as 
follows: (NPY 5’ long) CCG GTA ATG TAC CCC TCC AAG CCG; (NPY 5’ short) TA 
ATG TAC CCC TCC AAG CCG; (NPY 3’short) GC TCA ATA TCT CTG TCT GGT 
G; (NPY 3’ long) GGC CGC TCA ATA TCT CTG TCT GGT G. The PCR product was 
ligated into the AgeI-NotI sites of the AAV2 backbone plasmid, resulting in the plasmid 
pTR-CB-NPY.  Next, the fibronectin signal sequence (nucleotides 208–303) was derived 
from the rat fibronectin mRNA sequence (GenBank Accession No. X15906) and 
oligonucleotides corresponding to both strands were generated (Midland Certified 
Reagent Co.).  AgeI overhangs were included such that the annealed oligonucleotides 
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could be ligated in front of NPY, resulting in the plasmid pTR-CB-FIB-NPY.  For NPY 
13-36, the same cloning strategy was used, except the plasmid pTR-CB-FIB-NPY served 
as the PCR template and cloning backbone.  The primers used to generate NPY13-36 
were as follows: (NPY13-36 5’ long) 5’-CCG GTA ATG CCA GCA GAG GAC ATG-
3’, (NPY13-36 5’ short) 5’-TA ATG CCA GCA GAG GAC ATG GC-3’, (NPY13-36 3’ 
short) 5’-GC TCA ATA TCT CTG TCT GGT G-3’, (NPY13-36 3’ long) 5’-GGC CGC 
TCA ATA TCT CTG TCT GGT G-3’.  Again, the PCR product was ligated into the 
AgeI-NotI site of pTR-CB-FIB-NPY, replacing the “FIB-NPY”.  Then the annealed FIB 
oligonucleotides were ligated into the AgeI site resulting in the plasmid pTR-CB-FIB-
NPY13-36.  All plasmids were sequenced to verify accuracy.   
II.A.2.  Cloning Plasmids for Multiple Gene Product Delivery Vectors  
The plasmids pTR-CB-EGFP, pTR-CB-FIB-EGFP, and pTR-CB-FIB-GAL were 
generated as previously described (McCown 2006).  Briefly, gene expression is driven by 
the hybrid chicken beta-actin promoter, the mature coding sequence of the transgene is 
followed by the SV-40 polyA, and the cassette is flanked by AAV2 TRs.  The plasmid 
EGFP-N1 was purchased from BD-biosciences-clontech, and the GFP was digested out 
using AgeI-NotI restriction sites.  The fragment was gel purified and ligated into the 
AgeI-NotI sites of the AAV2 plasmid backbone, resulting in the plasmid pTR-CB-EGFP.  
Then the annealed FIB oligonucleotides were ligated into the AgeI site resulting in the 
plasmid pTR-CB-FIB-EGFP.  The galanin sequence was amplified by RT-PCR from rat 
brain RNA using primers directed to the mature peptide sequence, such that melting and 
reannealing of two separate PCR products resulted in 5’ AgeI and 3’ NotI overhangs 
(Zeng 1998).  The 3’ primer included a stop codon to properly terminate translation.  The 
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sequence of the primers used is as follows: (Gal 5’ long) 5’-CCG GTA ATG GGC TGG 
ACC CTG AAC-3’, (Gal 5’ short) 5’-TA ATG GGC TGG ACC CTG AAC-3’, (Gal 3’ 
short) 5’-GC TCA TGT GAG GCC ATG CTT G-3’, (Gal 3’ long) 5’-GGC CGC TCA 
TGT GAG GCC ATG CTT G-3’. The PCR product was ligated into the AgeI-NotI sites 
of the AAV2 plasmid backbone, resulting in the plasmid pTR-CB-GAL.  Then the 
annealed FIB oligonucleotides were ligated into the AgeI site resulting in the plasmid 
pTR-CB-FIB-GAL.  Using pTR-CB-FIB-GAL as a backbone, the other plasmids were 
generated by PCR so the furin cleavage consensus sequence arginine-lysine-arginine-
arginine-lysine-arginine (RKRRKR) was cloned in frame between two genes.  Briefly, 
two pairs of oligonucleotides were designed for each construct, such that a forward and 
reverse primer corresponded to each gene plus 3 of the six amino acids that make up the 
furin consensus sequence (see Table 2-1).  The oligonucleotides included the restriction 
sites NheI and NotI that would be used for cloning.  Two fragments each containing the 
gene of interest plus half of the furin consensus sequence were generated by PCR, then 
the products were digested with NheI and NotI, and ligated into the plasmid backbone 
using a sticky-blunt-sticky ligation.  All plasmids were sequenced to verify accuracy.   
II.A.3.  DNA Sequencing 
All DNA sequencing was performed by the UNC Lineberger Cancer Center DNA 
Sequencing Facility. Briefly, 10pmol of primer and 0.7μg of plasmid DNA were diluted 
in water to a final volume of 20μL.  Samples were further processed by the sequencing 
facility.  
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Table 2-1 PCR Primers for Multiple Gene Product Delivery Vectors 
Construct Name Primers Used Melting 
Temperature 
 
TR-CB-FIB-GAL-
RKRRKR-EGFP 
F1= GTACGGAAGTGTTACTTCTGCTC   
R1= 5’PTCTCTTTCTTGTGAGGCCATGCTT  
F2= 5’PAGAAAGAGAATGGTGAGCAAGGGCGAGGAGC 
R2= CTTATCATGTCTGGATCCCCGCGGCC 
55.0°C 
56.0°C 
66.0°C 
64.0°C 
TR-CB-FIB-EGFP-
RKRRKR-GAL 
F1= GTACGGAAGTGTTACTTCTGCTC 
R1= 5’PTCTCTTTCTCTTGTACAGCTCGTC 
F2= 5’PAGAAAGAGAGGCTGGACCTGAACAGCG 
R2= CTTATCATGTCTGGATCCCCGCGGCC 
55.0°C 
56.0°C 
64.0°C 
64.0°C 
TR-CB-FIB-GAL-
EGFP 
F1= GTACGGAAGTGTTACTTCTGCTC 
R1= 5’PTGTGAGGCCATGCTTGTCGCT 
F2= 5’PATGGTGAGCAAGGGCGAGGAGCTG 
R2= CTTATCATGTCTGGATCCCCGCGGCC 
55.0°C 
56.0°C 
63.0°C 
64.0°C 
TR-CB-FIB-GAL-
RKRRKR-NPY13-36 
F1= GTACGGAAGTGTTACTTCTGCTC 
R1= 5’PTCTCTTTCTTGTGAGGCCATGCTT   
F2= 5’P AGAAAGAGACCAGCAGAGGACATGGCC 
R2= CTTATCATGTCTGGATCCCCGCGGCC 
55.0°C 
56.0°C 
63.0°C 
64.0°C 
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II.B. In Vitro Methods 
II.B.1.  Cell Culture and Transfection 
293 cells were cells were maintained at 37°C in a 5% CO2 atmosphere in 
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine 
serum (FBS) and penicillin-streptomycin (PS).  Cells were plated at a density of 5.5x105 
cells per mL medium in 60mm dishes the day prior to transfection.  Cells were 
transfected using the polyethyleneimine (PEI) technique (Grieger, Choi et al. 2006).  
Forty-eight hours after transfection, cells were imaged then medium and lysates were 
harvested.  Briefly, medium was cleared by centrifugation at 2500 RPM at 4°C for 5 
minutes to remove any cellular debris.  Cells were scraped and rinsed with 2mL 
Dulbecco phosphate buffered saline (DPBS) then lysed using 1mL lysis buffer (50mM 
Tris pH8.0, 150mM NaCl, 50mM NaF, 1% NP-40) per 60mm plate.  Lysates were 
cleared by spinning in centrifuge at maximum speed at 4°C for 5 minutes, supernatant 
was transferred to a clean tube.   
II.B.2  Immunoprecipitation and Western Blotting  
Immunoprecipitation of GFP was performed on cleared medium and lysates.  
Briefly, medium and lysates were pre-incubated with 20μL Protein A Sepharose beads 
(Amersham Biosciences) and rocked for 1 hour at 4°C to remove non-specific binding.  
Supernatant was transferred to a clean tube.  For medium 50μL Protein A beads and 
10μL Living Colors Full-Length A.V. Polyclonal Antibody (BD) was added.  For lysates 
25μL Protein A beads and 5μL Living Colors Full-Length A.V. Polyclonal Antibody 
(BD) was added.  Samples were incubated overnight on a rocker at.  Supernatant was 
removed by vacuum and beads were washed 3 times using 1mL DPBS.  Load dye was 
added to beads along with water and betamercaptoethanol, then samples were boiled 5 
minutes and cooled to room temperature before loading on 10% Bis-Tris gel (NuPage) 
Samples were transferred by western blot to a nitrocellulose membrane and blocked using 
10% nonfat milk in tris buffered saline + 0.1% Tween (TBST).  Blot was incubated at 
4°C overnight in 1:1000 dilution of primary antibody Living Colors A.V. Monoclonal 
antibody JL-8 (BD).  Blot was rinsed 3 times 5 minutes in TBST then incubated in a 
1:3000 dilution of goat-anti-mouse HRP (Pierce)  Signal was detected using the West 
femto-chemiluminescence kit (Pierce) according to the manufacturer’s instructions. 
II.C. rAAV Production, Purification, and Characterization 
Recombinant AAV2 was produced and purified as previously described 
(Rabinowitz, Rolling et al. 2002) with the following modifications: 293 cells (10 15cm 
plates/prep)were transfected with 60μg transgene plasmid, 120μg XX-680, and 100μg 
PXR2 via the polyethyleneimine (PEI) technique.  Nuclei were isolated and lysed using 
sonication.  AAV particles were purified by cesium chloride density gradient.  Peak 
fractions were determined via dot blot hybridization, and extensively dialyzed against 
DPBS + 10% (wt/vol) D-sorbitol.  Final titer was determined by dot blot hybridization 
(modified southern blot) using a probe against the CB promoter sequence so all viruses 
could be titered on the same blot (see Figures 2-1 through 2-3) Infectious center assays 
(ICA) were performed using C12 cells (293 cells with Rep stably integrated) as 
previously described (Grieger, Choi et al. 2006) (see Figures 2-4 through 2-7).  AAV 
particles were analyzed to determine purity and ratio of empty to full particles by staining 
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Figure 2-1. Dot Blot, Standard Curve, and Titer Calculations for AAV2-CB-FIB-NPY and 
AAV2-CB-FIB-NPY13-36.  The top panel shows three dilutions (across) of the viruses 
performed in duplicate (down).  Dilutions of known amounts (nanograms) of one of the plasmids 
used to make the rAAV vectors were included (pTR-CB-FIB-NPY).  Upon hybridization with a 
radiolabeled probe that was complementary to a fragment of the CB promoter, a standard curve 
was generated (middle panel).  Then a linear regression analysis was done, and the derived 
equation (displayed in the upper left corner of the standard curve graph) was used to calculate the 
number of rAAV particles present in each dilution (bottom panel), then the average particles 
present per mL. 
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Figure 2-2. Dot Blot, Standard Curve, and Titer Calculations for AAV2-CB-FIB-GAL-RKRRKR-
FIB-EGFP, AAV2-CB-FIB-EGFP, and AAV2-CB-EGFP.  The left panel shows three dilutions (across) 
of the viruses performed in duplicate (down).  Dilutions of known amounts (nanograms) of one of the 
plasmids used to make the rAAV vectors were included (pTR-CB-FIB-GAL-RKRRKR-FIB-EGFP).  Upon 
hybridization with a radiolabeled probe that was complementary to a fragment of the CB promoter, a 
standard curve was generated (bottom panel).  Then a linear regression analysis was done, and the derived 
equation (displayed in the upper left corner of the standard curve graph) was used to calculate the number 
of rAAV particles present in each dilution (right panel), then the average particles present per mL.
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Figure 2-3. Dot Blot, Standard Curve, and Titer Calculations for Multiple Gene Product Delivery 
Vectors.  The left panel shows three dilutions (across) of the viruses performed in duplicate (down).  The 
virus order is as follows 1) upper left, AAV2-CB-FIB-GAL-RKRRKR-EGFP, 2) upper right, AAV2-CB-
FIB-EGFP-RKRRKR-GAL, 3) lower left, AAV2-CB-FIB-GAL-EGFP, and 4) lower right, AAV2-CB-
FIB-GAL-RKRRKR-NPY13-36.  Dilutions of known amounts (nanograms) of one of the plasmids used to 
make the rAAV vectors were included (pTR-CB-FIB-GAL-EGFP).  Upon hybridization with a 
radiolabeled probe that was complementary to a fragment of the CB promoter, a standard curve was 
generated (bottom panel).  Then a linear regression analysis was done, and the derived equation (displayed 
in the upper left corner of the standard curve graph) was used to calculate the number of rAAV particles 
present in each dilution (right panel), then the average particles present per mL. 
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Figure 2-4. Infectious Center Assay of AAV2-CB-FIB-GAL-RKRRKR-EGFP. 
A) 500 particles, B) 1000 particles, and C) 5000 particles of AAV2-CB-FIB-GAL-
RKRRKR-EGFP were co-infected with Ad in C12 cells, blotted on a membrane, and 
hybridized with radiolabeled probe that was complementary to a fragment of the CB 
promoter to determine the number of infectious units per mL (IU/mL).  This virus is 
3.6x109 IU/mL.   
AAV2-CB-FIB-GAL-RKRRKR-EGFP
A
B
C
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Figure 2-5. Infectious Center Assay of AAV2-CB-FIB-EGFP-RKRRKR-GAL. 
A) 500 particles, B) 1000 particles, and C) 5000 particles of AAV2-CB-FIB-EGFP-
RKRRKR-GAL were co-infected with Ad in C12 cells, blotted on a membrane, and 
hybridized with radiolabeled probe that was complementary to a fragment of the CB 
promoter to determine the IU/mL.  This virus is 1.0x109 IU/mL.   
AAV2-CB-FIB-EGFP-RKRRKR-GAL
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Figure 2-6. Infectious Center Assay of AAV2-CB-FIB-GAL-EGFP. 
A) 500 particles, B) 1000 particles, and C) 5000 particles of AAV2-CB-FIB-GAL-EGFP 
were co-infected with Ad in C12 cells, blotted on a membrane, and hybridized with 
radiolabeled probe that was complementary to a fragment of the CB promoter to 
determine the IU/mL.  This virus is 2.0x109 IU/mL.   
AAV2-CB-FIB-GAL-EGFP
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Figure 2-7. Infectious Center Assay of AAV2-CB-FIB-GAL-RKRRKR-NPY13-36.  
A) 500 particles, B) 1000 particles, and C) 5000 particles of AAV2-CB-FIB-GAL-
RKRRKR-NPY13-36 were co-infected with Ad in C12 cells, blotted on a membrane, and 
hybridized with radiolabeled probe that was complementary to a fragment of the CB 
promoter to determine the IU/mL.  This virus is 9.0x109 IU/mL.   
AAV2-CB-FIB-GAL-RKRRKR-NPY13-36
A B C
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with 1%  aqueous uranyl acetate and visualizing with transmission electron microscopy 
(LEO-EM910, accelerating voltage = 80 KV). 
II.D. In Vivo Methods  
II.D.1.  Experimental Animals  
All of the animals were pathogen-free male Sprague–Dawley rats obtained from 
Charles Rivers.  The animals were maintained in a 12 hour light–dark cycle and had free 
access to food and water. All care and procedures were in accordance with the Guide for 
the Care and Use of Laboratory Animals (DHHS Publication No. [NIH]85-23), and all 
procedures received prior approval by the University of North Carolina Institutional 
Animal Care and Usage Committee. 
II.D.2.  rAAV Vector Microinjection 
 For AAV infusions, rats were first were anesthetized with 50 milligrams per 
kilogram, intraperitoneal (mg/kg, ip) pentobarbital and placed into a stereotaxic frame.  
Using a 32 gauge stainless steel injector and a Sage infusion pump, the rats received 2 or 
3µL of virus (depending on virus titer) over 20 minutes into the piriform cortex (inter-
aural line (IAL) 6.7 millimeters (mm), lateral 6.0mm, vertical 8.4mm, according to the 
atlas of Paxinos and Watson, 1998) (see Figure 2-8).  The injector was left in place for 3 
minutes post-infusion to allow diffusion from the injectors.  In all cases, the incisions 
were sutured, and the animals were allowed to recover for a minimum of 7 days.   
45 
 
Figure 2-8. Coronal Section of the Rat Brain Depicting the Location of Vector 
Microinjection.  rAAV2 vector is stereotaxically injected bilaterally into the piriform 
cortex, denoted by arrows.  The coordinates are inter-aural line (IAL) 6.7 millimeters 
(mm), lateral 6.0mm, vertical 8.4mm, according to the atlas of Paxinos and Watson 
(1998).    
 
Interaural 6.70 mm Bregma -2.30 mm
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II.D.3.  In Vivo Detection of AAV-Derived NPY or NPY 13-36 
As previously described (Haberman, Samulski et al. 2003; Foti, Haberman et al. 
2007) the vector-derived NPY  could not be visualized in vivo by immunohistochemistry, 
likely due to the fact that the secreted NPY or NPY 13-36 would be rapidly degraded, 
especially during the perfusion procedure. Thus, in vivo activity of the vectors AAV-FIB-
NPY or NPY 13-36 was validated by demonstrating the presence of vector-derived 
mRNA. Two rats received AAV-FIB-NPY and two received AAV-FIB-NPY 13-36 
vector infusions into the piriform cortex as described above. Then, 1 week later, the 
animals received an overdose of pentobarbital (100mg/kg, ip) and were subsequently 
decapitated. The brain was removed, and the piriform cortex was dissected out.  The 
tissue was stored in RNAlater (Ambion, Austin, TX, USA) at -80°C. Subsequently, the 
RNA was extracted from the tissue (Promega SV-40 total RNA isolation kit; Madison, 
WI, USA) and reverse transcribed using AMV reverse transcriptase and oligo(dT) 
primers. The subsequent PCR used primers that were designed to span the FIB-NPY (and 
thus the FIB-NPY 13-36) sequence, which can only be derived from the rAAV vector: 
(FIB, 5’) 5’-CTA GCA GTC CTG TGC CTG-3’, (NPY and NPY13-36, 3’) 5’ –GCT 
CAA TAT CTC TGT CTG GTG-3’. 
 For the multiple gene product delivery vector AAV-CB-FIB-GAL-RKRRKR-
NPY13-36, the same procedure and primers were used with the following modifications: 
all seven animals receiving vector infusions in the piriform cortex were sacrificed 
immediately after the behavior data was collected from the kainic acid treatment 
(described in II.D.5.), and all animals were processed for vector-derived mRNA.       
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II.D.4.  In Vivo Detection of AAV-Derived GFP 
Although the GFP is likely being secreted in these animals, it is very stable with a 
fairly long half-life (around 80 hours (Kamau, Grimm et al. 2001).  This allows us to 
visualize the pattern of AAV transduction via GFP immunohistochemistry.  Ten days 
after piriform cortical infusion of AAV vectors containing GFP, the animals received an 
overdose of pentobarbital (100mg/kg, ip) and subsequently were perfused transcardially 
with ice-cold 100mM sodium phosphate-buffered saline (PBS) (pH 7.4), followed by 4% 
paraformaldehyde in 100mM phosphate buffer (pH 7.4). After overnight fixation in the 
paraformaldehyde–phosphate buffer, Vibratome sections (40μm thick) were taken and 
rinsed in PBS. The sections were mounted and GFP fluorescence was visualized on a 
Zeiss 510 confocal microscope.  
II.D.5.  Kainic Acid Treatment  
Seven days after piriform cortical infusion of the AAV vectors, the animals 
received a 10mg/kg ip dose of kainic acid (Cayman Chemical Co., Ann Arbor, MI, 
USA). Using the limbic seizure scale of Racine (Racine 1972), the latency was recorded 
to class I, II, III, IV, and V limbic seizure behaviors. Four hours after kainic acid 
treatment, the animals received an overdose of pentobarbital (100mg/kg, ip) and 
subsequently were perfused transcardially with ice-cold 100mM sodium phosphate-
buffered saline (PBS) (pH 7.4), followed by 4% paraformaldehyde in 100mM phosphate 
buffer (pH 7.4). After overnight fixation in the paraformaldehyde–phosphate buffer, 
Vibratome sections (40μm thick) were taken and rinsed in PBS. The sections were 
mounted and the infusion placement was determined.   
Chapter 3 
Results
 
III.A. rAAV-mediated Expression and Constitutive Secretion of NPY or NPY13-36 
Suppresses Seizure Activity In Vivo 
A gene therapy approach to suppress seizures is an attractive treatment for focal 
epilepsy.  Although previous studies validated the effectiveness of gene expression and 
constitutive secretion using galanin (McCown 2006), the same approach might not 
necessarily prove successful with NPY or the peptide fragment NPY13-36.  Therefore, 
we used a similar approach with the following modifications: AAV2 vectors were 
constructed where the hybrid chicken beta actin promoter drives expression of the FIB-
NPY or FIB-NPY13-36 coding sequences (see Figure 3-1).  Then, 2µL of recombinant 
AAV-FIB-NPY (3.3 X 1012 viral particles/mL) or AAV-FIB-NPY13-36 (3.0 X 1012 viral 
particles/mL) was infused bilaterally into the piriform cortex of rats, as previously 
described (McCown 2006).  Control rats received no infusion, as we have previously 
shown that vectors expressing and secreting reporter genes like GFP (AAV-FIB-EGFP), 
as well as vectors expressing peptides that lack secretion sequences (AAV-GAL) have no 
effect on seizure sensitivity, seizure behaviors, or seizure-induced cell death (Haberman, 
Samulski et al. 2003; McCown 2006).  One week later, the rats received a dose of 
10mg/kg, i.p. kainic acid to induce seizures.  We then recorded the time required to 
initiate limbic seizure behaviors. 
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Figure 3-1. AAV Vectors that Express and Constitutively Secrete NPY or NPY13-36  
AAV2 vectors were constructed where the hybrid chicken beta actin promoter (CB) 
drives expression of the FIB-NPY or FIB-NPY13-36 coding sequences. 
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Figure 3-2. The Effects of AAV-FIB-NPY and AAV-FIB-NPY13-36 Vectors on the 
Expression of Limbic Seizure Behaviors.  The latencies to wet dog shakes and limbic 
seizure behaviors were determined for 240 min post-kainic acid.  The numbers in the 
columns indicate the number of rats in each group that exhibited any seizure activity, 
compared to the total number of rats in that treatment group.     
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 As seen in Figure 3-2, both AAV treatment groups and the untreated control 
group developed wet dog shake behaviors with the same latency.Because the origin of 
wet dog shakes appears to be the hippocampus (Frush and McNamara 1986), a local 
action of the AAV-FIB-NPY or AAV-FIB-NPY13-36 in the piriform cortex would not be 
expected to influence these kainic acid-induced behaviors.  However, the findings do 
validate the uniformity of kainic acid administration across the different groups.  In 
marked contrast, however, onset of class III and class IV seizures was significantly 
delayed or completely blocked in rats receiving either AAV-FIB-NPY or AAV-FIB-
NPY13-36 compared to control (*t-test; P<0.01).  In fact, the majority of rats in both 
vector treated groups did not exhibit any seizure behavior at all, whereas all rats in the 
untreated group develop class III and class IV seizures within 90 minutes (see Figure 3-
2).  Thus, like findings with expression and secretion of galanin, NPY actions in the 
piriform cortex significantly attenuated seizure activity induced by the peripheral 
administration of the chemical convulsant kainic acid.  As previously discussed, the 
constitutive secretion of these peptides renders immunohistochemical identification 
untenable (Haberman, Samulski et al. 2003), but as previously shown for galanin 
(Haberman, Samulski et al. 2003; McCown 2006), the appropriate vector-derived NPY or 
NPY13-36 mRNA was present in the area of AAV infusion (see Figure 3-3).  Presence of 
vector derived mRNA supports the finding that over-expression of NPY or NPY13-36 in 
the piriform cortex is responsible for the preventing of seizure behavior.     
 
III.B. A Strategic Approach for Delivering Multiple Gene Products in the Brain 
Using a Single AAV Vector  
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Figure 3-3. The In Vivo Presence of FIB-NPY and FIB-NPY13-36 mRNA 1 Week 
after Vector Infusion into the Piriform Cortex.  The appropriate 208bp FIB-NPY (lane 
A) or 172bp FIB-NPY13-36 (lane C) product is present in the injected piriform cortex, 
while no product was found in an area slightly distal to the piriform cortex (lane B). 
Omission of the reverse transcriptase step (lanes D and E) indicated the absence of 
contaminating viral DNA. The left outside lane contains a 100bp DNA ladder with 
relevant sizes indicated on the left. 
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III.B.1.  In Vitro Characterization of Dual Reporter Gene Product Delivery Vectors 
Vectors delivering individual inhibitory neuropeptides to the brain to prevent 
seizures has been well studied (Mazarati and Wasterlain 2002; Haberman, Samulski et al. 
2003; Richichi, Lin et al. 2004; McCown 2006; Foti, Haberman et al. 2007), but to date 
no one has reported the simultaneous delivery of multiple neuropeptides.  To achieve 
this, we used a proteolytic strategy such that our plasmids contained a single 
promoterdriving expression of a single chimeric fusion protein containing the FIB 
secretion sequence.  Upon being sorted into the constitutive secretion pathway, the fusion 
protein should come in contact with the protease furin, and it then should be cleaved into 
two separate functional proteins which are then constitutively secreted from the cells.  
Using a strategy similar to Margaritis et al., (2004) we engineered our plasmids to 
contain a cleavage site for the intracellular protease, furin.  The cleavage consensus 
sequence arginine-lysine-arginine-arginine-lysine-arginine (RKRRKR) was cloned in 
frame as a linker between the coding sequences for the two gene products being 
delivered.      
 As a first proof of concept for the multiple gene product delivery vectors, we used 
the two reporter genes luciferase and GFP.  Since both gene products are reporter genes 
which typically do not undergo secretion from cells, we hypothesized that each gene 
would need a secretion sequence in order for the protein to be correctly trafficked within 
the cell.  Thus, we made constructs that contained either one FIB sequence (in front of the 
first gene luciferase) or two FIB sequences.  The constructs generated and characterized 
by in vitro protein assays were: CB-LUC, CB-FIB-LUC, CB-FIB-LUC-RKRRKR-
EGFP, and CB-FIB-LUC-RKRRKR-FIB-EGFP (see Figure 3-4).  In order to determine  
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Figure 3-4. AAV Vectors Characterized in Initial Multiple Gene Product Delivery 
Studies.  (A) CB-LUC is a negative control used in luciferase assays and 
immunoprecipitation then western blot (IP/WB) experiments to show that luciferase is 
expressed but not secreted in the absence of a FIB sequence. (B) CB-FIB-LUC is a 
positive control used in luciferase assays and IP/WB experiments for secretion of 
luciferase into the medium.  (C,D) CB-FIB-LUC-RKRRKR-EGFP and CB-FIB-LUC-
RKRRKR-FIB-EGFP are analyzed by IP/WB to determine if the two gene products are 
made as a fusion protein in the cell then cleaved from one another, and to examine if a 
single FIB sequence is sufficient for secretion of both gene products into the medium, or 
would two be necessary.   
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if the luciferase was secreted into the medium, we harvested medium and lysates and 
performed luciferase assays in the presence of luciferin substrate (see Figure 3-5).  To our 
surprise, luciferase activity was present in the medium of the non-secreted luciferase 
construct (CB-LUC), but is probably due to residual cell lysis and spilling out of the 
expressed transgene.  In addition, the absence of luciferase activity in the medium of the 
secreted constructs (CB-FIB-LUC, and CB-FIB-LUC-RKRRKR-EGFP) suggests either 
that the FIB sequence is interfering with the luminescence catalytic domain, or the 
luciferase protein is not being expressed.  Immunoprecipitation followed by Western 
blotting (IP/WB) was performed using antibodies to luciferase and GFP to distinguish 
between these possibilities (see Figures 3-6 and 3-7).  The luciferase IP/WB revealed that 
although there was a complete absence of secretion of luciferase protein into the medium 
(Figure 3-6, lanes 2-5), luciferase protein was detected in the all of the cell lysates 
(Figure 3-6, lanes 7-10).  Thus, luciferase expression is occurring, but that enzymatic 
function is abolished when the FIB sequence is included (see Figure 3-5, CB-FIB-LUC).  
In addition, the luciferase IP/WB reveals that the fusion protein of luciferase and GFP is 
being made in the cells (Figure 3-6, lanes 9-10) even though correctly processed 
luciferase is not seen in the lysates or the medium.  These results suggest that neither 
furin-mediated cleavage nor FIB-mediated secretion are occurring, and are in contrast to 
the data obtained with the GFP IP/WB (Figure 3-7).   
The GFP IP/WB revealed that some processing of the proteins was occurring, and 
that cleaved GFP was secreted into the medium in of CB-FIB-LUC-RKRRKR-FIB-
EGFP transfected cells.  CB-FIB-LUC-RKRRKR-EGFP and CB-FIB-LUC-RKRRKR-
FIB-EGFP suggest that two FIB sequences are necessary in order for cleaved GFP to be
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Figure 3-5. Luciferase Assay on Concentrated Medium. 
293 cells were transfected with the constructs listed above.  The medium was harvested 
48 hours later, and centrifuged in a concentrating column with a molecular weight cut off 
membrane of 10kDa.  Since firefly luciferase is around 61kDa it will be retained in the 
supernatant, while salts and smaller proteins flow through.  5mL samples were 
concentrated into 1mL, then 20μL of each sample was mixed with 100μL of luciferin 
solution in a 96 well plate and read in the luminometer.  Presence of luciferase activity in 
the medium of the non-secreted luciferase construct (CB-LUC) is probably due to 
residual cell lysis and spilling out of the expressed transgene.  Absence of luciferase 
activity with the secreted constructs (CB-FIB-LUC, and CB-FIB-LUC-RKRRKR-EGFP) 
suggests either that the FIB sequence is interfering with the luminescence catalytic 
domain, or that luciferase protein is not being expressed.   IP/WB was performed to 
distinguish between these possibilities, and to examine protein processing and trafficking.   
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Figure 3-6. Luciferase Antibody Protein Analysis of Luciferase-GFP Multiple Gene 
Product Delivery Constructs.  IP/WB using the same anti-luciferase polyclonal 
antibody to pull down and blot samples, hence the heavy and light chain antibody bands 
are visible at around 50kDa and 25kDa respectively.  Luciferase is around 61kDa and 
GFP is around 30kDa.  1 is rainbow marker, 2 is CB-LUC, 3 is CB-FIB-LUC, 4 is CB-
FIB-LUC-RKRRKR-EGFP, 5 is CB-FIB-LUC-RKRRKR-FIB-EGFP, 6 is untransfected 
control, 7 is CB-LUC, 8 is CB-FIB-LUC, 9 is CB-FIB-LUC-RKRRKR-EGFP, 10 is CB-
FIB-LUC-RKRRKR-FIB-EGFP.  No luciferase is present in the medium following 
transfection (lanes 2-6), however, luciferase is detected in all of the cell lysates (lanes 7-
10).  In addition, lanes 9 and 10 show that luciferase-GFP fusion protein is being made in 
the cells (98kDa), even though processed luciferase (61kDa) is not seen in the lysates or 
the medium.   
Medium 2-6             Lysates 7-10
Luciferase Antibody 
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Figure 3-7. GFP Antibody Protein Analysis of Luciferase-GFP Multiple Gene 
Product Delivery Constructs.  IP/WB using an anti-GFP polyclonal antibody to pull 
down and an anti-GFP monoclonal antibody to blot.  1 is CB-FIB-LUC-RKRRKR-
EGFP, 2 is CB-FIB-LUC-RKRRKR-FIB-EGFP, 3 is CB-FIB-EGFP, 4 is CB-FIB-LUC, 
5 is CB-FIB- LUC-RKRRKR-EGFP, 6 is CB-FIB-LUC-RKRRKR-FIB-EGFP, 7 is CB-
FIB-EGFP, 8 is CB-FIB-LUC, 9 is untransfected control.  CB-FIB-LUC-RKRRKR-
EGFP and CB-FIB-LUC-RKRRKR-FIB-EGFP (lanes 1-2) suggest that two FIB 
sequences are necessary in order for cleaved GFP to be secreted into the medium because 
it is absent in lane 1 but present in lane 2.  CB-FIB-EGFP (lane 3, 7) is a positive control 
showing GFP is secreted into the medium when FIB is present and is found within the 
cells.  CB-FIB-LUC (lanes 4, 8) is a negative control demonstrating that the GFP 
antibody does not cross-react with luciferase.  Lanes 5 and 6 show that luciferase-GFP 
fusion protein is made (98kDa), but the multiple bands suggest that it is also being 
degraded within the cells.  Fragments of luciferase-GFP fusion protein may not show up 
when probing with a luciferase antibody because the luciferase antibody may loose its 
binding capacity, however, this would not affect GFP antibody binding.  
Medium 1-4                   Lysates 5-9
GFP Antibody 
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secreted into the medium because GFP was absent in medium of CB-FIB-LUC-
RKRRKR-EGFP transfected cells, but present in the medium of CB-FIB-LUC-
RKRRKR-FIB-EGFP transfected cells (Figure 3-7, lanes 1-2).  However, multiple bands 
in the lysates for these constructs show that luciferase-GFP fusion protein is made and 
then degraded within the cells (Figure 3-7, lanes 5-6).  Fragments of luciferase-GFP 
fusion protein may not show up when probing with a luciferase antibody because the 
luciferase antibody may loose its binding capacity, however, this would not affect GFP 
antibody binding.  Taken together, we determined that luciferase would not be functional 
in these vectors because the protein was expressed but then degraded in the cells, thus it 
was not secreted.  Therefore we decided to retain the proteolytic vector strategy, but 
instead of luciferase, we would use the neuropeptide galanin along with GFP.      
III.B.2.  In Vitro Characterization of Double FIB Multiple Gene Product Delivery 
Vectors 
Because the initial luciferase data suggested that each gene would need its own 
FIB sequence, we made the following additional constructs: CB-FIB-GAL-RKRRKR-
FIB-EGFP and CB-FIB-EGFP-RKRRKR-FIB-GAL (see Figure 3-8).  These constructs 
were first characterized at the protein level in vitro (see Figures 3-9).  Due to the 
extremely rapid degradation of galanin in serum (Holst, Bersani et al. 1993), GFP 
secretion was assayed.  Constructs were made containing GFP and galanin in both 
possible orientations, assuring that GFP was correctly processed and cleaved from 
galanin whether it was 5’ or 3’ of the cleavage site.  The IP/WB revealed that while the 
construct CB-FIB-GAL-RKRRKR-FIB-EGFP resulted in secretion of cleaved GFP into 
the medium, the construct CB-FIB-EGFP-RKRRKR-FIB-GAL was not processed  
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Figure 3-8. Double FIB Multiple Gene Product Delivery Vectors. 
(A) CB-EGFP is a negative control used in IP/WB experiments to show that GFP is 
expressed but not secreted in the absence of a FIB sequence. (B) CB-FIB-EGFP is a 
positive control used in IP/WB experiments for secretion of GFP into the medium.  (C) 
CB-FIB-GAL-RKRRKR-FIB-EGFP and (D) CB-FIB-EGFP-RKRRKR-FIB-GAL are 
constructs designed to test cleavage and secretion of both gene products in IP/WB 
experiments in vitro, and to test the function of both gene products in vivo.       
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Figure 3-9. In Vitro Protein Analysis of Double FIB Multiple Gene Product Delivery 
Constructs.  The following constructs were transfected into 293 cells using PEI 
1mg/mL: 1) CB-FIB-EGFP; 2) CB-FIB-GAL-RKRRKR-FIB-EGFP; 3) CB-FIB-EGFP-
RKRRKR-FIB-GAL.  After 48 hours the lysate and medium were harvested and IP/WB 
was performed using an anti-GFP polyclonal antibody to pull down and an anti-GFP 
monoclonal antibody to blot.  Lane 1 shows GFP is present in the lysate and is also 
present in the medium.  Lane 2 shows that GFP is present in the lysate and is also in the 
medium.  Note that it appears to be the same size as lane 1 suggesting it has been cleaved 
from galanin.  Lane 3 shows that the GFP is not being processed correctly intracellularly, 
and intermediate products are present in the lysate.  While these intermediates do not 
seem to be secreted, the amount of correctly processed and secreted protein is reduced.  
Consequently, we did not use this construct for in vivo experiments.    
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correctly within the cells (see Figure 3-8).  Thus, we only made virus with CB-FIB-GAL-
RKRRKR-FIB-EGFP, CB-FIB-EGFP and CB-EGFP.   
III.B.3.  In Vivo Characterization of Double FIB Multiple Gene Delivery Vectors  
These viruses were titered by dot blot (see Figure 2-2) and injected into the rat 
piriform cortex to analyze the in vivo fluorescence patterns (see Figure 3-10).  The in vivo 
fluorescence patterns were similar to that of Haberman et al. (2003), such that when the 
FIB sequence was present, GFP was localized to the periphery of the neurons, which is 
highly suggestive of GFP secretion.  However, when the FIB sequence was absent, the 
neurons were uniformly fluorescent, suggesting cytoplasmic localization of GFP.  Upon 
determining that the GFP was functional, we decided to evaluate the function of galanin 
from the AAV2-CB-FIB-GAL-RKRRKR-FIB-EGFP construct in vivo.  In order for 
galanin to be functional it must not only be expressed, but also secreted, because the 
receptors for galanin are located on the exterior cell membrane.  Thus, if infusion of this 
construct into the piriform cortex is able to attenuate limbic seizure behavior following 
i.p. kainic acid administration, then functional galanin must have been secreted from the 
transduced cells.  As seen in Figure 3-11, infusion of AAV2-CB-FIB-GAL-RKRRKR-
FIB-EGFP significantly attenuated limbic seizures, and completely blocked seizure 
behavior in 3 of 4 animals.  While these experiments provided us with an initial proof of 
concept, we did not conduct any further experiments with AAV2-CB-FIB-GAL-
RKRRKR-FIB-EGFP, because the reciprocal construct CB-FIB-EGFP-RKRRKR-FIB-
GAL was not processed correctly within the cells.  This led us to hypothesize that having 
multiple FIB sequences may create sequence-dependent protein sorting and trafficking  
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Figure 3-10. In Vivo Fluorescence Pattern in Rat Cortex after Infusion of AAV2-
CB-FIB-GAL-RKRRKR-FIB-EGFP, AAV2-CB-FIB-EGFP, or AAV2-CB-EGFP.  
(A) AAV2-CB-FIB-GAL-RKRRKR-FIB-EGFP, (B) AAV2-CB-FIB-EGFP, (C) AAV2-
CB-EGFP.  (A, B) In vivo GFP patterns are highly suggestive of GFP secretion following 
infusion of AAV-CB-FIB-GAL-RKRRKR-FIB-EGFP and CB-FIB-GFP because there is 
a subcellular localization of GFP to the perimeter of neurons.  (C) Uniform fluorescence 
suggests cytoplasmic accumulation of GFP but not secretion after infusion of AAV-CB-
EGFP.  Each image was obtained with a confocal microscope using a 1.4μm thick slice 
through the middle of the cell.    
64 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11. The Effects of AAV2-CB-FIB-GAL-RKRRKR-FIB-EGFP on the 
Expression of Limbic Seizure Behaviors.  The latencies to wet dog shakes and limbic 
seizure behaviors were determined for 240 min post-kainic acid.  The numbers in the 
columns indicate the number of rats in each group that exhibited any seizure activity, 
compared to the total number of rats in that treatment group.  Infusion of AAV-CB-FIB-
GAL-RKRRKR-FIB-EGFP in the piriform cortex completely blocks limbic seizure 
behavior in 3 of 4 animals following i.p. kainic acid administration.  Control rats received 
no infusion, as we have previously shown that vectors expressing and secreting reporter 
genes like GFP (AAV-FIB-EGFP), as well as vectors expressing peptides that lack 
secretion sequences (AAV-GAL) have no effect on seizure sensitivity, seizure behaviors, 
or seizure-induced cell death.   
4/4 4/4 1/44/4
problems, thus we decided to explore if a single FIB sequence would be sufficient to 
cause secretion of both galanin and GFP in vitro and in vivo. 
III.B.4.  In Vitro Characterization of Single FIB Multiple Gene Product Delivery  
Vectors   
In order to determine if a single FIB sequence would be sufficient to cause 
secretion of both galanin and GFP, we generated and characterized the following 
constructs:  CB-EGFP, CB-FIB-EGFP, CB-FIB-GAL, CB-FIB-GAL-RKRRKR-EGFP, 
CB-FIB-EGFP-RKRRKR-GAL, CB-FIB-GAL-EGFP, and CB-FIB-GAL-RKRRKR-
NPY 13-36 (a construct used only for in vivo experiments and should allow secretion of 
two therapeutic neuropeptides) (see Figure 3-12).  Again, due to the extremely rapid 
degradation of galanin in serum (Holst, Bersani et al. 1993), GFP secretion was assayed.  
Constructs were made containing GFP and galanin in both possible orientations, assuring 
that GFP was correctly processed and cleaved from galanin whether it was 5’ or 3’ of the 
cleavage site.  In addition, we made a secreted non-cleavable control of galanin and GFP 
to demonstrate the size of a fusion of these two proteins.  Figure 3-13 shows that 
transfection of our constructs into 293 cells results in similar fluorescence patterns to that 
of Haberman et al. (2003) (Figure 3-13, A), and demonstrates that 1) indeed, a single FIB 
sequence was sufficient to allow secretion of both gene products (Figure 3-13, B lane 4), 
indicating that FIB designates the protein for secretion before furin cleaves it; 2) our 
proteins were correctly processed intracellularly regardless of position relative to the 
cleavage sequence and secreted into the medium (Figure 3-13, B-C, lanes 3-4); 3) in the 
absence of a cleavage sequence the uncleaved fusion protein is secreted into the medium 
(Figure 3-13, B lane 5); 4) the absence of fusion protein in the medium suggests that 
cleavage between GFP and galanin is 100% efficient (Figure 3-13, B, lanes 3-4).   
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Figure 3-12. AAV Vectors Characterized in Final Multiple Gene Product Delivery 
Studies.  (A) CB-EGFP is a negative control used in immunoprecipitation then western 
blot (IP/WB) experiments to show that GFP is expressed but not secreted in the absence 
of a FIB sequence. (B) CB-FIB-EGFP is a positive control used in IP/WB experiments 
for secretion of GFP into the medium.  (C) CB-FIB-GAL is a negative control used in 
IP/WB experiments to show that the GFP antibody does not cross-react to galanin or 
other non-specific proteins. (D,E) CB-FIB-GAL-RKRRKR-EGFP and CB-FIB-EGFP-
RKRRKR-GAL are used both for in vitro cleavage and secretion assay, and used for in 
vivo studies to test the function of both gene products.  (F) CB-FIB-GAL-EGFP is a non-
cleavable control for both in vitro and in vivo experiments.  (G) CB-FIB-GAL-
RKRRKR-NPY 13-36 is a construct used only for in vivo experiments and should allow 
secretion of two therapeutic neuropeptides.      
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Figure 3-13. In Vitro Characterization of Fluorescence Patterns, Cleavage, and Secretion of Proteins 
Derived from Multiple Gene Product Delivery Vectors. (A) GFP expression patterns in transfected 293 cells at low 
and high magnification.  (B-C) Immunoprecipitation and Western blotting of GFP from transfected cells; either conditioned 
medium (B) or cell lysate (C) was analyzed.  (1) CB-EGFP, GFP is expressed as seen in C lane 1, but is not secreted into the 
medium (B lane 1).  Cells have a bright and uniform distribution of intracellular GFP (A, panel 1).  (2) CB-FIB-EGFP, GFP is 
expressed and secreted into the medium (B-C, lane 2).  Fluorescence is concentrated around the perimeter, indicating secretion 
(A, panel 2).  (3) CB-FIB-EGFP-RKRRKR-GAL, GFP is cleaved from galanin and secreted into the medium (B, lane 3).  As 
seen in C lane 3, unprocessed protein is detected in the cell lysate.  (4) CB-FIB-GAL-RKRRKR-EGFP, GFP behaves the same 
as B and C lane 3, so correct processing and secretion occurs whether GFP is 5’ or 3’ of the cleavage sequence.  (5) CB-
FIB-GAL-EGFP, GFP cannot be cleaved from galanin because this construct lacks a cleavage sequence.  The fusion protein is 
still secreted due to the inclusion of FIB (B lane 5).  A small amount of degraded protein is present in the cell lysate, but does 
not get secreted (C lane 5).  Fluorescence patterns are similar with all secreted GFP constructs (A, panels 2-5), although 
intensity seems to be lower in A, 3, however, the relative amount of GFP detected in the medium is similar (B lanes 2-5). (6) 
CB-FIB-GAL, GFP is not present in the cells (A, panel 6), and the GFP antibody does not cross-react to galanin (B-C, lane 6).  
(7) Rainbow marker of known proteins from Amersham, size indicated to the right (B-C, lane 7).   
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III.B.5.  In Vivo Functional Test of Single FIB Multiple Gene Product Delivery 
Vectors  
In order to test the in vivo function of these proteins, we packaged our multiple 
gene product delivery constructs into AAV2 vectors where the CB promoter drives 
expression of the FIB-GAL-RKRRKR-EGFP, FIB-EGFP-RKRRKR-GAL, FIB-GAL-
EGFP, or FIB-GAL-RKRRKR-NPY13 36 coding sequence (see Figure 3-12).  Then, 
3µL of virus (1.0 X 1012 viral particles/mL) was infused bilaterally into the piriform 
cortex of rats, as previously described (McCown 2006) (see Figure 3-14).  Control rats 
received no infusion, as we have previously shown that vectors expressing and secreting 
reporter genes like GFP (AAV-FIB-EGFP), as well as vectors expressing peptides that 
lack secretion sequences (AAV-GAL) have no effect on seizure sensitivity, seizure 
behaviors, or seizure-induced cell death (Haberman, Samulski et al. 2003; McCown 
2006).  One week later, the rats received a dose of 10mg/kg, i.p. kainic acid, and 
subsequently, the time to limbic seizure behaviors was recorded.  As seen in Figure 3-14, 
the immunohistochemistry data presented shows that the GFP is functional in both 
orientations, but reveals that number of transduced cells is limited.  Figure 3-15 confirms 
the presence of vector-derived mRNA for the animals injected with AAV2-CB-FIB-
GAL-RKRRKR-NPY13-36.  As seen in Figure 3-16, all groups exhibited wet dog shakes 
(WDS) with similar latency, validating the efficacy and uniformity of the absorbed dose 
of kainic acid.  All vector treated animals showed a significant delay in the onset of class 
IV seizures (*t-test; P≤0.01).  A strong increase in the latency to seizure behavior 
demonstrates that the galanin gene product is in fact expressed, secreted, and functional 
regardless of whether it is 5’ or 3’ of the cleavage site in our multiple gene product     
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Figure 3-14. Immunofluorescence of Neurons in the Piriform Cortex That Have 
Been Transduced with GFP-containing Vectors.  The shaded area in the coronal 
section shows the range of placement within the piriform cortex of the AAV vector 
microinjections.  Sections were taken at the level of the needle track and processed for 
GFP fluorescence.  Presence of GFP protein reveals the virus transduction pattern, and 
confirms that our constructs are functional in both orientations in vivo.  The localization 
of GFP to the periphery of the cells is consistent with GFP secretion.   
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Figure 3-15. The In Vivo Presence of Vector-derived FIB-GAL-RKRRKR-NPY13-
36 mRNA 1 Week after Vector Infusion into the Piriform Cortex.  To validate viral 
transfer for the AAV2-CB-FIB-GAL-RKRRKR-NPY13-36 group, we performed RT-
PCR on tissue from the piriform cortex.  As seen in Figure 3-8, the appropriate vector 
derived mRNA (252bp) is present in all 7 animals injected with this vector (lanes A-G).   
The left outside lane contains a 50bp DNA ladder with the size indicated on the left.  
Omission of the reverse transcriptase step resulted in loss of the product (data not 
shown).  Together, Figures 3-13 and 3-14 confirm successful gene transfer occurred in all 
of our vector-treated groups.      
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Figure 3-16. The Effects of Multiple Gene Product Delivery Vectors on Limbic 
Seizure Behavior. The latencies to wet dog shakes and limbic seizure behaviors were 
determined for 180 min post-kainic acid.  All the animals regardless of treatment group 
developed wet dog shakes with similar latencies, suggesting an equivalent absorbed dose 
of kainic acid.  All AAV vector groups exhibited a significant delay in the time to class 
IV limbic seizures.  (FG-E is AAV2-CB-FIB-GAL-RKRRKR-EGFP, FE-G is AAV2-
CB-FIB-EGFP-RKRRKR-GAL, FG-NPY13-36 is AAV2-CB-FIB-GAL-RKRRKR-
NPY13-36, FGE is AAV2-CB-FIB-GAL-EGFP, and Control is kainic acid only with no 
vector; * signifies significance of p≤0.01 compared to Control using two-tailed t-test)   
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delivery vectors (CB-FIB-GAL-RKRRKR-EGFP + CB-FIB-EGFP-RKRRKR-GAL, 
Figure 3-16).  Unexpectedly, galanin was able to decrease seizure activity even when 
GFP was not cleaved (CB-FIB-GAL-EGFP, Figure 3-16).  While animals receiving 
AAV2-CB-FIB-GAL-RKRRKR-NPY13-36 did show a significant delay in the latency to 
class IV seizures compared to controls, having two therapeutic neuropeptides did not 
confer additional seizure protection over having a single therapeutic neuropeptide (Figure 
3-16).  Taken together, we can conclude that successful gene transfer occurred in all of 
the vector-treated groups, and that the gene products are functional in vivo, providing 
proof of concept.   
  
    
 
 
 
 
 
 
 
 
 
Chapter 4  
Discussion 
 
IV.A. rAAV-Mediated Expression and Constitutive Secretion of NPY or NPY13-36 
Suppresses Seizure Activity In Vivo 
Epilepsy is an attractive target for recombinant Adeno-associated virus (rAAV) 
gene therapy, because the temporal lobe structures involved in seizure genesis and 
propagation have been shown to be permissive to AAV gene transfer (Freese, Kaplitt et 
al. 1997; Vezzani, Michalkiewicz et al. 2002; Haberman, Samulski et al. 2003; Richichi, 
Lin et al. 2004; Klugmann, Symes et al. 2005; McCown 2006).  Recently, galanin and 
NPY have been delivered as transgenes in rAAV vectors, and shown to be effective in 
several epilepsy paradigms (Haberman, Samulski et al. 2003; Lin, Richichi et al. 2003; 
Richichi, Lin et al. 2004; McCown 2006).  While previous approaches utilize pre-pro 
cDNA sequences which rely on the cell to modulate release of the gene product, 
Haberman et al. (2003) were the first to use a novel secretion strategy whereby the 
secretion signal sequence from the constitutively secreted laminar protein fibronectin 
(FIB), is combined with the coding sequence for the active therapeutic peptide.  Results 
from Haberman et al. (2003) and McCown (2006) show that expression and constitutive 
secretion of galanin is not only achieved, but also effective in attenuating focal and 
limbic seizure activity.  In contrast, expression of galanin without the secretory signal or  
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expression and secretion of the reporter gene, GFP had no effect on seizure sensitivity 
(Haberman, Samulski et al. 2003; McCown 2006).    
In addition to galanin, rAAV delivery of NPY has also been shown to attenuate 
limbic seizures (Richichi, Lin et al. 2004).  While there is still some question as to which 
of the NPY receptors (Y1-Y5) mediates the anti-seizure activity, several studies have 
suggested a critical role for the Y2 receptor in mediating anti-epileptic actions (Colmers, 
Klapstein et al. 1991; Greber, Schwarzer et al. 1994; Dumont, Cadieux et al. 2000; 
Dumont, Cadieux et al. 2000; El Bahh, Cao et al. 2002; El Bahh, Balosso et al. 2005; Lin, 
Young et al. 2006).  Furthermore, it has been demonstrated that in epileptic tissue from 
patients (Furtinger, Pirker et al. 2001) and rodents (Kofler, Kirchmair et al. 1997; 
Schwarzer, Kofler et al. 1998) that Y1 receptors are downregulated while Y2 receptors 
are upregulated.  Taken together, these results suggest that when designing anti-
epileptogenic therapeutics, it may be advantageous to deliver Y2 preferring agonists.  In 
fact, acute intracerebral delivery of the Y2 receptor preferring agonist NPY13-36 reduces 
seizure susceptibility following systemic kainic acid administration (Vezzani, Moneta et 
al. 2000; Vezzani, Rizzi et al. 2000).  These data along with our current findings suggest 
NPY13-36 is a good candidate to use in a rAAV vector to treat epilepsy.  By using the 
FIB secretion strategy, we have the capability of expressing and constitutively secreting 
peptide fragments which have demonstrated receptor selectivity.  Thus, we evaluated the 
effects of AAV mediated expression and constitutive secretion of NPY and the peptide 
fragment NPY13-36 on kainic acid induced limbic seizures.   Our data demonstrates that 
seizures can be effectively controlled in rats using rAAV to deliver inhibitory 
neuropeptides to susceptible neurons.   
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Our approach differed with that of Richichi et al. who used a pre-pro form of 
NPY cDNA in their AAV vector (Richichi, Lin et al. 2004).  While their approach did 
confer some seizure protection, their effects are dependent on three caveats that our 
approach circumvents.  First, since they use the pre-pro form of NPY, it is likely that only 
a subset of transduced neurons will have the ability to correctly process the pre-pro 
protein into the active protein, which requires a whole host of proteins including but not 
limited to chaperones and pro-protein convertases.  Second, even the transduced neurons 
that are capable of processing pre-pro NPY (probably neurons that already contain and 
release NPY), have a limit to the amount of pre-pro protein that can be correctly 
processed and packaged into large core dense vesicles for release.  As the authors point 
out, pro-NPY could “spill over” into the constitutive pathway, resulting in the formation 
of some inactive pro-NPY that cannot be released by exocytosis (Burgess and Kelly 
1987), or worse, causes release of inactive protein that could act like a NPY receptor 
antagonist.  This is a concern especially because Richichi et al. are using a construct with 
a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), which 
dramatically increases the total amount of vector-mediated transgene expression 
(Donello, Loeb et al. 1998; Higashimoto, Urbinati et al. 2007).  Finally, even the pro-
NPY that is correctly processed into mature NPY is stored in large dense core vesicles 
and docked in pools which can only be released in the typical regulated fashion upon 
robust neuronal excitation (see Figure 4-1).  Usually, only high frequency action 
potentials can trigger their release (Hokfelt, Bartfai et al. 2003).  Since the NPY receptors 
are located on the outside of the neuronal membrane, NPY can only exert function upon    
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Figure 4-1. Regulated versus Constitutive Secretion in Neurons. 
(1) In the regulated pathway neuropeptides and other proteins are first synthesized as pro-
proteins in the endoplasmic reticulum, then they are sorted and processed in the golgi and 
trans golgi network, finally they are packaged in dense-core vesicles where they can be 
cleaved into their active forms and tethered in releasable pools until high frequency 
stimulation (depicted as a lightening bolt) causes exocytosis.   
(2) In the constitutive secretory pathway proteins are synthesized, sorted, and processed 
in a similar way, but once they are packaged into secretory vesicles and cleaved into 
active forms, they are continuously released via exocytosis independent of stimulation.      
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 release, so the manner in which the neuropeptide is released is critical to seizure 
prevention. 
Our approach circumvents all of these issues by using only the active peptide 
sequence fused to a constitutive secretion signal.  Hence, there is no pro-protein to 
process, and release happens in the absence of regulation.While our approach has proven 
effective for galanin and NPY, it would probably not work for dynorphin, an endogenous 
opioid neuropeptide with anti-seizure activity (Bonhaus, Rigsbee et al. 1987; Mazarati 
and Wasterlain 2002; Loacker, Sayyah et al. 2007).  Mazarati and Wasterlain (2002) 
showed that acute hippocampal delivery of dynorphin A(1-13) had a profound anti-
seizure effect in a rat model of self-sustaining status epilepticus, suggesting that 
dynorphin A(1-13) would be a good therapeutic candidate for our constitutive secretion 
vectors.  However, like most neuropeptides dynorphin A(1-13) is first expressed as a pro-
protein that gets cleaved into active forms of various lengths by a protease that recognizes 
basic amino acid residues (for review see (Simonato and Romualdi 1996).  After close 
examination of the amino acid sequence of dynorphin A(1-13) we discovered that it has a 
potential furin cleavage site at residues 6-9 which are R-R-I-R.  Hence, based on our 
results with the multiple peptide delivery vectors, we predict that designing an AAV 
vector where FIB mediates constitutive secretion of dynorphin A(1-13) would result in 
undesirable cleavage then secretion of fragments of the expressed protein.  This example 
illustrates an important concern when delivering gene products as therapeutics: their 
sequences must be carefully analyzed and perhaps even optimized for efficient transgene 
expression.  While our approach might not be effective for every transgene, we 
demonstrated that it is effective with NPY and with NPY13-36, confirming that it is now 
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possible to express and secrete active peptide fragments which allow for more selective 
receptor targeting.   Furthermore, using small peptide fragments in an AAV context could 
allow for multiple therapeutic peptides to be expressed from a single vector cassette.  It is 
likely that combination therapy will be the key to treating epilepsy and many other 
complex neurological disorders.   
IV.B. A Strategic Approach for Delivering Multiple Gene Products Using a Single 
AAV Vector  
 These experiments were conducted primarily to show that it is possible to use a 
single AAV vector that upon transduction causes cells to express and secrete two gene 
products simultaneously; and also to study the interaction of vector-mediated secretion of 
galanin and NPY on limbic seizure behavior.  We have shown in vitro and in vivo that 
our constructs mediate the expression of a chimeric fusion protein that upon intracellular 
processing gets cleaved and constitutively secreted as two functional proteins.  These 
results expand the utility of engineering a proteolytic cleavage site in an AAV vector 
cassette.   
While both galanin and NPY (and NPY13-36) have been extensively studied in 
seizure models (see IV.A.), combinations of these peptides in such models remain 
unexplored.  In order for the two neuropeptides to have a synergistic effect, they must 
have separate mechanisms of action, or at least divergent down stream pathways.  
Mazarati and Wasterlain (2002) concluded that a different pattern of anticonvulsant 
action was evident after the acute delivery of NPY versus galanin, suggesting that 
delivering both neuropeptides simultaneously could be advantageous.  However, it is 
clear from our experiments that galanin and NPY13-36 do not potentiate one another in 
the piriform cortex because simultaneous delivery did not result in a more complete 
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blockade of limbic seizure behavior.  This suggests that galanin and NPY13-36 may have 
the same mechanism of action and/or the same intracellular signaling pathways in the 
piriform cortex.  While unexpected, the data can be explained by carefully examining the 
mechanisms of action, receptor subtype distribution, and signaling cascades of both 
galanin and NPY in the piriform cortex.  Galanin has been shown to reduce glutamate 
release from presynaptic nerve terminals in the brain (Zini, Roisin et al. 1993).  All three 
galanin receptors (GALR1-3) are present in the piriform cortex (O'Donnell, Ahmad et al. 
1999; He, Counts et al. 2005; Mazarati, Lundstrom et al. 2006), but GALR2 and GALR3 
are the most abundant.  GALR1 and GALR3 can signal both by inhibiting adenylyl 
cyclase via a pertussis toxin-sensitive G-protein of the Gi/Go family (Parker, Izzarelli et 
al. 1995; Smith, Forray et al. 1997), by reducing the concentrations of cAMP (Branchek, 
Smith et al. 2000), or by activating G-protein-coupled inwardly rectifying potassium 
channels (GIRKs) (Smith, Walker et al. 1998; He, Counts et al. 2005; Mazarati, 
Lundstrom et al. 2006).  GALR2 stimulates inositol phospholipid turnover and 
intracellular calcium mobilization through a pertussis toxin-insensitive Gq/G11-type 
mechanism (Fathi, Cunningham et al. 1997; Smith, Forray et al. 1997).  This type of 
channel activation could increase seizure sensitivity, but this was not observed after 
AAV-mediated galanin secretion in the piriform cortex.  NPY has several receptors (Y1-
6), but the peptide fragment NPY13-36 has the highest affinity for the Y2 receptor 
(Y2R).  Y2R are primarily presynaptic, and their activation suppresses glutamate release 
(Colmers and Bleakman 1994; Greber, Schwarzer et al. 1994) via suppression of voltage-
dependent calcium influx through neuronal N-type calcium channels in presynaptic nerve 
terminals (Toth, Bindokas et al. 1993; Qian, Colmers et al. 1997).  Although galanin and 
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NPY receptors appear to have limited overlap in their downstream signaling pathways, 
the end result is still the same: both neuropeptides reduce presynaptic glutamate release.  
Therefore, a plausible explanation for the observed lack of potentiation in the piriform 
cortex is that a maximal effect for inhibition of presynaptic glutamate release is already 
achieved with the delivery of galanin.   
Another possibility may be that the concentration of furin in the transduced 
neurons could be in limited supply such that constitutive expression of our transcript with 
the strong CB promoter is overwhelming the cleavage pathway.  The consequence of this 
might be that a percentage of secreted protein will still be a galanin-NPY13-36 fusion 
protein.  Furin and other pro-protein convertases are known to be upregulated in neurons 
after seizures induced by kainic acid treatment (Meyer, Chretien et al. 1996), but this 
upregulation seems to occur primarily in the hippocampus, and is perhaps not as robust in 
the piriform cortex.  While our in vitro data suggests that cleavage is completely efficient 
(because we never detect fusion protein in the medium with galanin-GFP constructs), 
perhaps efficiency is related to the size and structure of the cleavable protein.  NPY13-36 
is very different from GFP in that it is much smaller.  In addition, it has been suggested 
that Y2R analogs and NPY13-36 may form hairpin or helical structures (Yao, Smith-
White et al. 2002), and this may mask the cleavage site.  The predicted results of a 
masked cleavage site would be that the majority of the secreted protein would be a 
galanin-NPY13-36 fusion protein.  The affinity of the fusion protein for the galanin 
receptors and/or the NPY receptors might be lower than that of either galanin or NPY 
alone, and may explain our observed results.  To rule out this possibility two more 
control vectors can be made.  The first vector can be a non-cleavable cassette with 
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galanin and NPY13-36.  If results from this vector are similar to the results from the 
cleavable vector, then it is likely that cleavage efficiency in vivo is poor.  Another vector 
that can be made is a cassette with an IRES sequence in between galanin and NPY13-36.  
While levels of translation will be unequal, at least both gene products will be secreted 
from the same transduced neuron, which would not happen 100% of the time with co-
infection of separate vectors.  If indeed the proteins are not cleaved from one another in 
vivo, it points to a potential liability when using a proteolytic strategy: each protein 
combination must be tested on a case by case basis to ensure proper folding and 
processing of the gene products are occurring.  It is likely that this vector strategy might 
not be universally suitable for all protein combinations.           
 Finally, compared to our previous experiments, transduction levels obtained with 
the multiple gene product delivery vectors were modest.  The limited spread of these 
vectors within the piriform cortex probably decreased the sphere of influence of the 
secreted neuropeptides.  This could explain the lack of complete protection from seizure 
behavior that delivering galanin alone in the piriform cortex has previously produced 
(McCown 2006).  Since the same AAV serotype and promoter was used, the change in 
the transduction pattern can not be explained by virus tropism.  Other possibilities include 
differences in virus infectivity, sequence-dependent problems with second strand 
synthesis, or sequence-dependent mRNA transcript instability.  The first hypothesis was 
investigated by performing an infectious center assay on the AAV vectors used in these 
experiments, and confirmed that they were within the normal range (see Figures 2-3, 2-4, 
2-5, 2-6).  The second hypothesis can be tested by using a self-complementary vector to 
bypass rate-limiting second strand synthesis.  Since the size of the promoter, transgene, 
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and polyA is around 2.5kb for AAV2-CB-FIB-GAL-RKRRKR-NPY13-36 it should fit 
into a double stranded cassette, although efficiency may be slightly lower than a 2kb 
construct.  Efforts are being made to shorten the CB promoter for more efficient use in 
double stranded vectors, and that would restore full infectivity to our construct because 
the largest element in our cassette is the CB promoter.  The third hypothesis can be tested 
by creating a construct that delivers both galanin and NPY13-36 from the same vector but 
as separate transcripts by using two promoters and polyA sequences.  While the results 
are not exactly what we expected, we did demonstrate the concept that an engineered 
proteolytic cleavage site can successfully be used in conjunction with a constitutive 
secretion signal sequence to allow multiple gene products to be expressed and secreted 
simultaneously, using a single cistron cassette in an AAV vector.   
Taken together, this body of work describes a gene therapy vector technology 
platform to express and constitutively secrete single and multiple proteins from 
transduced cells, and to deliver peptide fragments that are capable of selective receptor 
targeting.  While epilepsy is one model where this technology was applied, it should be 
easily transferable for the treatment of other neurological diseases such as Parkinson’s 
disease, Alzheimer’s disease, and stroke.   
 
 
 
 
 
 
Chapter 5 
The Future of AAV-mediated Gene Therapy in the Brain: Obstacles and 
Opportunities 
 
V.A. Brain-wide Vector Delivery 
One of the most challenging issues in gene therapy is delivering the vector to all 
the disease-affected tissues in the patient.  Although using gene therapy to treat a 
neurological disease limits the area of vector delivery, the complex organization and 
specialization of the substructures in the brain currently impedes global brain delivery.  
Some attempts have been made to deliver AAV vectors via intracerebroventricular (ICV) 
injection (Shenouda, Johns et al. 2006; Qing and Chen 2007) in the hopes that the 
cerebrospinal fluid (CSF) would carry the vector throughout the brain, however, no 
improvement in virus spread was achieved.  It appears that when delivered ICV, AAV 
vectors do not spread beyond the third ventricle or median eminence.  Some strategies 
exist to enhance the spread of AAV in the brain, such as co-administering mannitol 
(Bartlett, Samulski et al. 1998), heparin (Nguyen, Sanchez-Pernaute et al. 2001), and 
basic fibroblast growth factor (Hadaczek, Mirek et al. 2004).  Alternatively, convection-
enhanced delivery (an approach that uses bulk flow--maintaining a pressure gradient over 
time--to deliver and distribute molecules to large areas of brain tissue (Hadaczek, 
Kohutnicka et al. 2006), or multiple vector injections (McPhee, Janson et al. 2006) can be 
used to increase viral spread.  A third strategy to increase AAV vector transduction can  
84 
be achieved by altering critical capsid components of the vector (see the next section for 
a more detailed discussion of this point).  Until the technical hurdle of global brain 
delivery can be overcome, we must be realistic in our expectations of gene therapy to 
treat certain neurological diseases.  One factor that contributes to limited success is that 
AAV2 continues to be the vector of choice for animal experiments and clinical trials, 
(because it is the best characterized and most available serotype), however, it is the 
poorest of the serotypes at transducing cells beyond the area of injection.  While this 
quality is beneficial for diseases with a localized nature (like focal epilepsy), it is 
detrimental for most neurological diseases that involve multiple brain regions.  
While the brain’s complex structure does present a challenge, knowledge of 
neuroanatomy and neuronal projection pathways can be employed to design more 
efficient delivery paradigms.  For example, it has been reported that some but not all 
AAV serotypes can be transported in an anterograde or retrograde manner along axonal 
projections to a site distant from that of injection (Kaspar, Llado et al. 2003; Passini, 
Macauley et al. 2005; Provost, Le Meur et al. 2005).  In fact, Cearley and Wolfe (2006) 
showed that when the identical vector genome was cross-packaged into AAV7, 8, 9, or 
rh10 capsids, there was a difference not only in the transduction patterns of the different 
serotypes, but also in the ability of the packaged vector genome to undergo axonal 
transport to neuronal cell bodies distal to the injection site (Cearley and Wolfe 2006).  
Furthermore, they then used rAAV9 and showed that a single injection into the ventral 
tegmental area (VTA) resulted in delivery and transgene expression in several brain 
structures known to have reciprocal projections with the VTA (Cearley and Wolfe 2007).  
Injection in the VTA dramatically enhanced virus spread and therapeutic efficacy 
compared to injection of the same amount of virus in the striatum (Cearley and Wolfe 
2007).  Another group compared AAV serotype 1, 2, 5, 7, and 8 in a mouse model of the 
lysosomal storage disease Niemann-Pick type A (Dodge, Clarke et al. 2005).  Niemann-
Pick type A disease is caused by a deficiency in acid sphingomyelinase (ASM) activity.  
Thus, the serotypes were injected into the deep cerebellar nuclei (DCN), and evaluated 
for the ability to facilitate global distribution of the viral vector and gene product (ASM).    
The authors found that AAV1 was the superior serotype in all measures of disease 
correction, and that transduction was observed in the DCN and throughout the 
cerebellum, brainstem, midbrain, and spinal cord (Dodge, Clarke et al. 2005).  By 
understanding which brain regions are affected and how they project to one another, 
scientists can design more efficient vector delivery strategies that are tailored to each 
neurological disease.  Successful vector delivery is paramount for gene therapy to 
progress beyond clinical trials. 
V.B. Vector Safety, Tolerability, and Efficacy 
V.B.1.  Vector Targeting 
The goal of any Phase I clinical trial is to assess if an experimental treatment is 
safe and well tolerated by the patients; AAV-mediated gene therapy is no exception.  One 
way to contribute to the safety and tolerability of a treatment is to minimize off-target 
effects.  For AAV gene therapy in the brain, targeting subpopulations of cells can be 
achieved at two levels; one is by modifying the capsid so it is capable of binding and 
mediating viral entry into specific cell types, and the other is by transcriptional control, 
where the promoter and its associated cis and trans regulatory elements can be modified 
to limit vector-mediated gene expression to specific cell types and conditions.  
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where the promoter and its associated cis and trans regulatory elements can be modified 
to limit vector-mediated gene expression to specific cell types and conditions. 
V.B.1.a.  AAV Capsid-mediated Vector Targeting 
Capsid modification is one of the most rapidly progressing areas of AAV vector 
engineering.  Several targeting approaches have been used by various labs including 
genome transcapsidation, mixing of different serotypes to create mosaic capsids, domain 
swapping from different serotypes, peptide insertion to create chimeric capsids, and 
genetically shuffled AAV capsid gene libraries.  Each of these approaches might be a 
viable way to overcome some rate-limiting barriers in viral entry and post-entry in 
neurons, thereby improving gene transfer.   
Transcapsidation (sometimes referred to as pseudotyping) is the packaging of an 
AAV genome containing the TR from one serotype (usually type 2 because it is the best 
characterized and Food and Drug Administration (FDA) approved serotype) into the 
capsid of another serotype in order to shift the viral vector tropism (for an in depth review 
see (Choi, McCarty et al. 2005).  This strategy is being used extensively in the brain to 
increase the viral spread beyond the site of injection.  For example, rAAV2 vector 
genomes psuedotyped with capsids of AAV1 and AAV5 were compared to rAAV2 in 
several brain regions.  In this case, rAAV1 and rAAV5 had a more extensive area of 
transduction than rAAV2 in most regions examined (Burger, Gorbatyuk et al. 2004; 
Shevtsova, Malik et al. 2005).  As new serotypes are being discovered and characterized 
(Gao, Alvira et al. 2002; Gao, Alvira et al. 2003), it will not be long before we have an 
arsenal of serotypes that work best for each brain region, and possibly each neurological 
disease.   
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Mosaic capsid modification can also expand viral tropism because it involves 
mixing capsid subunits from different serotypes to create a hybrid capsid with receptor 
binding profiles conferred from each parent serotype (reviewed in (Wu, Asokan et al. 
2006).  It was shown that mosaic vectors can gain function compared to the parent 
serotypes (Rabinowitz, Rolling et al. 2002; Rabinowitz, Bowles et al. 2004).  An 
AAV1/AAV2 mosaic vector where the capsid input ratio was 1 to 1 was compared to an 
AAV2 vector after hippocampal delivery.  The AAV2 vector transduced only the hilar 
interneurons while the mosaic vector transduced the hilar interneurons and some 
pyramidal and granule cells (Richichi, Lin et al. 2004).  Although higher transduction 
efficiency was achieved by using the mosaic vector, the authors did not include an AAV1 
vector in this study.  Therefore, it cannot be determined if the mosaic vector would 
outperform each parent serotype.  In addition, this method of viral production actually 
yields non-uniform virions.  For example, even though in this case an equal ratio of type 
1 and type 2 helper plasmids were used, it is likely that not all particles will contain equal 
amounts of type 1 and type 2 subunits.  Since standardization of these preps is difficult, 
this method of capsid engineering will probably not transition to clinical trials.         
Chimeric vectors contain capsid proteins that have been modified by functional 
domain or amino acid swapping between different serotypes, or by genetically inserting 
peptide ligands into domains of the capsid to change its receptor binding profile 
(reviewed in (Wu, Asokan et al. 2006).  Bowles et al. applied the marker rescue approach 
to AAV capsid engineering so mutations that may help to target vectors but renders them 
non-infectious can be rescued by the addition of wild type capsid (Bowles, Rabinowitz et 
al. 2003).  By adding back wild type capsid with sequence homology and by selecting for 
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infectious particles using specific cell types, infectivity and vector targeting can be 
achieved.  This rescue may occur by host cell-mediated recombination at regions of 
homology between the wild type and mutant capsid subunits (Bowles, Rabinowitz et al. 
2003), or by limiting the number of mutation containing subunits that are incorporated 
into the capsid (Gigout, Rebollo et al. 2005).  Rational domain swapping is similar to 
marker rescue, but instead of relying on recombination to make changes in the capsid 
subunits, domains are chosen based on their three dimensional location in the assembled 
capsid and their potential to impact function while preserving capsid structure (like 
variable surface loops).  These domains are then swapped into the capsid subunits by 
cloning or other techniques.  Marker rescue and rational domain swapping are powerful 
techniques that when combined with specific cell-type selection can result in the 
generation of AAV vectors with novel transduction capabilities (Bowles, Rabinowitz et 
al. 2003; Hauck and Xiao 2003).   
Chimeric vectors can also be made by inserting peptide ligands into the capsid to 
target them to specific cell types expressing the complimentary receptors.  Recently, this 
approach was used with two peptide ligands that mimic binding domains for cytoplasmic 
dynein and NMDA receptors.  These peptides were genetically engineered into AAV2 
capsid proteins by directed mutagenesis, and it was shown that these chimeric AAV 
vectors exhibited significantly enhanced axonal uptake, allowing for more efficient 
retrograde transport (Xu, Ma et al. 2005).  The authors delivered AAV vectors to the 
tongue and analyzed the brain stem for viral DNA as a proof of concept of retrograde 
transport, but these vectors could be directly injected into the brain and analyzed for 
transduction efficiencies.           
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Fortunately for patients with neurological diseases, most AAV serotypes tested so 
far are neuro-tropic, making AAV a potentially ideal vector for treatment.  However, 
there are certain types of brain cancers like astrocytomas and gliomas, as well as diseases 
like multiple sclerosis and other demyelinating diseases that affect oligodendrocytes.  
These diseases could be treated with glia-tropic AAV vectors.  Actually, one group tried 
to use  AAV2 vectors where transgene expression was mediated by the oligodendrocyte-
specific myelin basic protein (MBP) promoter, to transduce diseased oligodendrocytes in 
a mouse model for the human demyelinating disease globoid cell leukodystrophy (Chen, 
McCarty et al. 1999).  In this mouse model called twitcher, demyelination occurs as a 
result of degenerating oligodendrocytes, the onset of which is around 20 postnatal days 
(Suzuki and Taniike 1995).  It was reported that transduction of the oligodendrocytes in 
the twitcher mice with AAV2 vectors was quite low (Chen, McCarty et al. 1999), 
highlighting the need for more effective glia-tropic AAV vectors.  While glial cells 
cannot be efficiently targeted and transduced in vivo with the serotypes currently 
available, engineering the AAV capsid could result in re-targeting the virus so it no 
longer primarily infects neurons.  DNA shuffling and error-prone PCR are powerful 
library-based approaches that direct the evolution of the capsid, and could be used to re-
target AAV vectors to glial cells.  DNA shuffling causes recombination to occur between 
homologous fragments generated from a pool of related genes.  Upon self-priming PCR, 
these fragments can reassemble into diverse sequences that are generated in a non-biased 
fashion.  Error-prone PCR also introduces random mutations that alone or in combination 
may confer unique or enhanced function (for review see (Yuan, Kurek et al. 2005).  Both 
of these techniques in combination with cell type-specific selection and repeated virus 
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cycling can result in lab engineered serotypes that may target and enhance transduction in 
refractory cell types such as glia.  In addition, these techniques were recently applied to 
AAV2 vectors to select for variants that can escape neutralizing antibodies (Maheshri, 
Koerber et al. 2006; Perabo, Endell et al. 2006), reinforcing the utility of these 
engineering approaches (see section V.B.2. for more detailed discussion).           
V.B.1.b.  Cell Type-specific Promoter-mediated Vector Targeting  
 Along with capsid engineering, another way to limit off-target effects is by 
restricting the expression of the transgene to the targeted cells by using cell type-specific 
promoters.  Cell type-specific promoters can only initiate transgene expression when 
specific transcription factors or transactivators recognize and bind to regulatory 
sequences within the promoter.  Expression of these transcription factors and 
transactivators is restricted to sub-populations of cells, and thus prevents ubiquitous 
transgene expression (for review see (Walther and Stein 1996).  Even though the 
naturally occurring AAV serotypes primarily transduce neurons, there is evidence to 
suggest that using tissue-specific transcription regulatory elements may increase the 
strength and persistence of gene expression in vivo (Klein, Meyer et al. 1998; Paterna, 
Moccetti et al. 2000; Xu, Janson et al. 2001; Klein, Hamby et al. 2002).  Some promising 
promoters that restrict transgene expression to neurons are the neuron-specific enolase 
(NSE), platelet-derived growth factor b-chain (PDGF-b), and the human synapsin 1 gene 
(hSYN) promoters.  Transgene expression in neurons was confirmed for these promoters 
by immunohistochemistry double labeling experiments, and persisted greater than 9 
months in multiple brain regions (Peel, Zolotukhin et al. 1997; Klein, Meyer et al. 1998; 
Paterna, Moccetti et al. 2000; Xu, Janson et al. 2001; Shevtsova, Malik et al. 2005).   
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In addition to neurons, the brain contains other cell types including astrocytes, 
macrophages, oligodendrocytes, and epithelial cells.  In combination with capsid 
engineering, it may be possible to direct and restrict AAV-mediated gene expression to 
these cell types.  Caution must be taken when trying to target AAV transduction to non-
neuronal cells using cell type-specific promoters, because it has been reported that even 
in the presence of glial cell-specific promoters, neuronal expression can still occur.  For 
example, in a study by Xu et al., high levels of neuronal expression and low levels of 
glial expression were found when using AAV2 vectors where gene expression was driven 
by the glial fibrillary acidic protein (GFAP) promoter (Xu, Janson et al. 2001).  The 
authors suggest that the observed “leakiness” of expression could be attributed to 
promoter-specific effects on enhancer elements within the TRs (Xu, Janson et al. 2001).  
This is likely the case because AAV TRs have been shown to posses transcriptional 
activity (Flotte, Afione et al. 1993; Haberman, McCown et al. 2000), suggesting that each 
cell type-specific promoter must be tested in vivo to confirm that transgene expression is 
in fact limited to the targeted cell population.  Furthermore, it is known that some 
promoters are inactivated over time in various brain regions, causing shutdown of 
transgene expression (McCown, Xiao et al. 1996; Klein, Meyer et al. 1998; Raol, Lund et 
al. 2006).  Thus, longevity of transgene expression should also be evaluated.  The clinical 
success of treating neurological diseases with AAV-mediated gene therapy will be 
greatly improved with the development of cell type-specific promoters that confer 
enhanced long-term gene expression.   
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V.B.1.c.  Inducible and Conditional Promoters 
 In addition to cellular targeting, temporal regulation of transgene expression is a 
desirable feature that enhances clinical safety of AAV-mediated gene therapy.  Precise 
control over the level of transgene expression is necessary, particularly when delivering 
potent neurotrophic factors and neuropeptides in the brain, because robust over-
expression has been shown to cause deleterious side effects (Kirik, Rosenblad et al. 2000; 
Georgievska, Kirik et al. 2002).  Regulation of transgene expression can be achieved 
through responsive/inducible elements within the promoter sequence of an AAV vector.     
Many synthetic and endogenous promoters have been exploited for the purpose of 
gene regulation including hypoxia-responsive promoters, metallothionein promoters, heat 
shock, and hormone-responsive promoters (Searle, Stuart et al. 1985; Fuqua, Blum-
Salingaros et al. 1989; No, Yao et al. 1996; Semenza, Jiang et al. 1996).  Hypoxia-
inducible and similar disease state-inducible systems have been incorporated into AAV 
vectors and may be appropriate for use with specific diseases (Phillips, Tang et al. 2002; 
Raol, Lund et al. 2006; Shen, Su et al. 2006; Shen, Fan et al. 2008).  Perhaps the most 
broadly applicable designs for use in an AAV vector are the FK506/rapamycin (Rivera, 
Clackson et al. 1996), tetracycline (tet) (Baron and Bujard 2000), and RU486 (Wang, 
Tsai et al. 2000) responsive systems (for an in depth review see (Haberman and McCown 
2002).  These responsive/inducible systems rely on chimeric transcription factors or 
transactivators that in the presence of an administered drug (tet, rapamycin, or 
mefipristone), bind/detach their promoter and allow/repress expression of the transgene.  
Hence, vector-mediated gene expression can be turned on or off by administering drugs, 
allowing baselines to be determined in the presence of vector but in the absence of gene 
93 
product.  Additionally, the same animals may be tested before and after drug 
administration, allowing for repeated-measures statistical analysis with improved 
statistical power.  
     The rapamycin responsive system has been used successfully in AAV vectors 
for gene expression in muscle (Rivera, Ye et al. 1999; Ye, Rivera et al. 1999; Johnston, 
Tazelaar et al. 2003), liver (Auricchio, Gao et al. 2002), eye (Auricchio, Rivera et al. 
2002), and more recently in the brain (Sanftner, Rivera et al. 2006).  But to date, the tet 
responsive system has been favored for gene delivery in the brain (Haberman, McCown 
et al. 1998; Fitzsimons, McKenzie et al. 2001; Chtarto, Bender et al. 2003; Jiang, 
Rampalli et al. 2004; Chtarto, Yang et al. 2007).  There have been a few problems 
reported with the use of tet responsive elements in AAV vectors, mainly that there is 
“leakiness” or incomplete silencing of gene expression in the “off” state (Folliot, Briot et 
al. 2003; Chenuaud, Larcher et al. 2004; Gafni, Pelled et al. 2004; Jiang, Rampalli et al. 
2004).  As mentioned above, AAV TRs have been shown to posses transcriptional 
activity (Flotte, Afione et al. 1993; Haberman, McCown et al. 2000), and therefore 
optimization and thorough in vivo testing will be needed to resolve this issue.  While 
some issues still need to be worked out, the combination of inducible/conditional 
responsive elements along with cell type-specific promoters represent an attractive means 
to target and regulate AAV-mediated gene expression.    
V.B.2.  Cis-acting Regulatory Elements 
 Although the serotype and the promoter can each play a role in determining the 
transduction efficiency, there are other regulatory elements that when included in AAV 
vector genomes can enhance transduction efficiency.  The locus control region (LCR) 
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(reviewed in (Kioussis and Festenstein 1997) and the scaffold attachment region (SAR) 
are gene regulatory elements that act in cis to ensure that active transcriptional units are 
established in cells.  LCRs work at the level of chromatin remodeling to keep an open 
chromatin configuration, thus allowing transcription of the gene to occur (Festenstein, 
Tolaini et al. 1996).  These regulatory elements have shown promise in generating 
transgenic animals where transgene integration and subsequent expression are required 
(Dillon and Grosveld 1993), but limited success has been achieved in using these 
elements in viral vectors (Novak, Harris et al. 1990; Plavec, Papayannopoulou et al. 
1993).  In contrast, inclusion of SAR elements in retroviral vectors have been found to 
confer robust and position-independent enhancement of transgene expression (Agarwal, 
Austin et al. 1998; Auten, Agarwal et al. 1999).  How the SAR elements enhance 
transgene expression is not well understood, but one hypothesis is that they act like 
insulators to allow local access of transcription factors to the enhancer/promoter 
sequences within the domain (Bode, Kohwi et al. 1992; Jenuwein, Forrester et al. 1997).  
In fact, companies such as Gene Detect are incorporating SAR elements into their 
commercially available AAV vector plasmids (see http://www.genedetect.com/rave.htm).     
 Perhaps the best known regulatory element used to enhance AAV-mediated 
transgene expression is the Woodchuck hepatitis B virus post-transcriptional regulatory 
element (WPRE).  WPRE has been shown to increase the steady-state level of 
mRNA and the efficiency of translation, resulting in higher levels of transgene synthesis 
(Loeb, Cordier et al. 1999).  Paterna et al. performed the first in vivo quantitative 
comparison of AAV vectors containing the PDGF-β promoter in conjunction with a 
WPRE in the substantia nigra (Paterna, Moccetti et al. 2000).  It was found that a WPRE 
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boosted gene expression 1.8 fold compared to vectors that contained the PDGF-β 
promoter and lacked a WPRE (Paterna, Moccetti et al. 2000).  Then Xu et al. tested a 
variety of promoters with and without a WPRE in four different brain regions (Xu, 
Janson et al. 2001).  They also found a WPRE to enhance gene expression from every 
AAV vector and in every brain region tested (Xu, Janson et al. 2001).  Other groups have 
also seen improved transduction using AAV constructs with a WPRE in the lung and eye, 
(Lipshutz, Titre et al. 2003; Virella-Lowell, Zusman et al. 2005), demonstrating that the 
WPRE is definitely effective in an AAV context.   
It should be noted that maximum levels of transgene expression are not always 
desirable, especially when intracellular processing of the transgene is needed.  It is not 
hard to envision certain cellular pathways as being rate limiting, and thus overwhelming 
them with protein may have deleterious effects.  In addition, as previously discussed, 
some gene products cause unwanted side effects when robustly expressed (Kirik, 
Rosenblad et al. 2000; Georgievska, Kirik et al. 2002).  Furthermore, Chrarto et al. show 
that incorporating a WPRE in a tet-responsive AAV vector caused increased leakiness 
such that the transgene GDNF was expressed at a 2.5 fold greater level in the off state 
than baseline levels or a tet construct lacking a WPRE (Chtarto, Yang et al. 2007).  Thus, 
careful consideration over the inclusion of regulatory elements should be taken when 
designing AAV vectors for pre-clinical and clinical trials where tight gene regulation may 
be paramount to safety and therapeutic efficacy.                       
V.B.3.  Immune Response 
 One of the biggest challenges in optimizing viral vectors for gene therapy pertains 
to the host-mediated immune response.  This response can occur at the cellular level via 
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two pathways: a transient innate inflammatory immune response (i.e. the release of 
cytokines, and the recruitment of monocytes and/or macrophages and neutrophils), and 
an adaptive immune response where cytotoxic T lymphocytes (CTL) infiltrate the area of 
vector injection.  In addition, the host-mediated immune response can occur at the 
humoral level, where antibodies are generated against the structural components of the 
virus or the proteins encoded by the virus.  Due to the unique cytoarchitecture of the 
brain and the fact that is circumscribed by the blood-brain barrier (BBB), the brain 
parenchyma is immune privileged under normal conditions, and has been shown to 
exhibit no salient adaptive immune response, and only a minimal innate and humoral 
response to viral antigens (Barker and Billingham 1977; Lowenstein 2002).  Perhaps this 
is because the brain is devoid of lymphoid tissue, and the parenchyma does not normally 
contain antigen-presenting dendritic cells, thus an adaptive immune response is not  
primed after viral vector delivery (Lowenstein 2002).  Consequently, studies examining 
the immune response to rAAV vectors in the brain have focused primarily on the humoral 
response and its impact on transgene expression.   
Earlier studies examined the effects of single and repeat administration of rAAV 
into naïve animals with no pre-existing immunity to AAV.  Lo et al. delivered AAV2-
LacZ vectors into the mouse brain and reported that serum antibodies to AAV capsid 
proteins and β-gal transgene were elicited between 2–4 months post administration, but 
did not correlate with transgene expression (Lo, Qu et al. 1999).  Furthermore, the 
presence of these antibodies did not consistently prevent transgene expression following 
re-administration of the same vector 2 months later (Lo, Qu et al. 1999).  In another re-
administration study by Mastakov et al., it was found that transgene expression was 
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diminished by approximately 5 to 10 fold in animals where the second injection was done 
within a 2-4 week interval, but no reduction was observed if the second injection was 
given 3 months the after first injection (Mastakov, Baer et al. 2002).  These experiments 
suggest that timing between multiple injections may have a critical effect on therapeutic 
efficacy of AAV-mediated gene therapy in the brain.  Moreover, if rAAV5 was first 
injected, then 2 weeks later the same vector cassette was packaged into AAV2 and 
injected, no decrease in transgene expression occurred, suggesting that the loss of 
transgene expression observed earlier was in fact due to neutralizing antibodies to the 
rAAV5 capsid (Mastakov, Baer et al. 2002).  Thus, sequential delivery of different rAAV 
serotypes into the brain avoids the host immune response.  However, this strategy may 
create new problems, because (as discussed in section V.A.) the different serotypes 
exhibit different transduction patterns in the brain.  Perhaps the identification and 
mutation of antigenic capsid epitopes that are recognized by neutralizing antibodies can 
be achieved without affecting receptor binding and thus the transduction profile.  In fact, 
Lochrie et al. tried to accomplish this using in silico modeling of antibody-capsid binding 
interactions, then mutated residues suspected of being immune epitopes (Lochrie, 
Tatsuno et al. 2006).  Other approaches include insertion of peptides in or near 
neutralizing epitopes (Huttner, Girod et al. 2003), or simultaneous recombination and 
mutagenesis of the AAV2 capsid gene followed by selection in the presence of human 
antisera (Maheshri, Koerber et al. 2006; Perabo, Endell et al. 2006).   Regardless of the 
method used to engineer the virus, unless the paradigm that the vector is tested in 
accurately reflects a clinical trial scenario, the utility and predictive value of the outcome 
will be diminished.    
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More recent experiments examining the humoral immune response have been 
conducted in animals that have been pre-immunized via peripheral exposure to AAV.  
This model more accurately represents the human population where an estimated 80% 
have circulating antibodies to the capsid proteins of wtAAV2, and 30% to 70% 
demonstrate the presence of neutralizing anti-capsid antibodies that can bind to the 
surface of the virus, thereby preventing attachment to cellular receptors and subsequent 
cellular uptake (Chirmule, Propert et al. 1999; Erles, Sebokova et al. 1999; Xiao, 
Chirmule et al. 1999; Hildinger, Auricchio et al. 2001; Halbert, Miller et al. 2006).  In a 
study by Sanftner et al., a peripheral injection of a rAAV2 non-expressing vector (lacking 
a promoter) was followed by bilateral intrastriatal injection of rAAV2 encoding a 
therapeutic transgene (Sanftner, Suzuki et al. 2004).  Neutralizing antibody titers after 
rAAV administration in the striatum were highest in the animals pre-immunized with 
higher doses of rAAV, and there was a weakly linear and negative relationship between 
antibody titer and transgene expression distribution (R2 = 0.30 (Sanftner, Suzuki et al. 
2004).  No evidence of abnormal morphology, cellular infiltration or inflammatory 
markers was found.  The authors concluded that rAAV vectors can transduce brain tissue 
in the context of pre-existing immunity, but that efficiency of transduction declines 
significantly in the presence of very high titers of neutralizing antibodies (Sanftner, 
Suzuki et al. 2004).  In contrast to these results, another group used a strategy of multiple 
pre-immunization injections with wtAAV2 and adjuvant, and found that the resulting 
high levels of circulating neutralizing antibodies were sufficient to completely block 
striatal transduction (Peden, Burger et al. 2004).  It has been suggested that the 
conflicting results between these two studies are likely due to differences in the 
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immunization strategies, surgical techniques, BBB integrity, rAAV formulations, and 
serological methodologies (McPhee, Janson et al. 2006).          
While the Peden study raises some concerns with using rAAV2 as a gene therapy 
vector in the brain, a couple of phase I clinical trials have already been completed with 
promising results (McPhee, Janson et al. 2006; Kaplitt, Feigin et al. 2007).  In the 
Canavan disease (CD) trial, an rAAV2 vector encoding a functional copy of the 
aspartoacylase gene (ASPA) was injected at 6 sites: bilaterally in the frontal, 
periventricular and occipital lobes (McPhee, Janson et al. 2006).  It was found that only 1 
of 10 subject had circulating neutralizing antibodies to AAV before rAAV 
administration, and 3 of 10 had circulating neutralizing antibodies to AAV after rAAV 
administration (McPhee, Janson et al. 2006).  Fortunately, the subject with pre-existing 
neutralizing antibodies had no adverse events, and a physiological response that was 
similar to the other subjects (McPhee, Janson et al. 2006).  In the Parkinson’s disease 
(PD) trial, 2 of 12 subjects had pre-existing neutralizing antibodies, but the levels did not 
change in any of the subjects following delivery of an AAV2 vector encoding glutamic 
acid decarboxylase (GAD) into the subthalamic nucleus (Kaplitt, Feigin et al. 2007).  The 
lack of induction of neutralizing antibodies in the PD study compared to the CD study 
may be attributed to fewer injection sites and therefore less BBB disruption.  Moreover, 
in the PD study there was no correlation between pre-existing immunity and clinical 
outcome, as measured by improvement in motor function while off medication (Kaplitt, 
Feigin et al. 2007).  Finally, there was no evidence of pre-existing antibodies to the 
transgene, and no induction of such antibodies at any time in any patient over the course 
of the 1 year study (Kaplitt, Feigin et al. 2007).  While the PD study was only an open 
label Phase I study, the results suggest that pre-existing immunity to wtAAV may not 
prevent effective AAV-mediated gene transfer in the human brain.    
V.C. Conclusions and Progress of Current Gene Therapy Clinical Trials in Brain 
 Many chronic neurological diseases do not respond to small molecule 
therapeutics, and have no effective long-term treatment.  In fact, as many as 98% of the 
candidate neuro-therapeutic drugs never get developed for clinical use because they have 
poor BBB permeability (Pardridge 2001).  Gene therapy is a promising alternative to 
continuous administration of neuro-therapeutic drugs, because vectors can be locally 
delivered to affected brain regions, where they mediate de novo synthesis of therapeutic 
compounds.  It has been shown that in vivo production of these therapeutic compounds 
are more effective than their acute infusion (Frim, Simpson et al. 1993; Frim, Uhler et al. 
1993; Venero, Beck et al. 1994; Martinez-Serrano and Bjorklund 1996).  In addition, 
long-term transgene expression can be achieved in the brain following a single vector 
injection.  For example, a single injection of an AAV vector into the striatum of primates 
resulted in sustained gene expression for more than 6 years (Bankiewicz, Forsayeth et al. 
2006).  It is likely that the same persistence will be achieved in the human brain because 
injections of rAAV in the muscle resulted in sustained gene expression upon biopsy 3.7 
years post-delivery (Jiang, Pierce et al. 2006).     
Currently, there are 12 open gene therapy clinical trials in the CNS, but most of 
them are being conducted with naked DNA as the delivery vector (see table 5-1).  Naked 
plasmid gene transfer is safe, easy to handle, and cost effective, but has generally been 
considered to be less efficient than viral gene transfer (Huang, Hung et al. 1999).   
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Table 5-1. Current Open Gene Therapy Trials for Neurological Diseases. 
This data is current to July 2007.  For more details on these clinical trials please see: 
http://www.wiley.co.uk/wileychi/genmed/clinical/ 
 
Trial ID Title Gene Disease Vector Phase 
UK-129 A multicenter, randomized, double 
blind, placebo-controlled study to 
evaluate the safety, tolerability, and 
efficacy of BHT-3009 when 
administered intramuscularly to 
patients with relapsing remitting 
multiple sclerosis (Protocol No. 
BHT-3009-03). EudraCT: 2005-
001340-22  
Myelin Basic Protein 
(MBP) 
Multiple 
Sclerosis 
Naked/Plasmid 
DNA 
I 
UK-132 A Phase II Double Blind, Cross-
over Study to Compare the Safety 
and Efficacy of 125, 250 and 
500µg/kg Monarsen (EN101) 
administered to Patients with 
Myasthenia Gravis. EudraCT: 
2005-002740-26  
Antisense 
Oligodeoxynucleotide 
against 
acetylcholinesterase  
Myasthenia 
Gravis 
Naked/Plasmid 
DNA 
II 
US-180 Phase I Single Dose-ranging Study 
Of Formulated hIGF-I Plasmid In 
Subjects With Cubital Tunnel 
Syndrome 
Insulin-like growth factor-
1 (IGF-1) 
Cubital Tunnel 
Syndrome 
Naked/Plasmid 
DNA 
I 
US-632 pVGI.1 (VEGF-2) Gene Transfer 
for Diabetic Neuropathy 
Vascular endothelial 
growth factor (VEGF) 
Diabetic 
Peripheral 
Neuropathy 
Naked/Plasmid 
DNA 
I/II 
US-656 A Phase I/II, Dose-escalation 
Clinical Trial of SB509 in Subjects 
with Diabetic Neuropathy 
VOP32E VEGF-A 
Transcription Factor 
Diabetic 
Peripheral 
Neuropathy 
Naked/Plasmid 
DNA 
I/II 
US-669 Hippocampal NPY Gene Transfer 
in Subjects with Intractable 
Temporal Lobe Epilepsy 
Neuropeptide Y (NPY) Epilepsy 
 
Adeno-
associated virus 
I 
US-689 A Phase I, Open-Label Study of 
CERE-120 (Adeno-Associated 
Virus Serotype 2 [AAV2]-
Neurturin [NTN]) to Assess the 
Safety and Tolerability of 
Intrastriatal Delivery to Subjects 
with Idiopathic Parkinson's Disease 
Neurturin (NTN) Parkinson's 
Disease 
Adeno-
associated virus 
I 
US-723 BHT-3009 Immunotherapy in 
Relapsing Remitting Multiple 
Sclerosis 
Myelin Basic Protein 
(MBP) 
Multiple 
Sclerosis  
Naked/Plasmid 
DNA 
II 
US-788 Multicenter, Randomized, Double-
blind, Sham Surgery-controlled 
Study of CERE-120 (Adeno-
Associated Virus Serotype 2 
[AAV2]-Neurturin [NTN]) to 
Assess the Efficacy and Safety of 
Bilateral Intraputamenal (IPu) 
Delivery in Subjects With 
Idiopathic Parkinson's Disease 
Neurturin (NTN) Parkinson's 
Disease 
Adeno-
associated virus 
 
II 
US-822 A Phase 2 Repeat Dosing Clinical 
Trial of SB-509 in Subjects with 
Diabetic Neuropathy 
Zinc finger DNA binding 
protein (ZPF-TF) 
Diabetic 
Peripheral 
Neuropathy 
Naked/Plasmid 
DNA 
II 
US-837 A Phase 2 Repeat Dosing Clinical 
Trial of SB-509 in Subjects with 
Moderate to Severe Diabetic 
Neuropathy and Unmeasurable 
Nerve Conduction Velocity 
Zinc finger DNA binding 
protein (ZPF-TF) 
Diabetic 
Peripheral 
Neuropathy 
Naked/Plasmid 
DNA 
II 
US-851 Cell-Based Gene Therapy Using 
MRC-MBP for Treatment of 
Multiple Sclerosis-Phase I/II 
Myelin Basic Protein 
(MBP) 
Multiple 
Sclerosis 
Retrovirus I/II 
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Perhaps when the initial AAV gene therapy clinical trials are completed and found to be 
well tolerated, more will be approved.   
A very exciting clinical trial is being initiated using AAV vectors to delivery NPY 
to the hippocampus of patients with intractable TLE.  It is the first gene therapy trial to be 
conducted in epileptic patients.  Pre-clinical studies including those that were presented 
in this thesis show that AAV-mediated delivery of NPY to the brain results in seizure 
suppression, and therefore has enormous therapeutic potential (Richichi, Lin et al. 2004;  
Foti, Haberman et al. 2007).  Although this trial will initially be a Phase I study and thus 
is not designed to assess transgene efficacy, it is still possible that subjects will obtain 
vector-mediated therapeutic benefits. 
Currently, the most promising neurological gene therapy trial is the AAV-
mediated delivery of neurturin (NTN) to the striatum of patients with advanced PD.  
NTN is a naturally occurring neurotrophic factor that has been shown to be 
neuroprotective and regenerative in the damaged dopaminergic neurons that undergo 
degeneration in PD  (Oiwa, Yoshimura et al. 2002).  Loss of dopaminergic innervation of 
the striatum as a consequence of substantia nigral degeneration results in the cardinal 
symptoms of PD, including tremor, rigidity, and the progressive inability to initiate and 
control physical movements (Lang and Lozano 1998).  In a recent press release the 
company conducting the trial announced that the AAV vector was well tolerated in the 
patients; and that the treatment appeared to reduce 8 of the 12 patients’ symptoms by 
approximately 52% at 24 months post-treatment (see 
http://www.medicalnewstoday.com/articles/91612.php).  Furthermore, a multi-center 
double-blind, controlled Phase II clinical trial completed enrollment in December of 
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2007, of 58 patients with advanced PD.  Two thirds of patients will be given the 
treatment and one third will be in a control group.  Clinical data from this trial are 
expected to be available in late 2008, and if the data are positive, a Phase III trial is 
expected to commence in 2009.  Thus, this may be the first AAV vector-mediated gene 
therapy to undergo Phase III testing.              
 In conclusion, AAV vectors have demonstrated clinical potential.  The most 
critical issues that will need to be addressed to ensure safe and effective gene therapy in 
the brain are increased gene transfer efficiency, target specificity, and the ability to 
regulate gene expression so maximal therapeutic efficacy can be reached with minimal 
adverse effects.  To this end, substantial progress is being made using recently developed 
techniques to engineer the virus, both at the structural level through capsid modification, 
and at the gene transcriptional level via promoter choice and regulatory element 
inclusion.  It is likely that the combination of these developments will facilitate clinical 
gene therapy.         
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Appendices 
 
Appendix A. Plasmids Generated and Characterized 
Table 6-1. Plasmids Generated and Characterized. 
Abbreviations are: ELISA: Enzyme-Linked ImmunoSorbent Assay; GAL: galanin; GDNF: glial cell 
derived neurotrophic factor; IP/WB: Immunoprecipitation and Western blotting; LUC: Luciferase GL3; 
NA: no assay performed; PCR: polymerase chain reaction; RFP: DsRed2-C1; RKLRKR: arginine-lysine-
leucine-arginine-lysine-arginine; RKRRKR: arginine-lysine-arginine-arginine-lysine-arginine; RT-PCR: 
Reverse transcriptase-polymerase chain reaction; WB: Western blotting.   
Constructs 
Generated 
Assays  Results 
ptTak-Dynorphin A 1-13 
FIB (has TR2) 
WB Protein doesn't stick to membranes and may be 
cleaved in vivo 
ptTAK-NPY13-36 FIB (has 
TR2) 
ELISA NPY13-36 detected in lysates only, not sensitive 
enough for detection upon secretion into medium 
CB-DsRed2-C1-FIB (CB-
FIB-RFP) (has TR2) 
WB DsRed antibody binds high molecular weight bands 
and is very poor at detecting proper size 
pTR-CB-FIB-EGFP-
RKLRKR-FIB-RFP  
WB GFP antibody detects fusion protein in lysates 
pTR-CB-FIB-EGFP-
RKLRKR-RFP 
WB GFP antibody detects fusion protein in lysates, and 
cleaved protein in medium 
pTR-CB-FIB-EGFP-
RKLGGG-RFP 
WB GFP antibody detects fusion protein in lysates 
pTR-CB-FIB-LUC 
(Luciferase GL3) 
WB and IP/WB 
and light assay 
Luciferase antibody detects protein in lysates but not 
medium so luciferase not secreted and not functional 
in light assay 
pTR-CB-FIB-LUC-
RKRRKR-EGFP 
WB and IP/WB 
and light assay 
Luciferase antibody detects protein in lysates but not 
medium so luciferase not secreted and not functional 
in light assay; GFP antibody detects fusion and 
cleaved protein in lysates 
pTR-CB-FIB-LUC-
RKRRKR-FIB-EGFP 
WB and IP/WB GFP antibody detects cleaved protein in medium and 
both cleaved and fusion proteins in lysates 
pTR-CB-FIB-GAL-
RKRRKR-EGFP 
IP/WB kainic acid 
test 
GFP antibody detects cleaved protein in medium and 
both fusion and cleaved protein in lysates; some 
seizure protection is observed but not to the extent of 
galanin alone  
pTR-CB-FIB-GAL-
RKRRKR-FIB-EGFP 
IP/WB kainic acid 
test 
GFP antibody detects cleaved protein in medium and 
both fusion and cleaved protein in lysates; galanin 
blocks seizures in vivo  
pTR-CB-FIB-EGFP-
RKRRKR-FIB-GAL 
IP/WB Misfolded so does not fluoresce in situ, but can be 
detected with GFP antibody in IP/WB 
pTR-CB-EGFP-RKRRKR-
FIB-GAL 
Transfection  Does fluoresce 
pTR-UF-WGDNF (CB-
human pre-pro GDNF plus 
WPRE and TR2) 
NA  
pTR-UF-GDNF (removed 
WPRE) 
ELISA/ made 
virus for 
collaboration 
GDNF is detected in medium and lysates; Publishing 
with this, article in press 
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pBS-SK-huNGF (human pre-
pro Nerve Growth Factor ) 
PCR Worked for cloning  
pTR-UF-NGF (cloned human 
pre-pro Nerve Growth Factor 
into UF-GDNF plasmid ) 
ELISA NGF detected in medium 
pTR-CB-NGF-RKRRKR-
GDNF 
ELISA Only GDNF detected in medium and lysates 
pTR-CB-FIB-NPY RT-PCR and 
kainic acid test  
Published with this (Foti, Haberman et al. 2007)  
pTR-CB-FIB-NPY13-36 RT-PCR and 
kainic acid test  
Published with this (Foti, Haberman et al. 2007) 
pCMV-Sport6-hGAL (human 
galanin) 
PCR Worked for cloning 
pTR-CB-hGAL NA  
pTR-CB-FIB-GAL-
RKRRKR-FIB-NPY 
NA  
pTR-CB-FIB-GAL-
RKRRKR-FIB-NPY13-36 
NA  
pTR-CB-FIB-GAL-EGFP IP/WB GFP antibody detects gal-GFP fusion protein in 
medium, but some degradation product present along 
with fusion in lysates 
pTR-CB-FIB-GAL-EGFP 
mut (ATG removed from 
GAL and EGFP) 
IP/WB kainic 
acid test 
GFP antibody detects gal-GFP fusion protein in 
medium, but some degradation product present along 
with fusion in lysates; some seizure protection is 
observed but not to the extent of galanin alone 
pN1-CB-FIB-EGFP-
RKRRKR-GAL (no TR for 
mutagenesis from EGFP N1 
plasmid) 
PCR Worked for cloning 
pN1-CB-FIB-GAL-
RKRRKR-EGFP (no TR for 
mutagenesis) 
PCR Worked for cloning 
pN1-CB-FIB-GAL-EGFP 
mut (no TR for mutagenesis) 
PCR Worked for cloning 
pTR-CB-KOZ-FIB-GAL-
EGFP mut (added Kozak 
sequence) 
IP/WB GFP antibody detects gal-GFP fusion protein in 
medium, but some degradation product present along 
with fusion in lysates 
pTR-CB-KOZ-FIB-GAL-
RKRRKR-EGFP mut (added 
Kozak sequence) 
IP/WB Construct does not behave properly in IP/WB 
pTR-CB-KOZ-FIB-EGFP-
RKRRKR-GAL mut (added 
Kozak sequence) 
IP/WB GFP antibody detects cleaved protein in medium and 
fusion proteins in lysates 
pTR-CB-KOZ-FIB-GAL-
RKRRKR-NPY13-36 (added 
Kozak sequence) 
NA  
pTR-CB-FIB-EGFP-RKR Transfection  Does fluoresce 
pTR-CB-FIB-ADNF made virus for 
collaboration 
 
pCMV-IL-10 NA  
pTR-CB-FIB-EGFP-
RKRRKR-GAL mut 
IP/WB kainic 
acid test 
GFP antibody detects cleaved protein in medium and 
fusion proteins in lysates; galanin blocks seizures in 
vivo 
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pTR-CB-FIB-GAL-
RKRRKR-NPY13-36 mut 
RT-PCR and 
kainic acid test  
Correct vector-derived mRNA product present after 
rAAV infection in vivo, and some seizure protection is 
observed but not to the extent of galanin or NPY13-36 
alone 
pTR-CB-FIB-GAL-
RKRRKR-EGFP mut 
IP/WB  Construct does not behave properly in IP/WB 
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Appendix B. Multiple Gene Product Delivery Vectors 
 Along with the other in vitro experiments to characterize the secreted proteins 
from our multiple gene product delivery vectors, an immunoprecipitation followed by 
SDS-PAGE and Coomassie staining for mass spectrometry analysis was performed on 
medium harvested from 293 cells transfected with the following constructs: CB-FIB-
EGFP, CB-FIB-GAL-RKRRKR-FIB-EGFP, CB-FIB-EGFP-RKRRKR-FIB-GAL, CB-
FIB-GAL-RKRRKR-EGFP, and CB-EGFP.  Upon mass spectrometry analysis, we found 
that all samples contained fragments of the FIB sequence and GFP, but not galanin; 
except the sample from CB-EGFP, which contained only GFP fragments (see Figure 6-
1).  While these results are promising, a positive control such as CB-FIB-GAL-EGFP 
must be included next time to assure that galanin can be detected in this assay. 
Appendix C. Nerve Growth Factor (NGF) and Glial Cell Derived Neurotrophic  
Factor (GDNF) 
In addition to epilepsy, there are many neurological diseases that can benefit from 
AAV-mediated gene therapy.  Neurodegeneration is a common pathology of several 
diseases (e.g. Huntington’s disease (HD), Parkinson’s disease (PD), Alzheimer’s disease 
(AD), and temporal lobe epilepsy (TLE), and if left unchecked causes progressive 
decline.  Neurotrophic factors have long been recognized to be neuroprotective, and there 
is a growing interest in using them as therapeutics. Several studies have shown that NGF, 
brain-derived neurotrophic factor (BDNF), and GDNF are each capable of protecting 
neurons from death in rat models of HD (Davies and Beardsall 1992; Frim, Short et al. 
1993; Galpern, Matthews et al. 1996; Martinez-Serrano and Bjorklund 1996; Perez-
Navarro, Arenas et al. 1996; Araujo and Hilt 1997; Araujo and Hilt 1998; Perez-Navarro, 
Arenas et al. 1999; Cruz-Aguado, Turner et al. 2000; Menei, Pean et al. 2000;  
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Figure 6-1. Immunoprecipitation Followed by SDS-PAGE and Coomassie Staining 
of Multiple Gene Product Delivery Vectors for Mass Spectrometry Analysis. 1, 7) 
Low molecular weight rainbow marker, 2) CB-FIB-EGFP, 3) CB-FIB-GAL-RKRRKR-
FIB-EGFP, 4) CB-FIB-EGFP-RKRRKR-FIB-GAL, 5) CB-FIB-GAL-RKRRKR-EGFP, 
6) CB-EGFP.  Constructs were transfected into 293 cells using PEI (1mg/mL), and 48 
hours later medium was harvested and immunoprecipitated using a GFP polyclonal 
antibody.  After SDS-PAGE, the gel was fixed in 25% isopropanol, 10% acetic acid, and 
65% sterile water, and stained overnight with Coomassie 0.01% in 10% acetic acid.  
Yellow boxes indicate the bands excised from the gel and digested in trypsin for protein 
laddering matrix assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS).  Samples 2-4 all contained fragments of the FIB signal sequence and 
GFP, but not galanin.  Sample 5 contained only GFP but not FIB or galanin.  Sample 6 
contained only antibody fragments.  While these results are promising, a positive control 
such as CB-FIB-GAL-EGFP must be included next time to assure that galanin can be 
detected in this assay.       
 
     
 
 
1 2 3 4 5 6 7
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Alberch, Perez-Navarro et al. 2002; Maksimovic, Jovanovic et al. 2002; McBride, During 
et al. 2003; Kells, Fong et al. 2004).  However, individual neurotrophic factors 
preferentially spare subpopulations of neurons, and this sparing may be influenced by the 
neurotrophic factor’s route of delivery.  For example, acute infusions of NGF prior to or 
concurrent with quinolinic acid (QA) spares the cholinergic interneurons of the striatum, 
but not the striatal GABA-ergic medium spiny neurons (primary neurons vulnerable to 
the degenerative cascade seen in HD) or the noncholinergic neurons (containing 
somatostatin, or NADPH-diaphorase) (Venero, Beck et al. 1994).  In contrast, when NGF 
is chronically secreted by genetically modified cells, it potently protects the cholinergic, 
GABA-ergic and noncholinergic neurons from QA induced degeneration (Frim, Uhler et 
al. 1993; Martinez-Serrano and Bjorklund 1996), and 3-NP induced degeneration (Frim, 
Simpson et al. 1993).  So, therapeutic gene delivery of neurotrophic factors yields more 
comprehensive protection for striatal neurons than acute infusions of the same factors.  
Similarly, ex vivo methods of delivering GDNF to the striatum only results in partial 
neuroprotection (Perez-Navarro, Arenas et al. 1996; Perez-Navarro, Arenas et al. 1999), 
thus, using an in vivo method of neurotrophic factor delivery may overcome this 
difficulty.  In fact, McBride et al use adeno-associated virus (AAV) as their method of 
therapeutic gene delivery to inject a GDNF expressing viral vector into the striatum of 
rats before 3-NP challenge (McBride, During et al. 2003).  They report significant 
reduction in lesion size (assessed by NeuN immunohistochemistry) and increased 
survival of striatal GABA-ergic neurons (assessed by a DARPP-32, a marker of GABA-
ergic terminals).  In addition, rats receiving GDNF perform better on motor tasks than 
controls, suggesting that viral-mediated gene transfer of GDNF into the striatum affords 
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neuroanatomical and behavioral protection from 3-NP.  Although striatal neuronal 
subtypes were not extensively evaluated in the McBride et al study, Kells et al used AAV 
to deliver BDNF or GDNF prior to QA lesioning rats and evaluated subpopulations of 
GABA-ergic striatal interneurons.  BDNF expression protected NOS-immunopositive 
neurons while GDNF protected parvalbumen immunopositive neurons (Kells, Fong et al. 
2004).  Since neither neurotrophic factor can afford complete protection when 
administered singly, a combination of neurotrophic factors should be used.  Therefore, 
we were interested in using our multiple gene product delivery vectors to deliver both 
NGF and GDNF in a rat model of Huntington’s disease.  NGF and GDNF are both 
synthesized as precursors that must be correctly assembled into homodimers, and cleaved 
into their active forms.  It has been reported that NGF needs its pro-sequence in order to 
fold properly (Rattenholl, Ruoppolo et al. 2001), so we opted not to use the FIB sequence 
to mediate secretion, but to use the pre-pro sequences of both NGF and GDNF (each 
containing their own secretion sequence) to ensure correct folding and secretion.  Using 
the same cloning strategy as described in Chapter 2, we constructed the following AAV-
compatible plasmids: TR-CB-EGFP, TR-CB-β-NGF, TR-CB-GDNF, and TR-CB-β-
NGF-RKRRKR-GDNF.  To characterize these constructs in vitro, we transfected them 
into 293 cells and harvested medium 48 hours post transfection, added leupeptin and 
aprotinin protease inhibitors, briefly centrifuged the medium to remove any cellular 
debris, and stored the medium at -80oC until use in Enzyme-Linked ImmunoSorbent 
Assay (ELISA).  We found we could only detect NGF from our TR-CB-β-NGF 
transfected samples and our NGF protein spiked samples, but not from our TR-CB-β-
NGF-RKRRKR-GDNF transfected samples (see Figure 6-2).  We were however  
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Figure 6-2. NGF and GDNF ELISA. 
Assay reveals that NGF is not detected in the medium following transfection of CB-β-NGF-
RKRRKR-GDNF, but GDNF is detected.  Note that the antibodies are specific for each 
neurotrophin and do not cross-react.   
NFG ELISA (Avg of Duplicates)
25
243
17 22
225
23
0
50
100
150
200
250
300
C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
CB-FIB-EGFP
CB-B-NGF
CB-GDNF
CB-B-NGF-RKRRKR-
GDNF
NGF Protein Spike
Untransfected Control
GDNF ELISA (Avg of Duplicates)
27 36
2356
2572
2758
26
0
500
1000
1500
2000
2500
3000
C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
CB-FIB-EGFP
CB-B-NGF
CB-GDNF
CB-B-NGF-RKRRKR-
GDNF
GDNF Protein Spike
Untransfected Control
112 
 
detecting GDNF from our GDNF protein spiked samples, TR-CB-GDNF transfected 
samples, and our TR-CB-β-NGF-RKRRKR-GDNF transfected samples (see Figure 6-2).  
This is a puzzling result at first glance because GDNF is the second gene product in our 
multi gene product delivery vector, so if we are detecting it, then it is likely that NGF is 
also expressed even though we cannot detect it.  These results can be explained if the 
NGF protein was indeed expressed but misfolded.  Misfolded NGF might not show up in 
an ELISA if the antibody cannot detect denatured protein.  This issue can be resolved by 
performing a western blot assay with an antibody designed to detect denatured protein.  
However, we felt it was not worth the expense to confirm that the NGF was being 
misfolded, because misfolded NGF is not functional and obviously not therapeutic.  We 
decided to discontinue this project, but we gleaned very critical information from these 
experiments about potential protein folding issues when using our multiple gene product 
delivery vectors.   
Appendix D. Publications 
Appendix D.1. Adeno-associated Virus-Mediated Expression and Constitutive  
  Secretion of NPY or NPY13-36 Suppresses Seizure Activity In Vivo.  
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Neuropeptide Y (NPY) is a 36–amino acid peptide that attenuates seizure activity 
following direct infusion or AAV-mediated expression in the CNS.  However, NPY 
activates all NPY receptor subtypes, potentially causing unwanted side effects.  NPY13-
36 is a C-terminal peptide fragment of NPY that primarily activates the NPY Y2 
receptor, thought to mediate the anti-seizure activity.  Therefore, we investigated if rAAV 
mediated expression and constitutive secretion of NPY or NPY13-36 could alter limbic 
seizure sensitivity.  Rats received bilateral piriform cortex infusions of AAV vectors that 
express and constitutively secrete full length NPY (AAV-FIB-NPY), or NPY13-36 
(AAV-FIB-NPY13-36).   Control rats received no infusion, as we have previously shown 
that vectors expressing and secreting reporter genes like GFP (AAV-FIB-EGFP), as well 
as vectors expressing peptides that lack secretion sequences (AAV-GAL) have no effect 
on seizures.  One week later, all animals received kainic acid (10 mg/kg, i.p.), and the 
latencies to wet dog shakes and limbic seizure behaviors were determined.  Although 
both control and vector treated rats developed wet dog shake behaviors with similar 
latencies, the latencies to class III and class IV limbic seizures were significantly 
prolonged in both NPY and NPY13-36 treated groups.  Thus, AAV-mediated expression 
and constitutive secretion of NPY and NPY13-36 is effective in attenuating limbic 
seizures, and provides a platform for delivering therapeutic peptide fragments with 
increased receptor selectivity.  
 
Key Words: Adeno-associated virus, gene therapy, epilepsy, seizures, kainic acid, 
neuropeptide Y, NPY13-36, piriform cortex  
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Epilepsy is an attractive target for recombinant Adeno-associated virus (rAAV) 
gene therapy, because the temporal lobe structures involved in seizure genesis and 
propagation have been shown to be permissive to AAV gene transfer.1-6  Recently, 
galanin and neuropeptide Y (NPY) have been delivered as transgenes in rAAV vectors, 
and shown to be effective in several epilepsy paradigms.1,3,6,7  While previous approaches 
utilize pre-pro cDNA sequences which rely on the cell to modulate release of the gene 
product, Haberman et al.3 were the first to use a novel secretion strategy whereby the 
secretion signal sequence from the constitutively secreted laminar protein fibronectin 
(FIB), is combined with the coding sequence for the active therapeutic peptide.  Results 
from Haberman et al.3 and McCown1 show that expression and constitutive secretion of 
galanin is not only achieved, but also effective in attenuating focal and limbic seizure 
activity.  In contrast, expression of galanin without the secretory signal or expression and 
secretion of the reporter gene, GFP had no effect on seizure sensitivity.1,3    
In addition to galanin, rAAV delivery of NPY has also been shown to attenuate 
limbic seizures,6 however, there is still some question as to which of the NPY receptors 
(Y1-Y5) mediates the anti-seizure activity.  Several studies have suggested a critical role 
for the Y2 receptor in mediating anti-epileptic actions.8-14  In addition, it has been 
demonstrated that in epileptic tissue from patients15 and rodents16,17 that Y1 receptors are 
downregulated while Y2 receptors are upregulated.  Taken together, these results suggest 
that when designing anti-epileptogenic therapeutics, it may be advantageous to deliver 
Y2 preferring agonists.  In fact, acute intracerebral delivery of the Y2 receptor preferring 
agonist NPY13-36 reduces seizure susceptibility following systemic kainic acid 
administration.18,19  These data suggest NPY13-36 would be a good candidate to use in an 
116 
rAAV vector to treat epilepsy.  By using the FIB secretion strategy, we have the 
capability of expressing and constitutively secreting peptide fragments which have 
demonstrated receptor selectivity.  Thus, we evaluated the effects of AAV mediated 
expression and constitutive secretion of NPY and the peptide fragment NPY13-36 on 
kainic acid induced limbic seizures.    
 Although previous studies validated the effectiveness of gene expression and 
constitutive secretion using galanin, the same approach might not necessarily prove 
successful with NPY or the peptide fragment NPY13-36.  Therefore, we used a similar 
approach with the following modifications: AAV 2 vectors were constructed where the 
hybrid chicken beta actin promoter drives expression of the FIB-NPY or FIB-NPY13-36 
coding sequences.  Then, 2 µl of recombinant AAV-FIB-NPY (3.3 X 1012 viral 
particles/ml) or AAV-FIB-NPY13-36 (3.0 X 1012 viral particles/ml) was infused 
bilaterally into the piriform cortex of rats, as previously described.1  Control rats received 
no infusion, as we have previously shown that vectors expressing and secreting reporter 
genes like GFP (AAV-FIB-EGFP), as well as vectors expressing peptides that lack 
secretion sequences (AAV-GAL) have no effect on seizure sensitivity, seizure behaviors, 
or seizure-induced cell death.1,3  One week later, the rats received a dose of 10 mg/kg, i.p. 
kainic acid, and subsequently, the time to limbic seizure behaviors was recorded.  As 
seen in Figure 1, both AAV treatment groups and the untreated control group developed 
wet dog shake behaviors with the same latency.  Because the origin of wet dog shakes 
appears to be the hippocampus,20 a local action of the AAV-FIB-NPY or AAV-FIB-
NPY13-36 in the piriform cortex would not be expected to influence these kainic acid-
induced behaviors.  However, the findings do validate the uniformity of kainic acid 
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administration across the different groups.  In marked contrast, the latency to class III or 
class IV limbic seizure activity was significantly increased in the AAV-FIB-NPY or 
AAV-FIB-NPY13-36 treated groups.  In fact, the majority of rats in both vector treated 
groups did not exhibit any seizure behavior at all, whereas all rats in the untreated group 
develop class III and class IV seizures within 90 minutes (see Figure 1).  Thus, like 
findings with expression and secretion of galanin, NPY actions in the piriform cortex 
significantly attenuated seizure activity induced by the peripheral administration of the 
chemical convulsant kainic acid.  As previously discussed, the constitutive secretion of 
these peptides renders immunohistochemical identification untenable,3 but as previously 
shown for galanin,1,3 the appropriate vector-derived NPY or NPY13-36 mRNA was 
present in the area of AAV infusion (see Figure 2).  Thus, not only does this gene therapy 
approach prove effective with NPY, but it is now also possible to express and secrete 
active fragments of peptides, allowing for more selective receptor targeting.   In addition, 
the use of smaller peptide fragments in an AAV context may allow for combinations of 
therapeutic peptides to be expressed from a single vector cassette.  It is likely that 
combination therapy will be the key to treating many complex neurological disorders.   
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FIGURES AND LEGENDS: 
 
Figure 1 – The effects of AAV-FIB-NPY and AAV-FIB-NPY13-36 vectors on the 
expression of limbic seizure behaviors.  Rats received bilateral infusions of AAV-FIB-
NPY (2µl/20 minutes; 3.3 X 1012 viral particles/ml) (N=7) or AAV-FIB-NPY13-36 
(2µl/20 minutes; 3.0 X 1012 viral particles/ml) (N=7) into the piriform cortex as 
previously described.1  Seven days later both vector treated groups and an untreated 
control group (N=8) received an i.p. injection of kainic acid (10 mg/kg).  The latencies to 
limbic seizure behaviors were determined for 240 minutes post-kainic acid.  Seizures 
were scored according to the Racine motor seizure grading scale.21  Briefly, class I 
seizures were scored when rats exhibited facial twitches and chewing, class II when head 
nodding, class III when contralateral forelimb clonus was observed, and class IV when 
bilateral forelimb clonus and rearing was observed.  All groups developed wet dog shakes 
with the same latencies, indicating the uniformity of kainic acid administration across the 
different groups.  In marked contrast, however, onset of class III and class IV seizures 
was significantly delayed or completely blocked in rats receiving either AAV-FIB-NPY 
or AAV-FIB-NPY13-36 compared to control.  (* t-test, p<0.01).  In fact, only 3/7 AAV-
FIB-NPY treated rats and 1/7 AAV-FIB-NPY13-36 treated rats developed any class III or 
class IV seizure behaviors over the entire 240 minute observation period.  All 8 rats in the 
untreated control group developed class III and class IV seizures within 90 minutes. 
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 Figure 2 – The in vivo presence of FIB-NPY and FIB-NPY13-36 mRNA one week after 
vector infusion into the piriform cortex.  The appropriate 208 bp FIB-NPY (lane A) or 
172 bp FIB-NPY13-36 (lane C) product is present in the injected piriform cortex while 
no product was found in an area slightly distal to the piriform cortex (lane B). Omission 
of the RT step (lanes D and E) indicated the absence of contaminating viral DNA.   The 
left outside lane contains a 100 base pair DNA step ladder (Invitrogen) with the size 
indicated on the left.  Rats received bilateral infusions of AAV-FIB-NPY (2µl/20 
minutes; 3.3 X 1012 viral particles/ml) (N=2) or AAV-FIB-NPY13-36 (2µl/20 minutes; 
3.0 X 1012 viral particles/ml) (N=2) into the piriform cortex as previously described.1  
Then, 1 week later, the animals received an overdose of pentobarbital (100 mg/kg, ip) 
and were subsequently decapitated. The brain was removed, and the piriform cortex was 
dissected out. The tissue was stored in RNAlater (Ambion, Austin, TX, USA) at -200C.  
Subsequently, the RNA was extracted from the tissue (Promega SV-40 total RNA 
isolation kit; Madison, WI, USA) and reverse transcribed using AMV reverse 
transcriptase and oligo (dT) primers. The subsequent PCR primers were designed to span 
the FIB-NPY (and thus the FIB-NPY13-36) sequence, which can only be derived from 
the rAAV vector (FIB, 5’- CTAGCAGTCCTGTGCCTG; NPY and NPY13-36, 3’-
GCTCAATATCTCTGTCTGGTG).   
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Appendix D.2. Viral Vector Gene Therapy 
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  About 2.1 million people in the United States have epilepsy (Hirtz, Thurman et al. 
2007), and with a world wide prevalence of approximately 1 percent (Hauser et al., 
1990), epilepsy represents one of the most common neurological diseases.   Not only can 
epilepsy be debilitating for patients, it also exacts a significant economic toll.  In the 
United States the estimated annual economic cost of epilepsy is 12.5 billion dollars, a 
figure that includes both the direct cost of treatment and the indirect costs such as lost 
productivity and wages (Shafer and Begley 2000).  Unfortunately, even with new AEDs 
available, the number of drug resistant epilepsies has not decreased (Loscher and Leppik 
2002).  In fact, 30–40% of all patients with epilepsy have medically intractable seizures, 
and only half of these patients are candidates for surgery (Shafer, et al. 1988; Engel et al. 
1992; Sander 1993; Siegel 2004).  Of those patients that undergo temporal lobe surgery, 
20% still have seizures post-op (Spencer et al. 1984), and surgical complications along 
with post-operative memory and language deficits can occur (Siegel 2004).  For all these 
reasons, improving epilepsy treatment remains a priority.   
Theoretically, a gene therapy approach to seizure suppression is an attractive 
alternative treatment option for focal epilepsy, the most common adult form (Semah et al. 
1998).  Focal epilepsy arises from a circumscribed, hyperexcitable network of neurons 
whose synchronous electrical discharge creates seizure activity.  To date, most gene 
therapy studies have employed viral vectors based upon adenovirus (AD), adeno-
associated virus (AAV), human immunodeficiency virus (HIV) or herpes simplex virus 
(HSV).  In all cases, these viral vectors have proven capable of transducing post-mitotic 
neurons which provides direct access to the cells responsible for generating and 
propagating the seizure activity.  Furthermore, these viral vectors have proven capable of 
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influencing brain function on a regional basis, so viral vector gene therapy should have 
the ability to influence sites of seizure genesis.  However, even with the promising results 
obtained using viral vectors (see table 1), a number of factors must be considered when 
modeling a gene therapy for the treatment of epilepsy.   
 
Identifying Potential Therapeutic Targets 
 
In general, epilepsy arises from a loss of inhibition, an enhanced state of 
excitation or a combination of both processes, so given this wide range of influences, a 
wealth of potential therapeutic targets exists.  On the most basic level, altering receptor or 
ion channel mediated function clearly has been shown to attenuate seizure activity.   For 
example, antiepileptic drugs (AEDs) exert their actions by (1) increasing GABAergic 
inhibition, (2) decreasing excitatory glutamatergic excitation (3) decreasing voltage-
dependant calcium release or (4) decreasing voltage-dependant Na+ conductance (Ure and 
Perassolo 2000).  Because AD, AAV, HSV-1 and HSV vectors exhibit a clear 
neurotropism, any of these targets are readily accessible by these viral vectors.  In 
addition, basic research has identified a number of other modulatory factors that likewise 
can attenuate seizure activity in vivo.  Prominent among this class are the neuropeptides, 
such as galanin and neuropeptide Y.  Although this extensive list of potential targets 
would seem to offer many opportunities, the major difficulty is establishing a strategy 
that is both effective and non-toxic.   
 
Excitatory Amino Acid Receptors 
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Excitatory amino acid receptors comprise an obvious target for anti-epileptic gene 
therapy, and certainly many studies have shown that N-methyl-D-aspartic acid (NMDA) 
receptors influence seizure sensitivity.  Because a fully functional receptor requires the 
NMDA receptor 1 protein (NMDAR1), removal of this subunit protein should 
significantly reduce NMDAR1 mediated excitation (Monyer et al., 1992; Hollmann and 
Heinmann, 1994).  Haberman et al. (2002) showed that AAV vector-mediated delivery of 
an antisense RNA specific to the NMDAR1 could indeed reduce NMDA receptor 
function in vitro and NMDAR1 protein in vivo.  Using a focal seizure model, CMV 
promoter driven expression of the NMDAR1 antisense significantly decreased the seizure 
susceptibility, proving the principle that viral vector derived antisense could influence 
native receptor function in vivo.  However, when expression of the same antisense 
construct was driven by a tetracycline regulated minimal CMV promoter (Haberman et 
al., 1998), the seizure susceptibility actually increased.  The fact that NMDA receptor 
mediated excitation can drive endogenous GABA inhibition provided a tenable 
explanation for these diametrically opposed results.  In the case of the CMV promoter, 
excitatory principal neurons likely comprised the preponderance of transduced cells, thus 
removal of NMDA receptor excitation blunted the seizure susceptibility.  In the case of 
the regulated minimal CMV promoter, the preponderance of gene expression probably 
occurred in inhibitory GABAergic interneurons, so removal of the endogenous excitatory 
drive to these interneurons would cause a state of increased seizure sensitivity.  The 
likelihood of such an occurrence was validated, when equal amounts of each AAV vector 
were administered together using different reporter genes.  Some neurons supported 
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expression from both promoters, but significant portions exhibited transduction from only 
one or the other of the promoters.  Thus, a slight change in only the promoter resulted in a 
dramatic shift in the final outcome of the gene expression.  These surprising findings 
greatly complicate the targeting of neurotransmitter receptor proteins or ion channels for 
the treatment of epilepsy.  Certainly, it is possible that the viral vector tropism and/or 
promoter tropism could differ between experimental animals and humans.  Thus, without 
some detailed a priori knowledge of the transduction pattern in humans, any 
manipulation of neurotransmitter receptor proteins or ion channels could lead either to the 
desired reduction of seizure susceptibility or a paradoxical heightening of seizure 
susceptibility.   
 
Inhibitory GABA Receptors 
 
GABA is the major inhibitory neurotransmitter in the adult brain.  Most fast 
synaptic inhibition in the mature brain is mediated by GABAA receptors (GABRs), 
pentameric anion-selective channels composed of multiple subunit subtypes (α1-6, β1-3, 
γ1-3, δ, ε, π, θ and ρ1-3).  GABAergic signaling has long been hypothesized to play an 
important role in the genesis of epilepsy, and many of the oldest and most commonly 
used anticonvulsants such as benzodiazepines and barbiturates act, at least in part, 
through augmentation of GABR activity.  Mutations in several different GABR subunits 
have been identified in families with generalized epilepsies (Macdonald et al., 2004).  In 
addition, several laboratories have identified changes in GABR function and subunit 
composition in human temporal lobe epilepsy (TLE) and in animal models of TLE (Buhl 
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et al., 1996; Gibbs et al., 1997; Brooks-Kayal et al., 1998, 1999).  Studies in humans with 
temporal lobe epilepsy (TLE) and in adult rodent models of TLE have found reduced 
expression of GABR α1 subunit gene and increased expression of GABR α4 subunit 
gene in the dentate gyrus (DG)(Brooks-Kayal et al., 1998,1999; Peng et al., 2004; Zhang 
et al., 2007).  These findings suggest that diminished α1 levels in dentate granule neurons 
(DGN) may contribute to epileptogenesis and/or that elevated α1 levels may be 
protective.  Certainly, reduction of GABR α1 subunit protein using an AAV that 
expressed a GABR α1 antisense RNA significantly increased focal seizure susceptibility 
(Xiao et al., 1997).   
To directly test the hypothesis that the expression of higher α1 subunit levels 
inhibits development of epilepsy after SE, an adeno-associated virus gene transfer vector 
(AAV) serotype 5 was designed to express a bicistronic RNA that codes for both the 
GABR α1 subunit as well as the reporter, enhanced yellow fluorescence protein (eYFP) 
(Raol et al., 2006).  Expression of this RNA was placed under control of the GABR α4 
core promoter region, because it was previously shown to be markedly activated in DG 
following SE (Roberts et al., 2005). AAV-vectors containing either the α1/eYFP fused 
cDNA (AAV-α1) or the eYFP-reporter only (AAV-eYFP) were injected into DG of adult 
rats, and SE was induced two weeks later by intraperitoneal injection of pilocarpine (385 
mg/kg).  Rats injected with AAV-α1 showed 3-fold higher levels of α1 subunits in DG 
by 2 weeks after SE compared to the control groups.  AAV-α1 injection resulted in a 3-
fold increase in the mean time to the first spontaneous seizure following SE, and only 
39% of AAV-α1 injected rats were observed to develop spontaneous seizures in the first 
4 weeks after SE, as compared to 100% of rats receiving sham-injections.  Because all 
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groups of rats experienced similar SE after pilocarpine injection, these findings provide 
the first direct evidence that increasing the levels of a single GABR subunit in DG can 
inhibit the development of spontaneous seizures after SE.   
Another unique aspect of this particular study involves the use of a condition-
specific promoter which when upregulated during a disease process, drives expression of 
a therapeutic gene.  In this case, the upregulation of the GABR α4 promoter drove 
expression of the α1 transgene which enhanced α1 expression in DG.  Unfortunately, this 
vector-derived expression lasted for only the first two weeks after SE.  To differentiate 
whether the decline in α1 subunit levels by 4 weeks after SE was due to loss of 
recombinant or endogenous α1 subunits, mRNA levels for eYFP (produced from the 
vector containing the fused α1/eYFP cDNAs) were assayed in AAV-injected rats 
sacrificed at 1 or 4 weeks after SE.  With presence of eYFP mRNA as a marker for co-
presence of α1, recombinant α1 mRNA levels were found to decline over 6-fold in AAV 
injected rats between 1 and 4 weeks after SE.  This finding suggests that either the 
GABRA4 promoter in the AAV vector was transcriptionally downregulated or that the 
recombinant α1/eYFP mRNAs were degraded.  A number of studies have demonstrated 
robust, long-term gene expression in the hippocampus after AAV transduction (Klein et 
al., 1998, Burger et al., 2004), but this stable expression is promoter dependent.  For 
example, McCown et al. (1996) showed that when gene expression was driven by a CMV 
promoter, the initial level of AAV mediated gene expression in the hippocampus declined 
over a period of 4 weeks whereas some other areas of brain exhibited no decline in gene 
expression.  Further studies will be required to define the precise mechanism responsible 
for the proposed decrease in activity of the recombinant GABRA4 promoter over time 
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and to rule out whether a change in mRNA stability may also play a role in declining 
levels of α1/eYFP transcript. 
In addition to the effects on seizures, AAV-mediated elevation of α1 expression 
was associated with a behavioral phenotype in a fraction of the AAV-α1 injected rats.  
Most of the AAV-α1 injected rats behaved similar to sham-injected rats, but 30% 
exhibited abnormal behaviors including excessive sedation, anorexia, and weight loss that 
persisted for days to weeks following SE.  This effect was not seen after SE in any of the 
other groups (including the AAV-eYFP control), suggesting that the effect likely resulted 
from elevated α1 levels rather than the effects of AAV injection or SE.  Such effects are 
not surprising given that α1-containing receptors are the major form of GABRs 
mediating sedation in the nervous system (Mohler et al., 2002). 
Genetic engineering approaches have also been used to augment other aspects of 
GABAergic neurotransmission.  Specifically, two groups have transplanted immortalized 
neurons genetically engineered to stably express the GABA synthesizing enzyme 
glutamic acid decarboxylase (GAD65 or GAD67) into different brain regions and 
examined the effects on induced and spontaneous seizures.   Transplant of these 
conditionally immortalized neurons engineered to produce GABA into either substantia 
nigra (SN) or piriform cortex of rats has been found to inhibit kindling (Thompson et al., 
2000; Gernert et al., 2002) and reduce the number and severity of kainic acid-induced 
seizures (Castillo et al., 2006).  Transplantation of GABA-producing neurons into SN 
also has been shown to reduce spontaneous seizures in a TLE model (Thompson and 
Suchomelova, 2004).  Injection of GABA-producing neurons under the control of 
tetracycline injected into SN 45-65 days following lithium-pilocarpine induced status 
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epilepticus reduced the number of spontaneous seizures and epileptiform discharges at 7-
8 days after transplantation compared to animals that received control cells or that 
received the GABA-producing cells plus doxycycline to inhibit GABA production 
(Thompson and Suchomelova, 2004).  Similarly, transplantation of GABA-producing 
cells into dentate gyrus raised GABA tissue concentrations, increased the afterdischarge 
threshold, shortened the afterdischarge duration and prolonged the latency to expression 
of the first stage 5 seizure in a hippocampal kindling model (Thompson, 2005).  Although 
the engineered cells show evidence of integration, this cell transplantation approach 
remains hampered by the limited long-term survival of the transplanted cells (Thompson 
and Suchomelova, 2004).   
Taken together, it is clear that by controlling GABAergic signaling either through 
discrete regulation of its receptor isoforms or through accessibility to its neurotransmitter 
GABA, it may be possible in the future to treat a multitude of diseases that stem from an 
imbalance between excitatory and inhibitory neurotransmission.  The challenge remains 
to develop better vehicles and approaches for the selective delivery of gene products over 
time in a therapeutically useful manner. 
 
Diverse Unrelated Targets 
 
A number of diverse, unrelated targets also have emerged from basic research that 
focused upon neuroprotection, not epilepsy.  Glial cell line-derived neurotrophic factor 
(GDNF) exerts a potent neuroprotective action in the CNS, especially on dopamine 
containing neurons (Choi-Lundberg er al., 1997; Mandel et al., 1997), and when infused 
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intraventricularly, GDNF attenuates kainic acid-induced seizures (Martin et al., 1995).  
Using viral vectors, Yoo et al. (2006) subsequently showed that AD mediated GDNF 
expression in the hippocampus attenuated behavioral seizures and cell death induced by 
peripheral kainic acid administration.  Similarly, Kanter-Schlifke et al. (2007A) used an 
AAV vector to overexpress glial cell line-derived neurotrophic factor (GDNF) in the 
hippocampus and found that this overexpression reduced the seizure severity in both 
hippocampal kindling, as well as kindled self-sustained status epilepticus.  Thus, viral 
vector-mediated expression of GDNF can influence seizure sensitivity.  Another anti-
apoptotic agent was identified by Perkins et al., (2003) who reported that the herpes 
simplex virus type 2 R1 protein kinase (ICP10 PK) exerted an antiapoptotic action in 
hippocampal cultures.  Based upon these findings, Laing et al. (2005) showed that nasal 
inoculation with a herpes simplex virus type 2 that contains the anti-apoptotic gene 
ICP10PK prevented both behavioral seizures and neuronal death elicited by peripheral 
kainic acid administration.  Thus, it appears that at least in these two instances, gene 
products with neuroprotective actions also can significantly influence seizure sensitivity.   
A second group of therapeutic targets have emerged from diverse modulators of 
synaptic excitation.  The protein homer 1a is induced by excessive excitation and is 
thought not only to modulate synaptic plasticity, but also to reduce postsynaptic calcium 
function (Ango et al., 2001).  Using this information, Klugman et al. (2005) found that 
AAV-mediated overexpression of Homer 1a attenuated electrographic seizure activity in 
a hippocampal status epilepticus model.  Another means to reduce excitation would be to 
inhibit the efficacy of synaptic transmission.  Clostridial toxin light chain digests the 
vesicle docking protein, synaptobrevin, which results in impaired synaptic transmission, 
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so Yang et al (2007) used AD vectors to express this protein in rat cortex.  AD-mediated 
expression of this protein attenuated both electrographic and behavioral seizures elicited 
by subsequent penicillin injection into the cortex.  Finally, a number of studies have 
established that adenosine potently inhibits neuronal activity (Dunwiddie and Masino, 
2001), so Huber et al., (2001) engineered fibroblasts to secrete adenosine.  When these 
cells were implanted into the ventricles of rats, both behavioral and electrographic 
seizures were attenuated in electrically kindled rats.  Although these studies established 
the anti-seizure potency of adenosine in vivo, the effect waned significantly 24 days post-
transplantation.  In total, these studies illustrate the wide range of targets by which 
various gene products can reduce neuronal excitation by in vivo viral gene therapy.   
 
Neuroactive Peptides 
 
Like other gene therapy studies, previous pharmacological findings with 
neuroactive peptides have provided a strong rationale for application in anti-epileptic 
gene therapy.  Of the many neuropeptides that can modulate neuronal excitability, 
galanin and neuropeptide Y have been most thoroughly characterized.  For example, the 
neuroactive peptides, galanin and neuropeptide Y (NPY), both attenuate seizure activity 
in vivo (Woldbye et al.,1997; Mazzarati et al.,1998.).  Key to any neuropeptide gene 
therapy, though, is the consideration of endogenous neuropeptide function.  Most 
neuroactive peptides are expressed initially as prepro-peptides, a form that presumably 
contains the appropriate information for trafficking to the pre-synaptic terminal and 
packaging into vesicles.  Thus, if a viral vector expresses a prepro-neuropeptide 
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sequence, one must assume that the transduced cells indeed contain the appropriate 
pathways for trafficking and release.  Whether determined by the vector or the promoter, 
the actual tropism of viral vectors is unknown in the human CNS, so as demonstrated for 
NMDA receptor gene therapy, successful neuropeptide gene therapy might require 
transduction and gene expression in the appropriate neuronal population.  Given these 
potential pitfalls, Haberman et al. (2003) devised a novel approach to peptide gene 
therapy focusing upon galanin.  The laminar protein, fibronectin occurs in most cell types 
and normally is secreted in a constitutive manner.  This constitutive secretion is 
determined by the secretory signal sequence for fibronectin.  Using AAV vectors 
Haberman et al. (2003) combined the secretory signal sequence for the laminar protein 
fibronectin with coding sequence for the active galanin neuropeptide (AAV-FIB-GAL).  
By attaching this secretory signal sequence to the coding sequence for the active galanin 
peptide, it was reasoned that the viral vector mediated expression would lead to the 
constitutive secretion of active galanin.  Thus, if the appropriate receptors exist in the 
area of transduction, different patterns of neuronal transduction should not adversely 
influence the outcome.  In fact these investigators showed that indeed AAV-FIB-GAL 
supported constitutive secretion of galanin in vitro, and in vivo sufficient galanin was 
secreted to significantly attenuate focal seizure activity and prevent kainic acid-induced 
neuronal cell death in the hippocampus.  If galanin was expressed in the absence of the 
FIB, or GFP was constitutively secreted, no effects were found on focal seizure 
sensitivity or cell death in the hippocampus.  Using this gene therapy approach, 
subsequent studies found that bilateral infusion of AAV-FIB-GAL into the piriform 
cortex prevented both electrographic and behavioral seizure activity induced by 
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peripheral kainic acid administration and significantly elevated the seizure initiation 
threshold in previously kindled rats (McCown, 2006).  In contrast, Lin et al. (2003) used 
AAV vectors to express human galanin in the hippocampus.  Even though these studies 
achieved much higher levels of vector derived gene expression in comparison to 
Haberman et al. (2003), the effects upon local infusion of kainic acid were restricted to a 
decrease in the number of seizures, not the seizure latency.  Furthermore, no neuronal 
protection was evident.  When these investigators further explored the effects of this 
approach, they found that galanin overexpression did not alter the course of electrical 
hippocampal kindling or modulate short term plasticity of mossy fiber CA3 synapses.  
Thus, just because high levels of a peptide are expressed in vivo, such expression does 
not necessarily lead to an increase in the peptide’s in vivo actions.   
 
Neuropeptide Y (NPY), like galanin, exhibits anti-seizure activity in vivo 
(Woldbye et al., 1997; Mazarati and Wasterlain, 2002), and a recent set of studies by 
Richichi et al. (2004) have shown that AAV-mediated expression of prepro-NPY exerts a 
range of anti-seizure effects. Expression of a human prepro-NPY gene prevented the 
appearance of status epilepticus after intracerebroventricular administration of kainic 
acid.  Also, hippocampal expression of prepro-NPY increased the electrical seizure 
threshold in the hippocampus and significantly retarded the rate of kindling 
epileptogenesis.  Another important facet of these studies involved the exploitation of 
different AAV serotypes.  A hybrid AAV1/2 serotype transduced a substantially wider 
range of neurons, when compared to the AAV2 serotype, and this increased transduction 
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translated to a greater effect of prepro-NPY expression.  Thus, these studies clearly 
established the anti-epileptic potential for vector derived prepro-NPY expression in vivo.   
A subsequent study by Foti et al. (2007) utilized the constitutive secretion 
approach to demonstrate not only the efficacy of vector derived NPY, but also , the 
efficacy of the NPY receptor specific fragment NPY(13-36).  Although some question 
remains as to which of the NPY receptors (Y1-Y5) mediates the anti-seizure activity, 
several studies have suggested a critical role for the Y2 receptor in mediating anti-
epileptic actions (Colmers et al., 1991; Greber et al., 1994; El Bahn et al., 2002, 2005; 
Lin  et al, 2006).  Because acute intracerebral delivery of the Y2 receptor preferring 
agonist NPY13-36 reduces seizure susceptibility following systemic kainic acid 
administration (Vezzani et al., 2000), Foti et al. (2007) used an AAV vector to express 
and constitutively secret NPY or NPY(13-36) in the rat piriform.  Similar to previous 
results with galanin (McCown, 2006), expression of either NPY or NPY(13-36) 
significantly suppressed limbic seizures elicited by subsequent peripheral kainic acid 
administration.  Thus, these studies showed that the constitutive secretory approach can 
effectively express and secrete receptor specific peptide fragments in vivo.   
 
Critical Considerations and Future Directions: 
 
 The wide range of gene therapy studies amply illustrate the potential of viral 
vector gene therapy as an effective treatment modality for epilepsy, but even with these 
positive findings, there are a number of considerations that will inevitably impact both 
the efficacy and the safety of this therapeutic approach.  Although many viral vectors 
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exhibit a neuronal tropism in vivo, one must always take into account how specific 
patterns of transduction might alter the outcome of therapeutic gene expression.  Viral 
vector tropism aside, as shown previously (Haberman et al., 2002) different promoters 
can lead to differential gene expression even within the context of the same viral vector.  
Because such a change can result in an unwanted outcome, one first must consider the 
need to transduce a specific cellular population and the consequences if such specificity 
is not achieved.  One obvious solution involves the use of cell specific promoters, such as 
that used by Raol et al. (2006) where expression would only be achieved in those cells 
that contain GABR α4 promoter activity.  However, as also seen by Raol et al. (2006) 
endogenous promoters may be susceptible to promoter silencing. Secondly, the most 
likely clinical population for gene therapy encompasses those individuals with intractable 
temporal lobe epilepsy who are surgical candidates.  In such a case, these individuals will 
have extensive seizure histories and inevitably varying degrees of hippocampal sclerosis.  
At present, most viral vector studies have examined the ability to transduce normal tissue.  
Thus, a second consideration is whether the viral vectors will support sufficient neuronal 
transduction in epileptic tissue with its associated pathology.  Finally, it is incumbent to 
demonstrate that the proposed gene therapy can prevent spontaneous seizure activity.  
Thus, to best model an effective gene therapy, viral vector transduction should be 
initiated in animals that exhibit spontaneous seizures.  As studies focus upon these 
aspects, it is likely that an effective anti-epileptic gene therapy will emerge.   
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Table 1. Potential Therapeutic Targets that Influence Seizure Behavior. 
 
Target  Placement  Delivery 
vector  
Experimental 
model  
Functional 
effect  
References  
 
Adenosine  
 
Intracerebroventricular 
 
Grafting of 
fibroblasts or 
myoblasts 
 
Hippocampal 
kindling  
Suppression of 
generalized 
seizures  
(Huber et al. 
,2001; 
Guttinger et 
al., 2005) 
Anti NMDA  Collicular cortex  AAV-CMV vector  
Focal 
electrical 
stimulation  
Increased 
seizure 
threshold  
(Haberman 
et al., 2002) 
   
AAV-TEToff 
vector  
 Decreased 
seizure 
threshold  
 
(Haberman 
et al., 2002) 
 
ASPA  
 
Intracerebroventricular 
 
Ad-CB vector  Spontaneous 
seizures in 
SER  
 
Transiently 
reduced 
incidence of 
tonic seizures  
(2 weeks) 
 
(Seki et al., 
2004) 
Cholecystokinin  Intracerebroventricular Lipofectin and plasmid 
Audiogenic 
seizure-prone 
rats  
 
Transient 
seizure 
inhibition  (1 
week) 
(Zhang et al., 
1997) 
GABAAR Hippocampus AAV-GABAR4 
Pilocarpine-
induced 
Status 
Epilepticus 
 
Transiently 
reduced 
spontaneous 
seizures (4 
weeks) 
(Raol et al., 
2006) 
GAD65  Anterior SN  
Grafting of 
neuronal or 
glial cell lines  
Entorhinal 
kindling  
Delayed rate of 
kindling  
(Thompson 
et al., 2000) 
 
 
 
Posterior SN  
 
Grafting of 
neuronal or 
glial cell lines 
  
Faster rate of 
kindling  
 
(Thompsonet 
al., 2000) 
  
Anterior SN  
 
Grafting 
neuronal cell 
line 
 
Pilocarpine-
induced 
Status 
Epilepticus  
 
Reduced 
spontaneous 
seizures  
 
(Thompson 
and 
Suchomelova 
2004) 
  
Piriform cortex  
 
Grafting 
neuronal cell 
line 
 
Amygdala 
kindling  
 
Increased 
threshold to 
seizures  
 
(Gernert et 
al., 2002) 
GAD67 SN pars reticulata 
 
Grafting of 
mixed 
neuronal and 
glial cell line  
Kainic acid ip Delayed seizure behavior 
(Castillo et 
al., 2006) 
Galanin  Collicular cortex  
 
AAV-TEToff 
vector+FIB 
secretory 
sequence 
 
Increased 
seizure 
threshold  
 
(Haberman 
et al., 2003) 
  
Hippocampus  
AAV-TEToff 
vector+FIB 
secretory 
sequence  
 
Kainic acid ip  
 
Neuroprotection  
 
(Haberman 
et al., 2003) 
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AAV-NSE 
vector+WPRE 
 
Kainic acid ih  
 
Reduced 
number of 
seizures  
 
(Lin, et al., 
2003) 
  
Piriform cortex  
 
AAV-CB 
vector+FIB 
secretory 
sequence  
 
Kainic acid ip  
 
Seizure 
inhibition  
 
(McCown, 
2006) 
    
Focal 
electrical 
stimulation 
 
Increased 
seizure 
threshold 
 
(McCown, 
2006) 
GDNF 
 
 
 
Hippocampus 
 
 
AAV-CB 
vector+WPRE 
 
 
Hippocampal 
kindling 
 
Decreased 
number of 
generalized 
seizures, 
increased 
seizure 
threshold 
 
(Kanter-
Schlifke et 
al., 2007) 
  
Hippocampus  
 
Ad-CMV 
vector 
 
Kainic acid ip 
 
Delayed seizure 
behaviors, 
neuroprotective 
 
(Yoo et al., 
2006) 
 
ICP10PK 
 
Intranasal vaccine 
 
HSV-2∆RR –
ICP10 vector 
 
Kainic acid ip 
 
Reduced 
seizure 
behaviors, 
neuroprotection 
 
(Laing et al., 
2006 ) 
 
NPY  
 
Hippocampus  
 
AAV-NSE 
vector+WPRE 
Kainic acid ih  
 
Delayed seizure 
behavior  
 
(Richichi et 
al. ,2004) 
    
 
Hippocampal 
kindling  
 
Increased 
seizure 
threshold and 
delayed rate of 
kindling  
 
(Richichi et 
al., 2004) 
  
Piriform cortex 
 
AAV-CB 
vector+FIB 
secretory 
sequence 
Kainic acid ip 
 
Reduced and 
delayed seizure 
behaviors 
 
(Foti, et al., 
2007) 
 
NPY 13-36 
 
Piriform cortex 
 
AAV-CB 
vector+FIB 
secretory 
sequence 
Kainic acid ip 
 
Reduced and 
delayed seizure 
behaviors 
 
(Foti, et al. 
,2007) 
Abbreviations are: AAV: adeno-associated virus; ASPA: aspartoacylase; Ad: adenoviral; CB: cytomegalovirus 
enhancer, chicken beta-actin promoter; CMV: cytomegalovirus; GAD: glutamic acid decarboxylase; GDNF: glial-
derived neurotrophic factor; ICP10PK: ICP 10 protein kinase; ih: intrahippocampal; ip: intraperitoneal; NMDA: N-
methyl-D- aspartate; NPY: Neuropeptide Y; NSE: neuron- specific enolase; SER: spontaneously epileptic rats; SN: 
substantia nigra;  TET off: tetracycline-off regulatable promoter; WPRE: woodchuck virus post-transcriptional 
regulatory element.  
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